[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ff4bLWT19wD4aLQOSieuBoZkwo9eIF22kA1Zr_iPjP3I":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":16,"truncated":17,"activeTrials":18,"phase3Count":19,"totalEnrollment":20,"activePrograms":21,"nonDrugCount":22,"topConditions":23,"upcomingReadouts":45,"phaseBuckets":93,"rows":100},"Daiichi Sankyo",[6,4,7,8,9,10,11,12,13,14,15],"Daiichi Sankyo Co., Ltd.","Daiichi Sankyo France","Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company","Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company","Daiichi Sankyo Brasil Farmacêutica LTDA","Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company","Daiichi Sankyo Turkey, a Daiichi Sankyo Company","Daiichi Sankyo Hong Kong Ltd., a Daiichi Sankyo Company","Daiichi Sankyo (Thailand) Ltd., a Daiichi Sankyo Company",412,false,66,95,245590,69,20,[24,27,30,33,35,38,41,43],{"name":25,"count":26},"Hypertension",22,{"name":28,"count":29},"Atrial Fibrillation",18,{"name":31,"count":32},"Type 2 Diabetes Mellitus",15,{"name":34,"count":32},"Essential Hypertension",{"name":36,"count":37},"Non-small Cell Lung Cancer",12,{"name":39,"count":40},"Venous Thromboembolism",11,{"name":42,"count":40},"Hypercholesterolemia",{"name":44,"count":40},"Breast Cancer",[46,51,56,61,65,70,75,79,83,88],{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT03030066","Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas","2021-01-31","DS-1001b",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT03529110","DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and\u002For Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]","2021-05-21","Trastuzumab deruxtecan",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT04488822","A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT","2021-10-27","Pexidartinib",{"nctId":62,"briefTitle":63,"date":64,"intervention":55},"NCT03734029","Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]","2022-01-11",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT04619004","HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","2022-11-21","Patritumab Deruxtecan",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT02732275","DS-3201b in Participants With Lymphomas","2022-12-31","DS-3201b",{"nctId":76,"briefTitle":77,"date":78,"intervention":50},"NCT04458272","A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma","2023-03-10",{"nctId":80,"briefTitle":81,"date":82,"intervention":60},"NCT04703322","A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan","2023-03-20",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT04703192","Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1\u002F2 Dual Inhibitor, for Relapsed\u002FRefractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)","2023-05-10","Valemetostat Tosylate",{"nctId":89,"briefTitle":90,"date":91,"intervention":92},"NCT04526691","Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)","2024-04-14","Datopotamab deruxtecan",[94,95,96,97,98,99],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[101,345,433,526,638,721,770,817,961,995,1040,1128,1183,1223,1255,1277,1299,1321,1405,1444,1484,1514,1616,1642,1675,1701,1719,1737,1755,1773,1791,1809,1827,1845,1863,1881,1899,1917,1959,2017,2044,2077,2108,2126,2144,2162,2180,2204,2230,2248,2274,2292,2317,2357,2385,2409,2427,2451,2469,2494,2512,2530,2548,2574,2599,2622,2647,2672,2696,2721,2784,2859,2927,2962,3016,3058,3096,3139,3166,3202,3228,3246,3271,3289,3315,3333,3357,3383,3401,3426,3444,3462,3485,3503,3521,3539,3562,3580,3598,3621,3639,3663,3681,3704,3722,3740,3758,3783,3806,3828,3846,3963,4064,4136,4206,4280,4331,4365,4415,4453,4494,4528,4550,4579,4601,4636,4658,4686,4720,4754,4789,4820,4842,4866,4884,4906,4930,4948,4966,4984,5002,5020,5038,5063,5081,5099,5125,5143,5161,5179,5202,5224,5248,5266,5290,5315,5333,5358,5376,5400,5418,5436,5454,5472,5490,5508,5526,5544,5562,5584,5611,5629,5647,5665,5683,5701,5719,5737,5755,5773,5798,5816,5834,5859,5912,5970,6020,6069,6113,6153,6179,6212,6243,6265,6295,6321,6354,6376,6400,6422,6449,6467,6490,6508,6532,6550,6575,6593,6617,6635,6664,6682,6707,6725,6743,6761,6785,6811,6829,6853,6871,6898,6916,6949,6967,6985,7003,7021,7039,7061,7079,7104,7128,7154,7172,7190,7213,7231,7254,7272,7327,7355,7384,7406,7428,7450,7472,7497,7521,7546,7569,7592,7610,7631,7649,7673,7697,7720,7742,7760,7785,7803,7821,7847,7865,7883,7906,7930,7948,7966,7984,8002,8025,8050,8072,8090,8116,8137,8158,8185,8203,8221,8239,8257,8275,8296,8319,8342,8363,8387,8405,8423,8449,8467,8485,8503,8521,8543,8561,8585,8603,8621,8639,8660,8678,8703,8721,8743,8765,8791,8809,8827,8845,8863,9025,9152,9235,9311,9392,9435,9461,9488,9506,9524,9549,9567,9591,9617,9635,9661,9686,9709,9735,9753],{"intervention":55,"totalTrials":22,"cells":102},{"EARLY_PHASE1":103,"PHASE1":106,"PHASE2":147,"PHASE3":183,"PHASE4":285,"NA":287},{"trials":104,"activeCount":105},[],0,{"trials":107,"activeCount":146,"soonestReadout":125},[108,120,133],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"NCT07015697","A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors","RECRUITING",[95],"2028-12-31","2025-07-17",76,[117],"Recurrent or Metastatic Solid Tumors",[119],"Trastuzumab Deruxtecan",{"nctId":121,"briefTitle":122,"status":123,"phases":124,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":131},"NCT04042701","DS8201a and Pembrolizumab in Participants With Locally Advanced\u002FMetastatic Breast or Non-Small Cell Lung Cancer","ACTIVE_NOT_RECRUITING",[95],"2025-07-21","2027-03-31","2020-02-10",115,[44,130],"Non-small Cell Lung Carcinoma",[55,55,132],"Pembrolizumab",{"nctId":134,"briefTitle":135,"status":136,"phases":137,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":144},"NCT03523572","Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer","COMPLETED",[95],"2021-07-22","2023-09-12","2018-08-02",86,[44,143],"Urothelial Carcinoma",[55,145],"Nivolumab",2,{"trials":148,"activeCount":105},[149,160,172],{"nctId":150,"briefTitle":151,"status":136,"phases":152,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":159},"NCT04644237","Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)",[96],"2022-12-23","2024-08-23","2021-03-19",152,[158],"Non-Small Cell Lung Cancer",[55],{"nctId":161,"briefTitle":162,"status":136,"phases":163,"primaryCompletion":164,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":171},"NCT04014075","DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)",[96],"2021-11-08","2024-02-13","2019-11-26",79,[169,170],"Adenocarcinoma Gastric Stage IV With Metastases","Adenocarcinoma - GEJ",[55],{"nctId":173,"briefTitle":174,"status":175,"phases":176,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":182},"NCT03505710","DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer","TERMINATED",[96],"2021-05-03","2024-04-17","2018-05-21",181,[158],[55],{"trials":184,"activeCount":284,"soonestReadout":54},[185,197,206,214,227,240,251,261,273],{"nctId":186,"briefTitle":187,"status":111,"phases":188,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":195},"NCT06819007","Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)",[97],"2028-11-01","2032-01-31","2025-03-19",582,[194],"Ovarian Cancer",[119,196],"Bevacizumab",{"nctId":198,"briefTitle":199,"status":111,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":205},"NCT05950945","Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer",[97],"2027-10-01","2023-12-30",250,[44],[119],{"nctId":52,"briefTitle":53,"status":123,"phases":207,"primaryCompletion":54,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":212},[97],"2026-07-30","2018-08-09",524,[44],[55,213],"Ado-trastuzumab emtansine",{"nctId":215,"briefTitle":216,"status":136,"phases":217,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":223},"NCT03523585","DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]",[97],"2022-06-30","2025-12-23","2018-08-01",608,[44],[55,224,225,226],"Capecitabine","Lapatinib","Trastuzumab",{"nctId":228,"briefTitle":229,"status":111,"phases":230,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":236},"NCT06899126","Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer",[97],"2030-03-05","2032-07-05","2025-10-24",686,[36],[119,237,238,239],"pembrolizumab","Pemetrexed","Chemotherapy",{"nctId":62,"briefTitle":63,"status":123,"phases":241,"primaryCompletion":64,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":246},[97],"2026-08-01","2018-12-27",557,[44],[55,224,247,248,249,250],"Eribulin","Gemcitabine","Paclitaxel","Nab-paclitaxel",{"nctId":252,"briefTitle":253,"status":111,"phases":254,"primaryCompletion":255,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":260},"NCT07022483","Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+\u002F2+) Endometrial Cancer",[97],"2032-03-23","2025-09-30",710,[259],"Endometrial Cancer",[119,239],{"nctId":262,"briefTitle":263,"status":111,"phases":264,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":272},"NCT06731478","Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer",[97],"2028-06-01","2030-02-01","2025-02-27",726,[270,271],"Gastric Cancer","Gastroesophageal Junction Cancer",[119,237,226,239],{"nctId":274,"briefTitle":275,"status":123,"phases":276,"primaryCompletion":277,"completion":277,"start":54,"enrollment":278,"conditions":279,"interventions":282},"NCT04704934","Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)",[97],"2026-08-31",490,[280,281],"Gastric Cancer, Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[55,283,249],"Ramucirumab",8,{"trials":286,"activeCount":105},[],{"trials":288,"activeCount":344,"soonestReadout":293},[289,301,313,322,332],{"nctId":290,"briefTitle":291,"status":111,"phases":292,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":300},"NCT05993234","A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)",[],"2026-12-01","2027-09-01","2023-12-05",257,[298,299],"HER2-positive Advanced Gastric Cancer","HER2-positive Gastroesophageal Junction Adenocarcinoma",[55],{"nctId":302,"briefTitle":303,"status":111,"phases":304,"primaryCompletion":305,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":312},"NCT06210776","A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)",[],"2028-03-01","2024-01-15",800,[309,310,44,311],"HER2-positive Breast Cancer","HER2-low Breast Cancer","Advanced Cancer",[55],{"nctId":314,"briefTitle":315,"status":136,"phases":316,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":321},"NCT05458401","EUropean Real-world Experience Of Previously Treated Advanced\u002FMetastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan",[],"2023-12-01","2022-11-11",256,[309],[55],{"nctId":323,"briefTitle":324,"status":111,"phases":325,"primaryCompletion":326,"completion":326,"start":267,"enrollment":327,"conditions":328,"interventions":331},"NCT06846996","Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China",[],"2027-07-31",260,[329,330],"HER2-positive Gastric Cancer","HER2-positive Gastroesophageal Junction",[55],{"nctId":333,"briefTitle":334,"status":111,"phases":335,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":343},"NCT05945732","DESTINY Breast Respond HER2-low Europe",[],"2028-09-01","2023-10-24",1155,[340,341,342],"Unresectable Breast Cancer","Metastatic Breast Cancer","HER2-low Expressing Breast Cancer",[55],4,{"intervention":132,"totalTrials":284,"cells":346},{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":367,"PHASE3":396,"PHASE4":429,"NA":431},{"trials":348,"activeCount":105},[],{"trials":350,"activeCount":146,"soonestReadout":125},[351,363],{"nctId":352,"briefTitle":353,"status":111,"phases":354,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":361},"NCT07182591","A Study of DS5361b in Participants With Advanced Solid Tumors",[95],"2030-03-18","2030-12-03","2025-10-02",192,[360],"Advanced Solid Tumor",[362,132],"DS5361b",{"nctId":121,"briefTitle":122,"status":123,"phases":364,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":365,"interventions":366},[95],[44,130],[55,55,132],{"trials":368,"activeCount":395,"soonestReadout":387},[369,383],{"nctId":370,"briefTitle":371,"status":175,"phases":372,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":377,"interventions":381},"NCT02452424","A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors",[95,96],"2018-08-17","2018-10-12","2015-07-02",78,[378,36,379,380,194],"Melanoma","Squamous Cell Carcinoma of the Head and Neck","Gastrointestinal Stromal Tumor (GIST)",[382,132],"PLX3397",{"nctId":384,"briefTitle":385,"status":111,"phases":386,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":393},"NCT06644768","A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations",[95,96],"2028-03-30","2030-04-30","2024-10-30",137,[36,392],"Lung Cancer",[394,237],"valemetostat tosylate",1,{"trials":397,"activeCount":344,"soonestReadout":423},[398,402,415,419],{"nctId":228,"briefTitle":229,"status":111,"phases":399,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":400,"interventions":401},[97],[36],[119,237,238,239],{"nctId":403,"briefTitle":404,"status":123,"phases":405,"primaryCompletion":406,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":411},"NCT05555732","Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)",[97],"2029-05-11","2023-01-11",1170,[410],"Metastatic Non Small Cell Lung Cancer",[412,132,238,413,414],"Datopotamab Deruxtecan","Carboplatin","Cisplatin",{"nctId":262,"briefTitle":263,"status":111,"phases":416,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":417,"interventions":418},[97],[270,271],[119,237,226,239],{"nctId":420,"briefTitle":421,"status":111,"phases":422,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":428},"NCT05215340","Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations",[97],"2028-02-29","2028-04-30","2022-03-04",740,[410],[412,132],{"trials":430,"activeCount":105},[],{"trials":432,"activeCount":105},[],{"intervention":434,"totalTrials":435,"cells":436},"Ifinatamab deruxtecan",7,{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":486,"PHASE4":513,"NA":515},{"trials":438,"activeCount":105},[],{"trials":440,"activeCount":105},[],{"trials":442,"activeCount":344,"soonestReadout":478},[443,452,464,474],{"nctId":444,"briefTitle":445,"status":111,"phases":446,"primaryCompletion":447,"completion":447,"start":448,"enrollment":449,"conditions":450,"interventions":451},"NCT06330064","A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)",[96],"2028-07-25","2024-04-10",520,[117],[434],{"nctId":453,"briefTitle":454,"status":111,"phases":455,"primaryCompletion":456,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":462},"NCT06362252","A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)",[95,96],"2026-09-30","2026-12-30","2024-07-22",123,[461],"Extensive Stage-small Cell Lung Cancer",[434,463,413],"Atezolizumab",{"nctId":465,"briefTitle":466,"status":111,"phases":467,"primaryCompletion":468,"completion":469,"start":470,"enrollment":203,"conditions":471,"interventions":473},"NCT04145622","Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors",[95,96],"2027-04-30","2029-10-31","2019-11-03",[360,472],"Malignant Solid Tumor",[434],{"nctId":475,"briefTitle":476,"status":123,"phases":477,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":484},"NCT05280470","Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)",[96],"2025-03-03","2026-12-15","2022-03-09",187,[483],"Extensive-stage Small-cell Lung Cancer",[485],"Ifinatamab Deruxtecan",{"trials":487,"activeCount":146,"soonestReadout":468},[488,501],{"nctId":489,"briefTitle":490,"status":111,"phases":491,"primaryCompletion":468,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":497},"NCT06203210","A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer",[97],"2029-02-22","2024-05-21",540,[496],"Small Cell Lung Cancer",[434,498,499,500],"Topotecan","Amrubicin","Lurbinectedin",{"nctId":502,"briefTitle":503,"status":111,"phases":504,"primaryCompletion":265,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":510},"NCT06644781","A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)",[97],"2029-11-01","2025-03-27",510,[509],"Esophageal Squamous Cell Carcinoma",[434,511,249,512],"Docetaxel","Irinotecan hydrochloride",{"trials":514,"activeCount":105},[],{"trials":516,"activeCount":105},[517],{"nctId":518,"briefTitle":519,"status":520,"phases":521,"conditions":522,"interventions":525},"NCT07535359","Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer","AVAILABLE",[],[523,524],"SCLC","Extensive-stage Small Cell Lung Cancer",[485],{"intervention":249,"totalTrials":40,"cells":527},{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":555,"PHASE3":609,"PHASE4":634,"NA":636},{"trials":529,"activeCount":105},[],{"trials":531,"activeCount":105},[532,543],{"nctId":533,"briefTitle":534,"status":136,"phases":535,"primaryCompletion":536,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":542},"NCT01525602","Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors",[95],"2017-12","2018-02","2012-05",74,[541],"Solid Tumors",[382,249],{"nctId":544,"briefTitle":545,"status":136,"phases":546,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":551,"interventions":553},"NCT01199055","CS-7017 in Combination With Carboplatin\u002FPaclitaxel in Subjects With Stage IIIb\u002FIV Non-small Cell Lung Cancer (NSCLC)",[95],"2011-04","2011-07","2010-03",16,[552],"Carcinoma, Non-Small-Cell Lung",[554,413,249],"CS-7017",{"trials":556,"activeCount":105},[557,567,579,589,598],{"nctId":558,"briefTitle":559,"status":175,"phases":560,"primaryCompletion":561,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":565},"NCT01512199","Phase 1b\u002F2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)",[95,96],"2015-01-28","2011-11",29,[341],[566,226,249,566,226,249],"U3-1287",{"nctId":568,"briefTitle":569,"status":136,"phases":570,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":577},"NCT00806286","Study of Carboplatin\u002FPaclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer",[96],"2012-01","2012-08","2008-12",111,[576],"Metastatic Non-small Cell Lung Cancer",[578,249,413],"CS7017",{"nctId":580,"briefTitle":581,"status":175,"phases":582,"primaryCompletion":583,"completion":583,"start":584,"enrollment":585,"conditions":586,"interventions":588},"NCT00603941","A Phase 1\u002F2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel",[95,96],"2011-12","2008-01",19,[587],"Anaplastic Thyroid Cancer",[554,249],{"nctId":590,"briefTitle":591,"status":136,"phases":592,"primaryCompletion":548,"completion":583,"start":593,"enrollment":594,"conditions":595,"interventions":596},"NCT00991796","CS-1008 With Carboplatin\u002FPaclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)",[96],"2009-06",109,[36],[597,249,413],"CS-1008",{"nctId":599,"briefTitle":600,"status":136,"phases":601,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":605,"interventions":608},"NCT00945191","Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer",[96],"2011-08-23","2009-10-06",24,[606,607],"Ovarian Cancer Stage IIIC","Ovarian Cancer Stage IV",[597,249,413],{"trials":610,"activeCount":344,"soonestReadout":64},[611,615,619,623],{"nctId":62,"briefTitle":63,"status":123,"phases":612,"primaryCompletion":64,"completion":242,"start":243,"enrollment":244,"conditions":613,"interventions":614},[97],[44],[55,224,247,248,249,250],{"nctId":502,"briefTitle":503,"status":111,"phases":616,"primaryCompletion":265,"completion":505,"start":506,"enrollment":507,"conditions":617,"interventions":618},[97],[509],[434,511,249,512],{"nctId":274,"briefTitle":275,"status":123,"phases":620,"primaryCompletion":277,"completion":277,"start":54,"enrollment":278,"conditions":621,"interventions":622},[97],[280,281],[55,283,249],{"nctId":624,"briefTitle":625,"status":111,"phases":626,"primaryCompletion":423,"completion":388,"start":627,"enrollment":628,"conditions":629,"interventions":631},"NCT06161025","A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[96,97],"2024-02-27",860,[630],"Solid Cancer",[632,249,498,633],"R-DXd","PLD",{"trials":635,"activeCount":105},[],{"trials":637,"activeCount":105},[],{"intervention":413,"totalTrials":639,"cells":640},10,{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":669,"PHASE3":698,"PHASE4":717,"NA":719},{"trials":642,"activeCount":105},[],{"trials":644,"activeCount":395,"soonestReadout":91},[645,649,658],{"nctId":544,"briefTitle":545,"status":136,"phases":646,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":647,"interventions":648},[95],[552],[554,413,249],{"nctId":89,"briefTitle":90,"status":123,"phases":650,"primaryCompletion":91,"completion":651,"start":652,"enrollment":653,"conditions":654,"interventions":656},[95],"2026-12-31","2020-09-15",145,[655],"Advanced or Metastatic NSCLC",[92,657,413,414],"KEYTRUDA®",{"nctId":659,"briefTitle":660,"status":136,"phases":661,"primaryCompletion":662,"completion":663,"start":664,"enrollment":32,"conditions":665,"interventions":666},"NCT02350712","Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer",[95],"2016-03","2016-06","2014-12",[379],[667,668,414,413],"Patritumab","Cetuximab",{"trials":670,"activeCount":395,"soonestReadout":456},[671,675,686,690,694],{"nctId":568,"briefTitle":569,"status":136,"phases":672,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":673,"interventions":674},[96],[576],[578,249,413],{"nctId":676,"briefTitle":677,"status":175,"phases":678,"primaryCompletion":679,"completion":680,"start":681,"enrollment":682,"conditions":683,"interventions":685},"NCT02633800","Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )",[96],"2018-01-11","2018-02-21","2015-12-22",87,[684],"Head and Neck Neoplasms",[667,668,414,413],{"nctId":453,"briefTitle":454,"status":111,"phases":687,"primaryCompletion":456,"completion":457,"start":458,"enrollment":459,"conditions":688,"interventions":689},[95,96],[461],[434,463,413],{"nctId":590,"briefTitle":591,"status":136,"phases":691,"primaryCompletion":548,"completion":583,"start":593,"enrollment":594,"conditions":692,"interventions":693},[96],[36],[597,249,413],{"nctId":599,"briefTitle":600,"status":136,"phases":695,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":696,"interventions":697},[96],[606,607],[597,249,413],{"trials":699,"activeCount":146,"soonestReadout":406},[700,704],{"nctId":403,"briefTitle":404,"status":123,"phases":701,"primaryCompletion":406,"completion":406,"start":407,"enrollment":408,"conditions":702,"interventions":703},[97],[410],[412,132,238,413,414],{"nctId":705,"briefTitle":706,"status":111,"phases":707,"primaryCompletion":708,"completion":709,"start":710,"enrollment":711,"conditions":712,"interventions":715},"NCT07129993","Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma",[96,97],"2029-06-01","2030-01-22","2025-09-26",630,[713,714],"Urothelial Cancer","Bladder Cancer",[716,413,414,248],"Dato-DXd",{"trials":718,"activeCount":105},[],{"trials":720,"activeCount":105},[],{"intervention":239,"totalTrials":722,"cells":723},5,{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":730,"PHASE4":766,"NA":768},{"trials":725,"activeCount":105},[],{"trials":727,"activeCount":105},[],{"trials":729,"activeCount":105},[],{"trials":731,"activeCount":344,"soonestReadout":265},[732,743,754,758,762],{"nctId":733,"briefTitle":734,"status":111,"phases":735,"primaryCompletion":736,"completion":736,"start":737,"enrollment":738,"conditions":739,"interventions":741},"NCT06578247","Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML",[97],"2030-06-26","2024-11-19",700,[740],"Leukemia",[742,239],"Quizartinib",{"nctId":744,"briefTitle":745,"status":136,"phases":746,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":751,"interventions":753},"NCT02668653","Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)",[97],"2021-08-13","2023-06-16","2016-09-01",539,[752,740],"Acute Myeloid Leukemia",[239,742],{"nctId":228,"briefTitle":229,"status":111,"phases":755,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":756,"interventions":757},[97],[36],[119,237,238,239],{"nctId":252,"briefTitle":253,"status":111,"phases":759,"primaryCompletion":255,"completion":255,"start":256,"enrollment":257,"conditions":760,"interventions":761},[97],[259],[119,239],{"nctId":262,"briefTitle":263,"status":111,"phases":763,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":764,"interventions":765},[97],[270,271],[119,237,226,239],{"trials":767,"activeCount":105},[],{"trials":769,"activeCount":105},[],{"intervention":412,"totalTrials":722,"cells":771},{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":792,"PHASE3":794,"PHASE4":804,"NA":806},{"trials":773,"activeCount":105},[],{"trials":775,"activeCount":146,"soonestReadout":91},[776,788],{"nctId":777,"briefTitle":778,"status":123,"phases":779,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":783,"interventions":786},"NCT03401385","First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)",[95],"2027-01-01","2018-01-31",890,[784,785,36],"Hormone Receptor Positive Breast Cancer","Triple Negative Breast Cancer",[412,787],"Steroid Containing Mouthwash",{"nctId":89,"briefTitle":90,"status":123,"phases":789,"primaryCompletion":91,"completion":651,"start":652,"enrollment":653,"conditions":790,"interventions":791},[95],[655],[92,657,413,414],{"trials":793,"activeCount":105},[],{"trials":795,"activeCount":146,"soonestReadout":423},[796,800],{"nctId":403,"briefTitle":404,"status":123,"phases":797,"primaryCompletion":406,"completion":406,"start":407,"enrollment":408,"conditions":798,"interventions":799},[97],[410],[412,132,238,413,414],{"nctId":420,"briefTitle":421,"status":111,"phases":801,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":802,"interventions":803},[97],[410],[412,132],{"trials":805,"activeCount":105},[],{"trials":807,"activeCount":105},[808],{"nctId":809,"briefTitle":810,"status":811,"phases":812,"conditions":813,"interventions":816},"NCT06279728","Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients","APPROVED_FOR_MARKETING",[],[814,815],"EGFRm Advanced Non-Small Cell Lung Cancer","EGFRm Metastatic Non-Small Cell Lung Cancer",[92],{"intervention":742,"totalTrials":818,"cells":819},14,{"EARLY_PHASE1":820,"PHASE1":834,"PHASE2":910,"PHASE3":935,"PHASE4":957,"NA":959},{"trials":821,"activeCount":105},[822],{"nctId":823,"briefTitle":824,"status":136,"phases":825,"primaryCompletion":826,"completion":826,"start":827,"enrollment":22,"conditions":828,"interventions":832},"NCT04459585","A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants",[94],"2020-10-20","2020-08-28",[829,830,831,742],"Healthy Subjects","Drug-drug Interaction","Pharmacokinetics",[833,742],"Dabigatran Etexilate Mesylate",{"trials":835,"activeCount":395,"soonestReadout":887},[836,845,854,863,874,883,891,901],{"nctId":837,"briefTitle":838,"status":136,"phases":839,"primaryCompletion":840,"completion":840,"start":841,"enrollment":435,"conditions":842,"interventions":844},"NCT03723681","Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)",[95],"2022-03-03","2018-11-05",[843],"Acute Myeloid Leukemia (AML)",[742],{"nctId":846,"briefTitle":847,"status":136,"phases":848,"primaryCompletion":849,"completion":849,"start":850,"enrollment":851,"conditions":852,"interventions":853},"NCT06772246","A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate",[95],"2025-06-12","2024-10-24",70,[829],[742],{"nctId":855,"briefTitle":856,"status":136,"phases":857,"primaryCompletion":138,"completion":138,"start":858,"enrollment":37,"conditions":859,"interventions":862},"NCT04473664","A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment",[95],"2020-09-22",[860,861],"Hepatic Impairment","Moderate Impaired Hepatic Function",[742],{"nctId":864,"briefTitle":865,"status":136,"phases":866,"primaryCompletion":867,"completion":867,"start":868,"enrollment":435,"conditions":869,"interventions":870},"NCT02834390","Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)",[95],"2017-10-19","2016-08-12",[752],[742,871,872,873],"Cytarabine","Idarubicin","Daunorubicin",{"nctId":875,"briefTitle":876,"status":175,"phases":877,"primaryCompletion":878,"completion":878,"start":879,"enrollment":639,"conditions":880,"interventions":881},"NCT03552029","Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)",[95],"2021-04-01","2018-12-12",[752],[742,882,882],"Milademetan",{"nctId":884,"briefTitle":885,"status":111,"phases":886,"primaryCompletion":887,"completion":887,"start":888,"enrollment":37,"conditions":889,"interventions":890},"NCT06740799","Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment",[95],"2026-10-31","2024-09-30",[860],[742],{"nctId":892,"briefTitle":893,"status":136,"phases":894,"primaryCompletion":895,"completion":895,"start":896,"enrollment":897,"conditions":898,"interventions":899},"NCT04459598","A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants",[95],"2020-10-14","2020-08-19",32,[829,830,831,742],[900,742],"Efavirenz",{"nctId":902,"briefTitle":903,"status":136,"phases":904,"primaryCompletion":905,"completion":905,"start":906,"enrollment":897,"conditions":907,"interventions":908},"NCT06740825","Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects",[95],"2024-12-09","2024-10-29",[829],[742,909],"Rufinamide",{"trials":911,"activeCount":395,"soonestReadout":916},[912,924],{"nctId":913,"briefTitle":914,"status":123,"phases":915,"primaryCompletion":916,"completion":916,"start":917,"enrollment":918,"conditions":919,"interventions":920},"NCT03793478","Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood",[95,96],"2027-05-01","2018-08-15",65,[752],[742,921,871,922,923],"Fludarabine","Intrathecal (IT) triple chemotherapy prophylaxis","Etoposide",{"nctId":925,"briefTitle":926,"status":136,"phases":927,"primaryCompletion":928,"completion":929,"start":930,"enrollment":931,"conditions":932,"interventions":934},"NCT02984995","Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3\u002FITD) Mutation",[96],"2018-03-28","2018-09-14","2016-12-08",37,[933],"Leukemia, Myeloid, Acute",[742],{"trials":936,"activeCount":395,"soonestReadout":736},[937,941,945],{"nctId":733,"briefTitle":734,"status":111,"phases":938,"primaryCompletion":736,"completion":736,"start":737,"enrollment":738,"conditions":939,"interventions":940},[97],[740],[742,239],{"nctId":744,"briefTitle":745,"status":136,"phases":942,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":943,"interventions":944},[97],[752,740],[239,742],{"nctId":946,"briefTitle":947,"status":136,"phases":948,"primaryCompletion":949,"completion":950,"start":951,"enrollment":952,"conditions":953,"interventions":955},"NCT02039726","(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive",[97],"2018-02-22","2020-09-08","2014-05",367,[954],"AML",[742,956],"Salvage Chemotherapy",{"trials":958,"activeCount":105},[],{"trials":960,"activeCount":105},[],{"intervention":414,"totalTrials":722,"cells":962},{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":975,"PHASE3":981,"PHASE4":991,"NA":993},{"trials":964,"activeCount":105},[],{"trials":966,"activeCount":395,"soonestReadout":91},[967,971],{"nctId":89,"briefTitle":90,"status":123,"phases":968,"primaryCompletion":91,"completion":651,"start":652,"enrollment":653,"conditions":969,"interventions":970},[95],[655],[92,657,413,414],{"nctId":659,"briefTitle":660,"status":136,"phases":972,"primaryCompletion":662,"completion":663,"start":664,"enrollment":32,"conditions":973,"interventions":974},[95],[379],[667,668,414,413],{"trials":976,"activeCount":105},[977],{"nctId":676,"briefTitle":677,"status":175,"phases":978,"primaryCompletion":679,"completion":680,"start":681,"enrollment":682,"conditions":979,"interventions":980},[96],[684],[667,668,414,413],{"trials":982,"activeCount":146,"soonestReadout":406},[983,987],{"nctId":403,"briefTitle":404,"status":123,"phases":984,"primaryCompletion":406,"completion":406,"start":407,"enrollment":408,"conditions":985,"interventions":986},[97],[410],[412,132,238,413,414],{"nctId":705,"briefTitle":706,"status":111,"phases":988,"primaryCompletion":708,"completion":709,"start":710,"enrollment":711,"conditions":989,"interventions":990},[96,97],[713,714],[716,413,414,248],{"trials":992,"activeCount":105},[],{"trials":994,"activeCount":105},[],{"intervention":996,"totalTrials":997,"cells":998},"T-DXd",3,{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1021,"PHASE3":1023,"PHASE4":1036,"NA":1038},{"trials":1000,"activeCount":105},[],{"trials":1002,"activeCount":146,"soonestReadout":1007},[1003,1012],{"nctId":1004,"briefTitle":1005,"status":123,"phases":1006,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":376,"conditions":1009,"interventions":1010},"NCT05765851","A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors",[95],"2026-06-30","2023-05-30",[360,44],[1011,996],"DS-1103a",{"nctId":1013,"briefTitle":1014,"status":111,"phases":1015,"primaryCompletion":189,"completion":189,"start":1016,"enrollment":1017,"conditions":1018,"interventions":1019},"NCT06244485","A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors",[95],"2024-02-16",210,[360],[1020,996,716],"Valemetostat tosylate",{"trials":1022,"activeCount":105},[],{"trials":1024,"activeCount":395,"soonestReadout":1029},[1025],{"nctId":1026,"briefTitle":1027,"status":111,"phases":1028,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":1032,"conditions":1033,"interventions":1035},"NCT06174987","A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)",[97],"2026-08-03","2028-01-17","2024-01-05",50,[311,1034],"Metastatic Cancer",[996],{"trials":1037,"activeCount":105},[],{"trials":1039,"activeCount":105},[],{"intervention":60,"totalTrials":284,"cells":1041},{"EARLY_PHASE1":1042,"PHASE1":1053,"PHASE2":1086,"PHASE3":1096,"PHASE4":1117,"NA":1126},{"trials":1043,"activeCount":105},[1044],{"nctId":1045,"briefTitle":1046,"status":136,"phases":1047,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":550,"conditions":1050,"interventions":1052},"NCT04223635","Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants",[94],"2020-10-02","2020-01-07",[1051],"Moderate Hepatic Impairment",[60],{"trials":1054,"activeCount":105},[1055,1067,1077],{"nctId":1056,"briefTitle":1057,"status":136,"phases":1058,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":897,"conditions":1062,"interventions":1064},"NCT03291288","Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)",[95],"2018-09-26","2021-04-16","2018-02-26",[1063],"Drug Interaction Potential",[1065,1066,60],"Tolbutamide","Midazolam",{"nctId":1068,"briefTitle":1069,"status":136,"phases":1070,"primaryCompletion":1071,"completion":1071,"start":1072,"enrollment":550,"conditions":1073,"interventions":1075},"NCT03138759","Effect of Probenecid on Pexidartinib Pharmacokinetics",[95],"2017-03-30","2017-02-27",[1074],"Pharmacokinetics in Healthy Volunteers",[60,1076],"Probenecid",{"nctId":1078,"briefTitle":1079,"status":136,"phases":1080,"primaryCompletion":1081,"completion":1082,"start":663,"enrollment":37,"conditions":1083,"interventions":1085},"NCT02734433","Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors",[95],"2017-06-13","2021-05-28",[1084],"Advanced Solid Tumors",[60],{"trials":1087,"activeCount":395,"soonestReadout":82},[1088],{"nctId":80,"briefTitle":81,"status":123,"phases":1089,"primaryCompletion":82,"completion":1090,"start":1091,"enrollment":1092,"conditions":1093,"interventions":1095},[96],"2026-05-31","2021-03-15",9,[1094],"Tenosynovial Giant Cell Tumor",[60],{"trials":1097,"activeCount":395,"soonestReadout":59},[1098,1105],{"nctId":57,"briefTitle":58,"status":123,"phases":1099,"primaryCompletion":59,"completion":1100,"start":1101,"enrollment":1102,"conditions":1103,"interventions":1104},[97],"2026-02-28","2020-09-25",40,[1094],[60],{"nctId":1106,"briefTitle":1107,"status":136,"phases":1108,"primaryCompletion":1109,"completion":1110,"start":1111,"enrollment":1112,"conditions":1113,"interventions":1116},"NCT02371369","Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)",[97],"2017-03-27","2021-04-30","2015-05-11",120,[1114,1115,1094],"Pigmented Villonodular Synovitis","Giant Cell Tumors of the Tendon Sheath",[60],{"trials":1118,"activeCount":105},[1119],{"nctId":1120,"briefTitle":1121,"status":136,"phases":1122,"primaryCompletion":1123,"completion":1123,"start":826,"enrollment":897,"conditions":1124,"interventions":1125},"NCT04526704","Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib",[98],"2023-07-07",[1094],[60],{"trials":1127,"activeCount":105},[],{"intervention":69,"totalTrials":344,"cells":1129},{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1164,"PHASE4":1179,"NA":1181},{"trials":1131,"activeCount":105},[],{"trials":1133,"activeCount":105},[],{"trials":1135,"activeCount":395,"soonestReadout":68},[1136,1146,1155],{"nctId":1137,"briefTitle":1138,"status":136,"phases":1139,"primaryCompletion":1140,"completion":1141,"start":1142,"enrollment":1143,"conditions":1144,"interventions":1145},"NCT02980341","Phase I\u002FII Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer",[95,96],"2021-08-16","2023-09-07","2016-11-28",182,[341],[69],{"nctId":1147,"briefTitle":1148,"status":175,"phases":1149,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":1102,"conditions":1152,"interventions":1154},"NCT04479436","A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer",[96],"2022-02-03","2020-09-14",[1153],"Metastatic Colorectal Cancer",[69],{"nctId":66,"briefTitle":67,"status":123,"phases":1156,"primaryCompletion":68,"completion":1157,"start":1158,"enrollment":1159,"conditions":1160,"interventions":1163},[96],"2026-07-03","2021-02-02",277,[1161,1162],"Non-Small Cell Lung Cancer Metastatic","Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor",[69,69],{"trials":1165,"activeCount":395,"soonestReadout":1170},[1166],{"nctId":1167,"briefTitle":1168,"status":123,"phases":1169,"primaryCompletion":1170,"completion":1007,"start":1171,"enrollment":1172,"conditions":1173,"interventions":1177},"NCT05338970","HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy",[97],"2024-05-31","2022-07-08",586,[1174,1175,1176],"Nonsquamous Non-small Cell Lung Cancer","EGFR L858R","EGFR Exon 19 Deletion",[69,1178],"Platinum-based chemotherapy",{"trials":1180,"activeCount":105},[],{"trials":1182,"activeCount":105},[],{"intervention":511,"totalTrials":997,"cells":1184},{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1200,"PHASE3":1202,"PHASE4":1219,"NA":1221},{"trials":1186,"activeCount":105},[],{"trials":1188,"activeCount":105},[1189],{"nctId":1190,"briefTitle":1191,"status":1192,"phases":1193,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":105,"conditions":1197,"interventions":1198},"NCT01245543","Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors","WITHDRAWN",[95],"2013-03","2013-06","2010-11",[541],[1199,511],"AC480IV",{"trials":1201,"activeCount":105},[],{"trials":1203,"activeCount":146,"soonestReadout":1208},[1204,1215],{"nctId":1205,"briefTitle":1206,"status":123,"phases":1207,"primaryCompletion":1208,"completion":1209,"start":1210,"enrollment":1211,"conditions":1212,"interventions":1213},"NCT04656652","Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)",[97],"2024-05-10","2027-02-15","2020-12-21",605,[36],[1214,511],"DS-1062a",{"nctId":502,"briefTitle":503,"status":111,"phases":1216,"primaryCompletion":265,"completion":505,"start":506,"enrollment":507,"conditions":1217,"interventions":1218},[97],[509],[434,511,249,512],{"trials":1220,"activeCount":105},[],{"trials":1222,"activeCount":105},[],{"intervention":248,"totalTrials":997,"cells":1224},{"EARLY_PHASE1":1225,"PHASE1":1227,"PHASE2":1229,"PHASE3":1241,"PHASE4":1251,"NA":1253},{"trials":1226,"activeCount":105},[],{"trials":1228,"activeCount":105},[],{"trials":1230,"activeCount":105},[1231],{"nctId":1232,"briefTitle":1233,"status":136,"phases":1234,"primaryCompletion":1235,"completion":1235,"start":1236,"enrollment":918,"conditions":1237,"interventions":1239},"NCT00521404","Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer",[96],"2010-08-20","2007-08-15",[1238],"Pancreatic Cancer",[597,1240],"gemcitabine",{"trials":1242,"activeCount":146,"soonestReadout":64},[1243,1247],{"nctId":62,"briefTitle":63,"status":123,"phases":1244,"primaryCompletion":64,"completion":242,"start":243,"enrollment":244,"conditions":1245,"interventions":1246},[97],[44],[55,224,247,248,249,250],{"nctId":705,"briefTitle":706,"status":111,"phases":1248,"primaryCompletion":708,"completion":709,"start":710,"enrollment":711,"conditions":1249,"interventions":1250},[96,97],[713,714],[716,413,414,248],{"trials":1252,"activeCount":105},[],{"trials":1254,"activeCount":105},[],{"intervention":238,"totalTrials":146,"cells":1256},{"EARLY_PHASE1":1257,"PHASE1":1259,"PHASE2":1261,"PHASE3":1263,"PHASE4":1273,"NA":1275},{"trials":1258,"activeCount":105},[],{"trials":1260,"activeCount":105},[],{"trials":1262,"activeCount":105},[],{"trials":1264,"activeCount":146,"soonestReadout":406},[1265,1269],{"nctId":228,"briefTitle":229,"status":111,"phases":1266,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":1267,"interventions":1268},[97],[36],[119,237,238,239],{"nctId":403,"briefTitle":404,"status":123,"phases":1270,"primaryCompletion":406,"completion":406,"start":407,"enrollment":408,"conditions":1271,"interventions":1272},[97],[410],[412,132,238,413,414],{"trials":1274,"activeCount":105},[],{"trials":1276,"activeCount":105},[],{"intervention":498,"totalTrials":146,"cells":1278},{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1285,"PHASE4":1295,"NA":1297},{"trials":1280,"activeCount":105},[],{"trials":1282,"activeCount":105},[],{"trials":1284,"activeCount":105},[],{"trials":1286,"activeCount":146,"soonestReadout":468},[1287,1291],{"nctId":489,"briefTitle":490,"status":111,"phases":1288,"primaryCompletion":468,"completion":492,"start":493,"enrollment":494,"conditions":1289,"interventions":1290},[97],[496],[434,498,499,500],{"nctId":624,"briefTitle":625,"status":111,"phases":1292,"primaryCompletion":423,"completion":388,"start":627,"enrollment":628,"conditions":1293,"interventions":1294},[96,97],[630],[632,249,498,633],{"trials":1296,"activeCount":105},[],{"trials":1298,"activeCount":105},[],{"intervention":716,"totalTrials":146,"cells":1300},{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1309,"PHASE3":1311,"PHASE4":1317,"NA":1319},{"trials":1302,"activeCount":105},[],{"trials":1304,"activeCount":395,"soonestReadout":189},[1305],{"nctId":1013,"briefTitle":1014,"status":111,"phases":1306,"primaryCompletion":189,"completion":189,"start":1016,"enrollment":1017,"conditions":1307,"interventions":1308},[95],[360],[1020,996,716],{"trials":1310,"activeCount":105},[],{"trials":1312,"activeCount":395,"soonestReadout":708},[1313],{"nctId":705,"briefTitle":706,"status":111,"phases":1314,"primaryCompletion":708,"completion":709,"start":710,"enrollment":711,"conditions":1315,"interventions":1316},[96,97],[713,714],[716,413,414,248],{"trials":1318,"activeCount":105},[],{"trials":1320,"activeCount":105},[],{"intervention":1322,"totalTrials":435,"cells":1323},"Ezetimibe",{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1364,"PHASE3":1366,"PHASE4":1380,"NA":1393},{"trials":1325,"activeCount":105},[],{"trials":1327,"activeCount":105},[1328,1339,1347,1356],{"nctId":1329,"briefTitle":1330,"status":136,"phases":1331,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":1334,"conditions":1335,"interventions":1336},"NCT07268625","Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid \u002F Ezetimibe, and Atorvastatin",[95],"2026-02-24","2025-12-09",58,[829],[1337,1322,1338],"Bempedoic acid","Atorvastatin",{"nctId":1340,"briefTitle":1341,"status":136,"phases":1342,"primaryCompletion":1343,"completion":1343,"start":1344,"enrollment":1334,"conditions":1345,"interventions":1346},"NCT07235189","A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin",[95],"2026-01-28","2025-10-28",[829],[1337,1322,1338],{"nctId":1348,"briefTitle":1349,"status":136,"phases":1350,"primaryCompletion":1351,"completion":1351,"start":1352,"enrollment":1334,"conditions":1353,"interventions":1354},"NCT07182383","Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin",[95],"2025-11-24","2025-09-29",[829],[1337,1322,1355],"Rosuvastatin",{"nctId":1357,"briefTitle":1358,"status":136,"phases":1359,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":1334,"conditions":1362,"interventions":1363},"NCT07201545","Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid \u002F Ezetimibe and Rosuvastatin",[95],"2025-12-10","2025-10-07",[829],[1337,1322,1355],{"trials":1365,"activeCount":105},[],{"trials":1367,"activeCount":395,"soonestReadout":265},[1368],{"nctId":1369,"briefTitle":1370,"status":1371,"phases":1372,"primaryCompletion":265,"completion":1373,"start":1374,"enrollment":1375,"conditions":1376,"interventions":1379},"NCT07474649","A Study of Bempedoic Acid\u002FEzetimibe\u002FHigh-intensity Statin in Patients Without Cardiovascular Events","NOT_YET_RECRUITING",[97],"2028-10-02","2026-06-01",103,[1377,1378,42],"Coronary Atherosclerosis","Mixed Dyslipidemia",[1337,1322,1355,1338],{"trials":1381,"activeCount":105},[1382],{"nctId":1383,"briefTitle":1384,"status":136,"phases":1385,"completion":1386,"start":1387,"enrollment":1388,"conditions":1389,"interventions":1390},"NCT00185107","Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol",[98],"2005-10","2005-03",45,[42],[1391,1322,1392],"Colesevelam Hydrochloride","Simvastatin",{"trials":1394,"activeCount":395,"soonestReadout":326},[1395],{"nctId":1396,"briefTitle":1397,"status":111,"phases":1398,"primaryCompletion":326,"completion":1399,"start":1400,"enrollment":1401,"conditions":1402,"interventions":1404},"NCT06686615","A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia",[],"2028-01-31","2025-02-12",2000,[1403,1378],"Primary Hypercholesterolemiia",[1337,1322,1355,1338],{"intervention":1337,"totalTrials":1406,"cells":1407},6,{"EARLY_PHASE1":1408,"PHASE1":1410,"PHASE2":1428,"PHASE3":1430,"PHASE4":1436,"NA":1438},{"trials":1409,"activeCount":105},[],{"trials":1411,"activeCount":105},[1412,1416,1420,1424],{"nctId":1329,"briefTitle":1330,"status":136,"phases":1413,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":1334,"conditions":1414,"interventions":1415},[95],[829],[1337,1322,1338],{"nctId":1340,"briefTitle":1341,"status":136,"phases":1417,"primaryCompletion":1343,"completion":1343,"start":1344,"enrollment":1334,"conditions":1418,"interventions":1419},[95],[829],[1337,1322,1338],{"nctId":1348,"briefTitle":1349,"status":136,"phases":1421,"primaryCompletion":1351,"completion":1351,"start":1352,"enrollment":1334,"conditions":1422,"interventions":1423},[95],[829],[1337,1322,1355],{"nctId":1357,"briefTitle":1358,"status":136,"phases":1425,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":1334,"conditions":1426,"interventions":1427},[95],[829],[1337,1322,1355],{"trials":1429,"activeCount":105},[],{"trials":1431,"activeCount":395,"soonestReadout":265},[1432],{"nctId":1369,"briefTitle":1370,"status":1371,"phases":1433,"primaryCompletion":265,"completion":1373,"start":1374,"enrollment":1375,"conditions":1434,"interventions":1435},[97],[1377,1378,42],[1337,1322,1355,1338],{"trials":1437,"activeCount":105},[],{"trials":1439,"activeCount":395,"soonestReadout":326},[1440],{"nctId":1396,"briefTitle":1397,"status":111,"phases":1441,"primaryCompletion":326,"completion":1399,"start":1400,"enrollment":1401,"conditions":1442,"interventions":1443},[],[1403,1378],[1337,1322,1355,1338],{"intervention":1355,"totalTrials":722,"cells":1445},{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1468,"PHASE3":1470,"PHASE4":1476,"NA":1478},{"trials":1447,"activeCount":105},[],{"trials":1449,"activeCount":105},[1450,1460,1464],{"nctId":1451,"briefTitle":1452,"status":136,"phases":1453,"primaryCompletion":1454,"completion":1454,"start":1455,"enrollment":604,"conditions":1456,"interventions":1458},"NCT03699774","Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy Volunteers",[95],"2015-07-06","2015-05-12",[1457],"Drug Pharmacokinetics in Healthy Volunteers",[1459,1355],"DS-8500a",{"nctId":1348,"briefTitle":1349,"status":136,"phases":1461,"primaryCompletion":1351,"completion":1351,"start":1352,"enrollment":1334,"conditions":1462,"interventions":1463},[95],[829],[1337,1322,1355],{"nctId":1357,"briefTitle":1358,"status":136,"phases":1465,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":1334,"conditions":1466,"interventions":1467},[95],[829],[1337,1322,1355],{"trials":1469,"activeCount":105},[],{"trials":1471,"activeCount":395,"soonestReadout":265},[1472],{"nctId":1369,"briefTitle":1370,"status":1371,"phases":1473,"primaryCompletion":265,"completion":1373,"start":1374,"enrollment":1375,"conditions":1474,"interventions":1475},[97],[1377,1378,42],[1337,1322,1355,1338],{"trials":1477,"activeCount":105},[],{"trials":1479,"activeCount":395,"soonestReadout":326},[1480],{"nctId":1396,"briefTitle":1397,"status":111,"phases":1481,"primaryCompletion":326,"completion":1399,"start":1400,"enrollment":1401,"conditions":1482,"interventions":1483},[],[1403,1378],[1337,1322,1355,1338],{"intervention":1338,"totalTrials":344,"cells":1485},{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1498,"PHASE3":1500,"PHASE4":1506,"NA":1508},{"trials":1487,"activeCount":105},[],{"trials":1489,"activeCount":105},[1490,1494],{"nctId":1329,"briefTitle":1330,"status":136,"phases":1491,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":1334,"conditions":1492,"interventions":1493},[95],[829],[1337,1322,1338],{"nctId":1340,"briefTitle":1341,"status":136,"phases":1495,"primaryCompletion":1343,"completion":1343,"start":1344,"enrollment":1334,"conditions":1496,"interventions":1497},[95],[829],[1337,1322,1338],{"trials":1499,"activeCount":105},[],{"trials":1501,"activeCount":395,"soonestReadout":265},[1502],{"nctId":1369,"briefTitle":1370,"status":1371,"phases":1503,"primaryCompletion":265,"completion":1373,"start":1374,"enrollment":1375,"conditions":1504,"interventions":1505},[97],[1377,1378,42],[1337,1322,1355,1338],{"trials":1507,"activeCount":105},[],{"trials":1509,"activeCount":395,"soonestReadout":326},[1510],{"nctId":1396,"briefTitle":1397,"status":111,"phases":1511,"primaryCompletion":326,"completion":1399,"start":1400,"enrollment":1401,"conditions":1512,"interventions":1513},[],[1403,1378],[1337,1322,1355,1338],{"intervention":1515,"totalTrials":284,"cells":1516},"DS-8201a",{"EARLY_PHASE1":1517,"PHASE1":1519,"PHASE2":1563,"PHASE3":1597,"PHASE4":1612,"NA":1614},{"trials":1518,"activeCount":105},[],{"trials":1520,"activeCount":105},[1521,1531,1541,1552],{"nctId":1522,"briefTitle":1523,"status":136,"phases":1524,"primaryCompletion":929,"completion":1525,"start":1526,"enrollment":37,"conditions":1527,"interventions":1530},"NCT03368196","DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein",[95],"2022-09-28","2018-04-02",[1528,1529],"Adenocarcinoma, Gastric","Neoplasm, Breast",[1515],{"nctId":1532,"briefTitle":1533,"status":136,"phases":1534,"primaryCompletion":1535,"completion":1536,"start":1537,"enrollment":1538,"conditions":1539,"interventions":1540},"NCT02564900","Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors",[95],"2019-02-01","2023-12-22","2015-09-01",292,[1084],[1515,1515,1515],{"nctId":1542,"briefTitle":1543,"status":136,"phases":1544,"primaryCompletion":1059,"completion":1545,"start":1546,"enrollment":1102,"conditions":1547,"interventions":1549},"NCT03383692","Study of DS-8201a for Participants With Advanced Solid Malignant Tumors",[95],"2023-09-11","2018-01-12",[1548],"Neoplasm Metastasis",[1515,1550,1551],"Ritonavir","Itraconazole",{"nctId":1553,"briefTitle":1554,"status":136,"phases":1555,"primaryCompletion":1556,"completion":1557,"start":1558,"enrollment":1559,"conditions":1560,"interventions":1562},"NCT03366428","Phase 1 Study to Evaluate the Effect of DS-8201a on the QT\u002FQTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer",[95],"2018-12-05","2021-02-19","2017-12-26",51,[1561],"Malignant Neoplasm of Breast",[1515],{"trials":1564,"activeCount":105},[1565,1575,1585],{"nctId":1566,"briefTitle":1567,"status":175,"phases":1568,"primaryCompletion":1569,"completion":1570,"start":1571,"enrollment":1572,"conditions":1573,"interventions":1574},"NCT03248492","A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)",[96],"2019-03-21","2024-05-06","2017-08-25",253,[44],[1515],{"nctId":1576,"briefTitle":1577,"status":136,"phases":1578,"primaryCompletion":1579,"completion":1580,"start":1581,"enrollment":141,"conditions":1582,"interventions":1584},"NCT03384940","DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)",[96],"2019-08-09","2020-11-10","2018-02-23",[1583],"Colorectal Neoplasm",[1515],{"nctId":1586,"briefTitle":1587,"status":136,"phases":1588,"primaryCompletion":1589,"completion":1590,"start":1591,"enrollment":1592,"conditions":1593,"interventions":1595},"NCT03329690","DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]",[96],"2019-11-08","2020-12-11","2017-11-02",233,[1594],"Neoplasm, Gastrointestinal",[1515,1596],"Physician's Choice",{"trials":1598,"activeCount":395,"soonestReadout":1603},[1599],{"nctId":1600,"briefTitle":1601,"status":123,"phases":1602,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":1607,"interventions":1610},"NCT04622319","A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)",[97],"2025-07-02","2028-06-20","2020-12-04",1600,[1608,1609],"HER2-Positive Primary Breast Cancer","Residual Invasive Breast Cancer",[1515,1611],"T-DM1",{"trials":1613,"activeCount":105},[],{"trials":1615,"activeCount":105},[],{"intervention":226,"totalTrials":997,"cells":1617},{"EARLY_PHASE1":1618,"PHASE1":1620,"PHASE2":1622,"PHASE3":1628,"PHASE4":1638,"NA":1640},{"trials":1619,"activeCount":105},[],{"trials":1621,"activeCount":105},[],{"trials":1623,"activeCount":105},[1624],{"nctId":558,"briefTitle":559,"status":175,"phases":1625,"primaryCompletion":561,"completion":561,"start":562,"enrollment":563,"conditions":1626,"interventions":1627},[95,96],[341],[566,226,249,566,226,249],{"trials":1629,"activeCount":395,"soonestReadout":265},[1630,1634],{"nctId":215,"briefTitle":216,"status":136,"phases":1631,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":1632,"interventions":1633},[97],[44],[55,224,225,226],{"nctId":262,"briefTitle":263,"status":111,"phases":1635,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":1636,"interventions":1637},[97],[270,271],[119,237,226,239],{"trials":1639,"activeCount":105},[],{"trials":1641,"activeCount":105},[],{"intervention":224,"totalTrials":997,"cells":1643},{"EARLY_PHASE1":1644,"PHASE1":1646,"PHASE2":1659,"PHASE3":1661,"PHASE4":1671,"NA":1673},{"trials":1645,"activeCount":105},[],{"trials":1647,"activeCount":105},[1648],{"nctId":1649,"briefTitle":1650,"status":136,"phases":1651,"primaryCompletion":1652,"completion":1652,"start":1653,"conditions":1654,"interventions":1656},"NCT00077077","DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors",[95],"2006-01","2004-02",[1655],"Unspecified Adult Solid Tumor, Protocol Specific",[1657,1658],"DJ-927","capecitabine",{"trials":1660,"activeCount":105},[],{"trials":1662,"activeCount":395,"soonestReadout":64},[1663,1667],{"nctId":215,"briefTitle":216,"status":136,"phases":1664,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":1665,"interventions":1666},[97],[44],[55,224,225,226],{"nctId":62,"briefTitle":63,"status":123,"phases":1668,"primaryCompletion":64,"completion":242,"start":243,"enrollment":244,"conditions":1669,"interventions":1670},[97],[44],[55,224,247,248,249,250],{"trials":1672,"activeCount":105},[],{"trials":1674,"activeCount":105},[],{"intervention":1214,"totalTrials":146,"cells":1676},{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1681,"PHASE3":1691,"PHASE4":1697,"NA":1699},{"trials":1678,"activeCount":105},[],{"trials":1680,"activeCount":105},[],{"trials":1682,"activeCount":105},[1683],{"nctId":1684,"briefTitle":1685,"status":136,"phases":1686,"primaryCompletion":78,"completion":1687,"start":1688,"enrollment":390,"conditions":1689,"interventions":1690},"NCT04484142","Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)",[96],"2026-02-04","2021-03-30",[36],[1214],{"trials":1692,"activeCount":395,"soonestReadout":1208},[1693],{"nctId":1205,"briefTitle":1206,"status":123,"phases":1694,"primaryCompletion":1208,"completion":1209,"start":1210,"enrollment":1211,"conditions":1695,"interventions":1696},[97],[36],[1214,511],{"trials":1698,"activeCount":105},[],{"trials":1700,"activeCount":105},[],{"intervention":196,"totalTrials":395,"cells":1702},{"EARLY_PHASE1":1703,"PHASE1":1705,"PHASE2":1707,"PHASE3":1709,"PHASE4":1715,"NA":1717},{"trials":1704,"activeCount":105},[],{"trials":1706,"activeCount":105},[],{"trials":1708,"activeCount":105},[],{"trials":1710,"activeCount":395,"soonestReadout":189},[1711],{"nctId":186,"briefTitle":187,"status":111,"phases":1712,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":1713,"interventions":1714},[97],[194],[119,196],{"trials":1716,"activeCount":105},[],{"trials":1718,"activeCount":105},[],{"intervention":213,"totalTrials":395,"cells":1720},{"EARLY_PHASE1":1721,"PHASE1":1723,"PHASE2":1725,"PHASE3":1727,"PHASE4":1733,"NA":1735},{"trials":1722,"activeCount":105},[],{"trials":1724,"activeCount":105},[],{"trials":1726,"activeCount":105},[],{"trials":1728,"activeCount":395,"soonestReadout":54},[1729],{"nctId":52,"briefTitle":53,"status":123,"phases":1730,"primaryCompletion":54,"completion":208,"start":209,"enrollment":210,"conditions":1731,"interventions":1732},[97],[44],[55,213],{"trials":1734,"activeCount":105},[],{"trials":1736,"activeCount":105},[],{"intervention":499,"totalTrials":395,"cells":1738},{"EARLY_PHASE1":1739,"PHASE1":1741,"PHASE2":1743,"PHASE3":1745,"PHASE4":1751,"NA":1753},{"trials":1740,"activeCount":105},[],{"trials":1742,"activeCount":105},[],{"trials":1744,"activeCount":105},[],{"trials":1746,"activeCount":395,"soonestReadout":468},[1747],{"nctId":489,"briefTitle":490,"status":111,"phases":1748,"primaryCompletion":468,"completion":492,"start":493,"enrollment":494,"conditions":1749,"interventions":1750},[97],[496],[434,498,499,500],{"trials":1752,"activeCount":105},[],{"trials":1754,"activeCount":105},[],{"intervention":500,"totalTrials":395,"cells":1756},{"EARLY_PHASE1":1757,"PHASE1":1759,"PHASE2":1761,"PHASE3":1763,"PHASE4":1769,"NA":1771},{"trials":1758,"activeCount":105},[],{"trials":1760,"activeCount":105},[],{"trials":1762,"activeCount":105},[],{"trials":1764,"activeCount":395,"soonestReadout":468},[1765],{"nctId":489,"briefTitle":490,"status":111,"phases":1766,"primaryCompletion":468,"completion":492,"start":493,"enrollment":494,"conditions":1767,"interventions":1768},[97],[496],[434,498,499,500],{"trials":1770,"activeCount":105},[],{"trials":1772,"activeCount":105},[],{"intervention":247,"totalTrials":395,"cells":1774},{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1779,"PHASE3":1781,"PHASE4":1787,"NA":1789},{"trials":1776,"activeCount":105},[],{"trials":1778,"activeCount":105},[],{"trials":1780,"activeCount":105},[],{"trials":1782,"activeCount":395,"soonestReadout":64},[1783],{"nctId":62,"briefTitle":63,"status":123,"phases":1784,"primaryCompletion":64,"completion":242,"start":243,"enrollment":244,"conditions":1785,"interventions":1786},[97],[44],[55,224,247,248,249,250],{"trials":1788,"activeCount":105},[],{"trials":1790,"activeCount":105},[],{"intervention":250,"totalTrials":395,"cells":1792},{"EARLY_PHASE1":1793,"PHASE1":1795,"PHASE2":1797,"PHASE3":1799,"PHASE4":1805,"NA":1807},{"trials":1794,"activeCount":105},[],{"trials":1796,"activeCount":105},[],{"trials":1798,"activeCount":105},[],{"trials":1800,"activeCount":395,"soonestReadout":64},[1801],{"nctId":62,"briefTitle":63,"status":123,"phases":1802,"primaryCompletion":64,"completion":242,"start":243,"enrollment":244,"conditions":1803,"interventions":1804},[97],[44],[55,224,247,248,249,250],{"trials":1806,"activeCount":105},[],{"trials":1808,"activeCount":105},[],{"intervention":512,"totalTrials":395,"cells":1810},{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1815,"PHASE3":1817,"PHASE4":1823,"NA":1825},{"trials":1812,"activeCount":105},[],{"trials":1814,"activeCount":105},[],{"trials":1816,"activeCount":105},[],{"trials":1818,"activeCount":395,"soonestReadout":265},[1819],{"nctId":502,"briefTitle":503,"status":111,"phases":1820,"primaryCompletion":265,"completion":505,"start":506,"enrollment":507,"conditions":1821,"interventions":1822},[97],[509],[434,511,249,512],{"trials":1824,"activeCount":105},[],{"trials":1826,"activeCount":105},[],{"intervention":283,"totalTrials":395,"cells":1828},{"EARLY_PHASE1":1829,"PHASE1":1831,"PHASE2":1833,"PHASE3":1835,"PHASE4":1841,"NA":1843},{"trials":1830,"activeCount":105},[],{"trials":1832,"activeCount":105},[],{"trials":1834,"activeCount":105},[],{"trials":1836,"activeCount":395,"soonestReadout":277},[1837],{"nctId":274,"briefTitle":275,"status":123,"phases":1838,"primaryCompletion":277,"completion":277,"start":54,"enrollment":278,"conditions":1839,"interventions":1840},[97],[280,281],[55,283,249],{"trials":1842,"activeCount":105},[],{"trials":1844,"activeCount":105},[],{"intervention":1611,"totalTrials":395,"cells":1846},{"EARLY_PHASE1":1847,"PHASE1":1849,"PHASE2":1851,"PHASE3":1853,"PHASE4":1859,"NA":1861},{"trials":1848,"activeCount":105},[],{"trials":1850,"activeCount":105},[],{"trials":1852,"activeCount":105},[],{"trials":1854,"activeCount":395,"soonestReadout":1603},[1855],{"nctId":1600,"briefTitle":1601,"status":123,"phases":1856,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":1857,"interventions":1858},[97],[1608,1609],[1515,1611],{"trials":1860,"activeCount":105},[],{"trials":1862,"activeCount":105},[],{"intervention":632,"totalTrials":395,"cells":1864},{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1871,"PHASE4":1877,"NA":1879},{"trials":1866,"activeCount":105},[],{"trials":1868,"activeCount":105},[],{"trials":1870,"activeCount":105},[],{"trials":1872,"activeCount":395,"soonestReadout":423},[1873],{"nctId":624,"briefTitle":625,"status":111,"phases":1874,"primaryCompletion":423,"completion":388,"start":627,"enrollment":628,"conditions":1875,"interventions":1876},[96,97],[630],[632,249,498,633],{"trials":1878,"activeCount":105},[],{"trials":1880,"activeCount":105},[],{"intervention":633,"totalTrials":395,"cells":1882},{"EARLY_PHASE1":1883,"PHASE1":1885,"PHASE2":1887,"PHASE3":1889,"PHASE4":1895,"NA":1897},{"trials":1884,"activeCount":105},[],{"trials":1886,"activeCount":105},[],{"trials":1888,"activeCount":105},[],{"trials":1890,"activeCount":395,"soonestReadout":423},[1891],{"nctId":624,"briefTitle":625,"status":111,"phases":1892,"primaryCompletion":423,"completion":388,"start":627,"enrollment":628,"conditions":1893,"interventions":1894},[96,97],[630],[632,249,498,633],{"trials":1896,"activeCount":105},[],{"trials":1898,"activeCount":105},[],{"intervention":1178,"totalTrials":395,"cells":1900},{"EARLY_PHASE1":1901,"PHASE1":1903,"PHASE2":1905,"PHASE3":1907,"PHASE4":1913,"NA":1915},{"trials":1902,"activeCount":105},[],{"trials":1904,"activeCount":105},[],{"trials":1906,"activeCount":105},[],{"trials":1908,"activeCount":395,"soonestReadout":1170},[1909],{"nctId":1167,"briefTitle":1168,"status":123,"phases":1910,"primaryCompletion":1170,"completion":1007,"start":1171,"enrollment":1172,"conditions":1911,"interventions":1912},[97],[1174,1175,1176],[69,1178],{"trials":1914,"activeCount":105},[],{"trials":1916,"activeCount":105},[],{"intervention":87,"totalTrials":344,"cells":1918},{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1927,"PHASE3":1953,"PHASE4":1955,"NA":1957},{"trials":1920,"activeCount":105},[],{"trials":1922,"activeCount":395,"soonestReadout":189},[1923],{"nctId":1013,"briefTitle":1014,"status":111,"phases":1924,"primaryCompletion":189,"completion":189,"start":1016,"enrollment":1017,"conditions":1925,"interventions":1926},[95],[360],[1020,996,716],{"trials":1928,"activeCount":146,"soonestReadout":86},[1929,1938,1949],{"nctId":84,"briefTitle":85,"status":123,"phases":1930,"primaryCompletion":86,"completion":1931,"start":1932,"enrollment":1933,"conditions":1934,"interventions":1937},[96],"2027-02-19","2021-06-03",155,[1935,1936],"Relapsed\u002FRefractory Peripheral T-Cell Lymphoma","Adult T Cell Leukemia\u002FLymphoma",[87],{"nctId":1939,"briefTitle":1940,"status":136,"phases":1941,"primaryCompletion":1942,"completion":1943,"start":1944,"enrollment":1945,"conditions":1946,"interventions":1948},"NCT04102150","Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia\u002FLymphoma",[96],"2021-04-24","2024-10-27","2019-11-21",25,[1947],"Adult T-cell Leukemia\u002FLymphoma",[87],{"nctId":384,"briefTitle":385,"status":111,"phases":1950,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":1951,"interventions":1952},[95,96],[36,392],[394,237],{"trials":1954,"activeCount":105},[],{"trials":1956,"activeCount":105},[],{"trials":1958,"activeCount":105},[],{"intervention":1960,"totalTrials":344,"cells":1961},"HER3-DXd",{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1986,"PHASE3":2003,"PHASE4":2005,"NA":2007},{"trials":1963,"activeCount":105},[],{"trials":1965,"activeCount":146,"soonestReadout":1970},[1966,1977],{"nctId":1967,"briefTitle":1968,"status":123,"phases":1969,"primaryCompletion":1970,"completion":468,"start":1971,"enrollment":1972,"conditions":1973,"interventions":1975},"NCT04676477","HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer",[95],"2025-01-31","2021-06-11",246,[1974],"Non-Small Cell Lung Cancer (NSCLC)",[1960,1960,1976,1976,1960,1960,1976],"Osimertinib",{"nctId":1978,"briefTitle":1979,"status":123,"phases":1980,"primaryCompletion":1981,"completion":651,"start":1982,"enrollment":1983,"conditions":1984,"interventions":1985},"NCT03260491","U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer",[95],"2026-03-31","2017-10-30",312,[1974],[1960,1960,1960],{"trials":1987,"activeCount":395,"soonestReadout":294},[1988],{"nctId":1989,"briefTitle":1990,"status":111,"phases":1991,"primaryCompletion":294,"completion":1992,"start":1993,"enrollment":426,"conditions":1994,"interventions":2002},"NCT06172478","A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors",[96],"2028-10-10","2024-02-26",[360,378,1995,270,1996,1997,259,714,1998,1999,2000,2001,392,44],"Head and Neck Cancer","Ovarian Carcinoma","Cervical Cancer","Esophageal Cancer","Pancreatic Carcinoma","Prostate Cancer","Non-small Cell Lung Cancer (NSCLC)",[1960],{"trials":2004,"activeCount":105},[],{"trials":2006,"activeCount":105},[],{"trials":2008,"activeCount":105},[2009],{"nctId":2010,"briefTitle":2011,"status":2012,"phases":2013,"conditions":2014,"interventions":2016},"NCT06099639","Medical Access Program for Patritumab Deruxtecan","NO_LONGER_AVAILABLE",[],[2015],"Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer",[1960],{"intervention":50,"totalTrials":146,"cells":2018},{"EARLY_PHASE1":2019,"PHASE1":2021,"PHASE2":2030,"PHASE3":2038,"PHASE4":2040,"NA":2042},{"trials":2020,"activeCount":105},[],{"trials":2022,"activeCount":395,"soonestReadout":49},[2023],{"nctId":47,"briefTitle":48,"status":123,"phases":2024,"primaryCompletion":49,"completion":277,"start":2025,"enrollment":2026,"conditions":2027,"interventions":2029},[95],"2017-01-19",47,[2028],"Glioma",[50],{"trials":2031,"activeCount":395,"soonestReadout":78},[2032],{"nctId":76,"briefTitle":77,"status":123,"phases":2033,"primaryCompletion":78,"completion":277,"start":2034,"enrollment":1945,"conditions":2035,"interventions":2037},[96],"2020-07-08",[2036],"WHO Grade II Glioma",[50],{"trials":2039,"activeCount":105},[],{"trials":2041,"activeCount":105},[],{"trials":2043,"activeCount":105},[],{"intervention":871,"totalTrials":997,"cells":2045},{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2065,"PHASE3":2071,"PHASE4":2073,"NA":2075},{"trials":2047,"activeCount":105},[],{"trials":2049,"activeCount":105},[2050,2054],{"nctId":864,"briefTitle":865,"status":136,"phases":2051,"primaryCompletion":867,"completion":867,"start":868,"enrollment":435,"conditions":2052,"interventions":2053},[95],[752],[742,871,872,873],{"nctId":2055,"briefTitle":2056,"status":136,"phases":2057,"primaryCompletion":2058,"completion":2058,"start":2059,"enrollment":585,"conditions":2060,"interventions":2061},"NCT01390337","A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)",[95],"2015-02","2011-10",[933],[2062,2063,2064],"AC220","daunorubicin","cytarabine",{"trials":2066,"activeCount":395,"soonestReadout":916},[2067],{"nctId":913,"briefTitle":914,"status":123,"phases":2068,"primaryCompletion":916,"completion":916,"start":917,"enrollment":918,"conditions":2069,"interventions":2070},[95,96],[752],[742,921,871,922,923],{"trials":2072,"activeCount":105},[],{"trials":2074,"activeCount":105},[],{"trials":2076,"activeCount":105},[],{"intervention":2078,"totalTrials":146,"cells":2079},"DS-5141b",{"EARLY_PHASE1":2080,"PHASE1":2082,"PHASE2":2084,"PHASE3":2102,"PHASE4":2104,"NA":2106},{"trials":2081,"activeCount":105},[],{"trials":2083,"activeCount":105},[],{"trials":2085,"activeCount":395,"soonestReadout":2098},[2086,2094],{"nctId":2087,"briefTitle":2088,"status":136,"phases":2089,"primaryCompletion":826,"completion":826,"start":2090,"enrollment":284,"conditions":2091,"interventions":2093},"NCT02667483","Study of DS-5141b in Patients With Duchenne Muscular Dystrophy",[95,96],"2015-10",[2092],"Duchenne Muscular Dystrophy",[2078],{"nctId":2095,"briefTitle":2096,"status":123,"phases":2097,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":284,"conditions":2100,"interventions":2101},"NCT04433234","Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy",[96],"2027-01-31","2020-06-30",[2092],[2078],{"trials":2103,"activeCount":105},[],{"trials":2105,"activeCount":105},[],{"trials":2107,"activeCount":105},[],{"intervention":921,"totalTrials":395,"cells":2109},{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2114,"PHASE3":2120,"PHASE4":2122,"NA":2124},{"trials":2111,"activeCount":105},[],{"trials":2113,"activeCount":105},[],{"trials":2115,"activeCount":395,"soonestReadout":916},[2116],{"nctId":913,"briefTitle":914,"status":123,"phases":2117,"primaryCompletion":916,"completion":916,"start":917,"enrollment":918,"conditions":2118,"interventions":2119},[95,96],[752],[742,921,871,922,923],{"trials":2121,"activeCount":105},[],{"trials":2123,"activeCount":105},[],{"trials":2125,"activeCount":105},[],{"intervention":922,"totalTrials":395,"cells":2127},{"EARLY_PHASE1":2128,"PHASE1":2130,"PHASE2":2132,"PHASE3":2138,"PHASE4":2140,"NA":2142},{"trials":2129,"activeCount":105},[],{"trials":2131,"activeCount":105},[],{"trials":2133,"activeCount":395,"soonestReadout":916},[2134],{"nctId":913,"briefTitle":914,"status":123,"phases":2135,"primaryCompletion":916,"completion":916,"start":917,"enrollment":918,"conditions":2136,"interventions":2137},[95,96],[752],[742,921,871,922,923],{"trials":2139,"activeCount":105},[],{"trials":2141,"activeCount":105},[],{"trials":2143,"activeCount":105},[],{"intervention":923,"totalTrials":395,"cells":2145},{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2150,"PHASE3":2156,"PHASE4":2158,"NA":2160},{"trials":2147,"activeCount":105},[],{"trials":2149,"activeCount":105},[],{"trials":2151,"activeCount":395,"soonestReadout":916},[2152],{"nctId":913,"briefTitle":914,"status":123,"phases":2153,"primaryCompletion":916,"completion":916,"start":917,"enrollment":918,"conditions":2154,"interventions":2155},[95,96],[752],[742,921,871,922,923],{"trials":2157,"activeCount":105},[],{"trials":2159,"activeCount":105},[],{"trials":2161,"activeCount":105},[],{"intervention":463,"totalTrials":395,"cells":2163},{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2168,"PHASE3":2174,"PHASE4":2176,"NA":2178},{"trials":2165,"activeCount":105},[],{"trials":2167,"activeCount":105},[],{"trials":2169,"activeCount":395,"soonestReadout":456},[2170],{"nctId":453,"briefTitle":454,"status":111,"phases":2171,"primaryCompletion":456,"completion":457,"start":458,"enrollment":459,"conditions":2172,"interventions":2173},[95,96],[461],[434,463,413],{"trials":2175,"activeCount":105},[],{"trials":2177,"activeCount":105},[],{"trials":2179,"activeCount":105},[],{"intervention":2181,"totalTrials":395,"cells":2182},"DS-3939a",{"EARLY_PHASE1":2183,"PHASE1":2185,"PHASE2":2187,"PHASE3":2198,"PHASE4":2200,"NA":2202},{"trials":2184,"activeCount":105},[],{"trials":2186,"activeCount":105},[],{"trials":2188,"activeCount":395,"soonestReadout":2193},[2189],{"nctId":2190,"briefTitle":2191,"status":111,"phases":2192,"primaryCompletion":2193,"completion":1209,"start":2194,"enrollment":494,"conditions":2195,"interventions":2197},"NCT05875168","First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors",[95,96],"2026-10-20","2023-08-18",[360,2196],"Metastatic Solid Tumor",[2181],{"trials":2199,"activeCount":105},[],{"trials":2201,"activeCount":105},[],{"trials":2203,"activeCount":105},[],{"intervention":2205,"totalTrials":395,"cells":2206},"DS3790a",{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2224,"PHASE4":2226,"NA":2228},{"trials":2208,"activeCount":105},[],{"trials":2210,"activeCount":105},[],{"trials":2212,"activeCount":395,"soonestReadout":2217},[2213],{"nctId":2214,"briefTitle":2215,"status":111,"phases":2216,"primaryCompletion":2217,"completion":2217,"start":2218,"enrollment":2219,"conditions":2220,"interventions":2222},"NCT07220616","A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies",[95,96],"2030-11-30","2026-01-16",420,[2221],"Hematological Malignancies",[2205,2223,2223],"Combination drug",{"trials":2225,"activeCount":105},[],{"trials":2227,"activeCount":105},[],{"trials":2229,"activeCount":105},[],{"intervention":2223,"totalTrials":395,"cells":2231},{"EARLY_PHASE1":2232,"PHASE1":2234,"PHASE2":2236,"PHASE3":2242,"PHASE4":2244,"NA":2246},{"trials":2233,"activeCount":105},[],{"trials":2235,"activeCount":105},[],{"trials":2237,"activeCount":395,"soonestReadout":2217},[2238],{"nctId":2214,"briefTitle":2215,"status":111,"phases":2239,"primaryCompletion":2217,"completion":2217,"start":2218,"enrollment":2219,"conditions":2240,"interventions":2241},[95,96],[2221],[2205,2223,2223],{"trials":2243,"activeCount":105},[],{"trials":2245,"activeCount":105},[],{"trials":2247,"activeCount":105},[],{"intervention":2249,"totalTrials":395,"cells":2250},"Quizartinib High Dose",{"EARLY_PHASE1":2251,"PHASE1":2253,"PHASE2":2255,"PHASE3":2268,"PHASE4":2270,"NA":2272},{"trials":2252,"activeCount":105},[],{"trials":2254,"activeCount":105},[],{"trials":2256,"activeCount":395,"soonestReadout":2261},[2257],{"nctId":2258,"briefTitle":2259,"status":111,"phases":2260,"primaryCompletion":2261,"completion":2262,"start":2263,"enrollment":2264,"conditions":2265,"interventions":2266},"NCT06824168","Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission",[96],"2028-06-06","2032-07-14","2025-07-18",130,[752,740],[2249,2267],"Quizartinib Low Dose",{"trials":2269,"activeCount":105},[],{"trials":2271,"activeCount":105},[],{"trials":2273,"activeCount":105},[],{"intervention":2267,"totalTrials":395,"cells":2275},{"EARLY_PHASE1":2276,"PHASE1":2278,"PHASE2":2280,"PHASE3":2286,"PHASE4":2288,"NA":2290},{"trials":2277,"activeCount":105},[],{"trials":2279,"activeCount":105},[],{"trials":2281,"activeCount":395,"soonestReadout":2261},[2282],{"nctId":2258,"briefTitle":2259,"status":111,"phases":2283,"primaryCompletion":2261,"completion":2262,"start":2263,"enrollment":2264,"conditions":2284,"interventions":2285},[96],[752,740],[2249,2267],{"trials":2287,"activeCount":105},[],{"trials":2289,"activeCount":105},[],{"trials":2291,"activeCount":105},[],{"intervention":2293,"totalTrials":395,"cells":2294},"Raludotatug deruxtecan",{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2299,"PHASE3":2311,"PHASE4":2313,"NA":2315},{"trials":2296,"activeCount":105},[],{"trials":2298,"activeCount":105},[],{"trials":2300,"activeCount":395,"soonestReadout":2305},[2301],{"nctId":2302,"briefTitle":2303,"status":123,"phases":2304,"primaryCompletion":2305,"completion":2305,"start":2306,"enrollment":2307,"conditions":2308,"interventions":2310},"NCT06660654","A Study of Raludotatug Deruxtecan in Participants With Advanced\u002FMetastatic Solid Tumors (REJOICE-PanTumor01)",[96],"2027-09-30","2025-01-06",200,[360,2309],"Metastatic Solid Tumors",[2293],{"trials":2312,"activeCount":105},[],{"trials":2314,"activeCount":105},[],{"trials":2316,"activeCount":105},[],{"intervention":74,"totalTrials":997,"cells":2318},{"EARLY_PHASE1":2319,"PHASE1":2321,"PHASE2":2349,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2320,"activeCount":105},[],{"trials":2322,"activeCount":395,"soonestReadout":73},[2323,2333,2340],{"nctId":2324,"briefTitle":2325,"status":175,"phases":2326,"primaryCompletion":2327,"completion":2327,"start":2328,"enrollment":2329,"conditions":2330,"interventions":2332},"NCT03110354","DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)",[95],"2021-03-09","2017-04-05",28,[933,2331],"Leukemia, Lymphocytic, Acute",[74],{"nctId":2334,"briefTitle":2335,"status":136,"phases":2336,"primaryCompletion":2337,"completion":2337,"start":1944,"enrollment":2329,"conditions":2338,"interventions":2339},"NCT04276662","Study of Single-dose DS-3201b in Participants With Hepatic Impairment",[95],"2021-02-23",[860],[74],{"nctId":71,"briefTitle":72,"status":123,"phases":2341,"primaryCompletion":73,"completion":2342,"start":2343,"enrollment":2344,"conditions":2345,"interventions":2348},[95],"2027-12-31","2016-03-31",100,[2346,2347],"Lymphoma, Malignant","Non-hodgkin Lymphoma",[74,74],{"trials":2350,"activeCount":105},[],{"trials":2352,"activeCount":105},[],{"trials":2354,"activeCount":105},[],{"trials":2356,"activeCount":105},[],{"intervention":1976,"totalTrials":146,"cells":2358},{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2377,"PHASE3":2379,"PHASE4":2381,"NA":2383},{"trials":2360,"activeCount":105},[],{"trials":2362,"activeCount":395,"soonestReadout":1970},[2363,2367],{"nctId":1967,"briefTitle":1968,"status":123,"phases":2364,"primaryCompletion":1970,"completion":468,"start":1971,"enrollment":1972,"conditions":2365,"interventions":2366},[95],[1974],[1960,1960,1976,1976,1960,1960,1976],{"nctId":2368,"briefTitle":2369,"status":175,"phases":2370,"primaryCompletion":2371,"completion":2371,"start":2372,"enrollment":2373,"conditions":2374,"interventions":2375},"NCT03255083","DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer",[95],"2020-09-04","2019-04-10",13,[2001],[2376,1976],"DS-1205c",{"trials":2378,"activeCount":105},[],{"trials":2380,"activeCount":105},[],{"trials":2382,"activeCount":105},[],{"trials":2384,"activeCount":105},[],{"intervention":2386,"totalTrials":395,"cells":2387},"DS-1055a",{"EARLY_PHASE1":2388,"PHASE1":2390,"PHASE2":2401,"PHASE3":2403,"PHASE4":2405,"NA":2407},{"trials":2389,"activeCount":105},[],{"trials":2391,"activeCount":395,"soonestReadout":2396},[2392],{"nctId":2393,"briefTitle":2394,"status":123,"phases":2395,"primaryCompletion":2396,"completion":2396,"start":2397,"enrollment":1102,"conditions":2398,"interventions":2400},"NCT04419532","A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors",[95],"2027-07-01","2020-10-09",[2399,311,2196],"Solid Tumor",[2386],{"trials":2402,"activeCount":105},[],{"trials":2404,"activeCount":105},[],{"trials":2406,"activeCount":105},[],{"trials":2408,"activeCount":105},[],{"intervention":1011,"totalTrials":395,"cells":2410},{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2419,"PHASE3":2421,"PHASE4":2423,"NA":2425},{"trials":2412,"activeCount":105},[],{"trials":2414,"activeCount":395,"soonestReadout":1007},[2415],{"nctId":1004,"briefTitle":1005,"status":123,"phases":2416,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":376,"conditions":2417,"interventions":2418},[95],[360,44],[1011,996],{"trials":2420,"activeCount":105},[],{"trials":2422,"activeCount":105},[],{"trials":2424,"activeCount":105},[],{"trials":2426,"activeCount":105},[],{"intervention":2428,"totalTrials":395,"cells":2429},"DS9051b",{"EARLY_PHASE1":2430,"PHASE1":2432,"PHASE2":2443,"PHASE3":2445,"PHASE4":2447,"NA":2449},{"trials":2431,"activeCount":105},[],{"trials":2433,"activeCount":395,"soonestReadout":305},[2434],{"nctId":2435,"briefTitle":2436,"status":111,"phases":2437,"primaryCompletion":305,"completion":305,"start":2438,"enrollment":1102,"conditions":2439,"interventions":2442},"NCT07189403","A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer",[95],"2025-11-04",[2440,2441],"Advanced or Metastatic Adrenocortical Carcinoma","Metastatic Castration-resistant Prostate Cancer",[2428],{"trials":2444,"activeCount":105},[],{"trials":2446,"activeCount":105},[],{"trials":2448,"activeCount":105},[],{"trials":2450,"activeCount":105},[],{"intervention":787,"totalTrials":395,"cells":2452},{"EARLY_PHASE1":2453,"PHASE1":2455,"PHASE2":2461,"PHASE3":2463,"PHASE4":2465,"NA":2467},{"trials":2454,"activeCount":105},[],{"trials":2456,"activeCount":395,"soonestReadout":780},[2457],{"nctId":777,"briefTitle":778,"status":123,"phases":2458,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":2459,"interventions":2460},[95],[784,785,36],[412,787],{"trials":2462,"activeCount":105},[],{"trials":2464,"activeCount":105},[],{"trials":2466,"activeCount":105},[],{"trials":2468,"activeCount":105},[],{"intervention":2470,"totalTrials":395,"cells":2471},"Valemetostat",{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2486,"PHASE3":2488,"PHASE4":2490,"NA":2492},{"trials":2473,"activeCount":105},[],{"trials":2475,"activeCount":395,"soonestReadout":1399},[2476],{"nctId":2477,"briefTitle":2478,"status":111,"phases":2479,"primaryCompletion":1399,"completion":2480,"start":2481,"enrollment":2482,"conditions":2483,"interventions":2484},"NCT07244341","A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)",[95],"2029-11-30","2025-12-03",60,[2441],[2470,2485],"Darolutamide",{"trials":2487,"activeCount":105},[],{"trials":2489,"activeCount":105},[],{"trials":2491,"activeCount":105},[],{"trials":2493,"activeCount":105},[],{"intervention":2485,"totalTrials":395,"cells":2495},{"EARLY_PHASE1":2496,"PHASE1":2498,"PHASE2":2504,"PHASE3":2506,"PHASE4":2508,"NA":2510},{"trials":2497,"activeCount":105},[],{"trials":2499,"activeCount":395,"soonestReadout":1399},[2500],{"nctId":2477,"briefTitle":2478,"status":111,"phases":2501,"primaryCompletion":1399,"completion":2480,"start":2481,"enrollment":2482,"conditions":2502,"interventions":2503},[95],[2441],[2470,2485],{"trials":2505,"activeCount":105},[],{"trials":2507,"activeCount":105},[],{"trials":2509,"activeCount":105},[],{"trials":2511,"activeCount":105},[],{"intervention":657,"totalTrials":395,"cells":2513},{"EARLY_PHASE1":2514,"PHASE1":2516,"PHASE2":2522,"PHASE3":2524,"PHASE4":2526,"NA":2528},{"trials":2515,"activeCount":105},[],{"trials":2517,"activeCount":395,"soonestReadout":91},[2518],{"nctId":89,"briefTitle":90,"status":123,"phases":2519,"primaryCompletion":91,"completion":651,"start":652,"enrollment":653,"conditions":2520,"interventions":2521},[95],[655],[92,657,413,414],{"trials":2523,"activeCount":105},[],{"trials":2525,"activeCount":105},[],{"trials":2527,"activeCount":105},[],{"trials":2529,"activeCount":105},[],{"intervention":362,"totalTrials":395,"cells":2531},{"EARLY_PHASE1":2532,"PHASE1":2534,"PHASE2":2540,"PHASE3":2542,"PHASE4":2544,"NA":2546},{"trials":2533,"activeCount":105},[],{"trials":2535,"activeCount":395,"soonestReadout":355},[2536],{"nctId":352,"briefTitle":353,"status":111,"phases":2537,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":2538,"interventions":2539},[95],[360],[362,132],{"trials":2541,"activeCount":105},[],{"trials":2543,"activeCount":105},[],{"trials":2545,"activeCount":105},[],{"trials":2547,"activeCount":105},[],{"intervention":2549,"totalTrials":395,"cells":2550},"DS-6000a",{"EARLY_PHASE1":2551,"PHASE1":2553,"PHASE2":2566,"PHASE3":2568,"PHASE4":2570,"NA":2572},{"trials":2552,"activeCount":105},[],{"trials":2554,"activeCount":395,"soonestReadout":2559},[2555],{"nctId":2556,"briefTitle":2557,"status":123,"phases":2558,"primaryCompletion":2559,"completion":1007,"start":2560,"enrollment":2561,"conditions":2562,"interventions":2565},"NCT04707248","A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors",[95],"2026-04-30","2020-12-22",179,[2563,2564],"Renal Cell Carcinoma","Ovarian Tumor",[2549,2549],{"trials":2567,"activeCount":105},[],{"trials":2569,"activeCount":105},[],{"trials":2571,"activeCount":105},[],{"trials":2573,"activeCount":105},[],{"intervention":2575,"totalTrials":395,"cells":2576},"DS-2243a",{"EARLY_PHASE1":2577,"PHASE1":2579,"PHASE2":2591,"PHASE3":2593,"PHASE4":2595,"NA":2597},{"trials":2578,"activeCount":105},[],{"trials":2580,"activeCount":395,"soonestReadout":2585},[2581],{"nctId":2582,"briefTitle":2583,"status":111,"phases":2584,"primaryCompletion":2585,"completion":2585,"start":2586,"enrollment":2587,"conditions":2588,"interventions":2590},"NCT06644755","First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors",[95],"2028-11-30","2024-11-14",150,[541,2589],"Sarcoma",[2575],{"trials":2592,"activeCount":105},[],{"trials":2594,"activeCount":105},[],{"trials":2596,"activeCount":105},[],{"trials":2598,"activeCount":105},[],{"intervention":2600,"totalTrials":395,"cells":2601},"DS3610a",{"EARLY_PHASE1":2602,"PHASE1":2604,"PHASE2":2614,"PHASE3":2616,"PHASE4":2618,"NA":2620},{"trials":2603,"activeCount":105},[],{"trials":2605,"activeCount":395,"soonestReadout":336},[2606],{"nctId":2607,"briefTitle":2608,"status":111,"phases":2609,"primaryCompletion":336,"completion":2610,"start":2611,"enrollment":851,"conditions":2612,"interventions":2613},"NCT07159126","A Study of DS3610a in Participants With Advanced Solid Tumor",[95],"2031-02-01","2025-10-09",[541,2309],[2600],{"trials":2615,"activeCount":105},[],{"trials":2617,"activeCount":105},[],{"trials":2619,"activeCount":105},[],{"trials":2621,"activeCount":105},[],{"intervention":2623,"totalTrials":395,"cells":2624},"Combination of bempedoic acid and ezetimibe",{"EARLY_PHASE1":2625,"PHASE1":2627,"PHASE2":2629,"PHASE3":2631,"PHASE4":2633,"NA":2635},{"trials":2626,"activeCount":105},[],{"trials":2628,"activeCount":105},[],{"trials":2630,"activeCount":105},[],{"trials":2632,"activeCount":105},[],{"trials":2634,"activeCount":105},[],{"trials":2636,"activeCount":395,"soonestReadout":336},[2637],{"nctId":2638,"briefTitle":2639,"status":123,"phases":2640,"primaryCompletion":336,"completion":2641,"start":2642,"enrollment":2643,"conditions":2644,"interventions":2646},"NCT07206472","A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia",[],"2029-03-01","2026-03-03",2560,[2645,1378],"Primary Hypercholesterolaemia",[2623],{"intervention":2648,"totalTrials":395,"cells":2649},"TURALIO™",{"EARLY_PHASE1":2650,"PHASE1":2652,"PHASE2":2654,"PHASE3":2656,"PHASE4":2658,"NA":2660},{"trials":2651,"activeCount":105},[],{"trials":2653,"activeCount":105},[],{"trials":2655,"activeCount":105},[],{"trials":2657,"activeCount":105},[],{"trials":2659,"activeCount":105},[],{"trials":2661,"activeCount":395,"soonestReadout":2666},[2662],{"nctId":2663,"briefTitle":2664,"status":111,"phases":2665,"primaryCompletion":2666,"completion":2666,"start":2667,"enrollment":2668,"conditions":2669,"interventions":2671},"NCT04635111","A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment",[],"2036-06-01","2021-01-07",30,[2670,1094],"Hepatotoxicity",[2648],{"intervention":2673,"totalTrials":395,"cells":2674},"Bempedoic acid and\u002For its fixed-dose combination with ezetimibe",{"EARLY_PHASE1":2675,"PHASE1":2677,"PHASE2":2679,"PHASE3":2681,"PHASE4":2683,"NA":2685},{"trials":2676,"activeCount":105},[],{"trials":2678,"activeCount":105},[],{"trials":2680,"activeCount":105},[],{"trials":2682,"activeCount":105},[],{"trials":2684,"activeCount":105},[],{"trials":2686,"activeCount":395,"soonestReadout":2691},[2687],{"nctId":2688,"briefTitle":2689,"status":123,"phases":2690,"primaryCompletion":2691,"completion":2691,"start":2692,"enrollment":2693,"conditions":2694,"interventions":2695},"NCT04579367","Treatment With Bempedoic Acid and\u002For Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia",[],"2026-10-30","2021-01-15",5000,[42,1378],[2673],{"intervention":2697,"totalTrials":395,"cells":2698},"No drug",{"EARLY_PHASE1":2699,"PHASE1":2701,"PHASE2":2703,"PHASE3":2705,"PHASE4":2707,"NA":2709},{"trials":2700,"activeCount":105},[],{"trials":2702,"activeCount":105},[],{"trials":2704,"activeCount":105},[],{"trials":2706,"activeCount":105},[],{"trials":2708,"activeCount":105},[],{"trials":2710,"activeCount":395,"soonestReadout":2715},[2711],{"nctId":2712,"briefTitle":2713,"status":123,"phases":2714,"primaryCompletion":2715,"completion":2716,"start":2717,"enrollment":2718,"conditions":2719,"interventions":2720},"NCT07092254","Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer",[],"2025-11-28","2026-06-12","2025-09-01",760,[785],[2697],{"intervention":2722,"totalTrials":1406,"cells":2723},"Colesevelam hydrochloride",{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2728,"PHASE3":2740,"PHASE4":2776,"NA":2782},{"trials":2725,"activeCount":105},[],{"trials":2727,"activeCount":105},[],{"trials":2729,"activeCount":105},[2730],{"nctId":2731,"briefTitle":2732,"status":136,"phases":2733,"primaryCompletion":2734,"completion":2735,"start":2736,"enrollment":2737,"conditions":2738,"interventions":2739},"NCT00361153","Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus",[96],"2006-10","2007-03","2006-05",35,[31],[2722],{"trials":2741,"activeCount":105},[2742,2752,2760,2769],{"nctId":2743,"briefTitle":2744,"status":136,"phases":2745,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":2748,"conditions":2749,"interventions":2751},"NCT00147719","WelChol® With Metformin in Treating Patients With Type 2 Diabetes",[97],"2006-07","2004-06",300,[2750],"Type 2 Diabetes",[2722],{"nctId":2753,"briefTitle":2754,"status":136,"phases":2755,"primaryCompletion":2756,"completion":2756,"start":2747,"enrollment":2757,"conditions":2758,"interventions":2759},"NCT00147758","WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes",[97],"2006-08",400,[2750],[2722],{"nctId":2761,"briefTitle":2762,"status":136,"phases":2763,"primaryCompletion":2764,"completion":2764,"start":2765,"enrollment":2766,"conditions":2767,"interventions":2768},"NCT00151762","Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes",[97],"2007-07","2004-12",780,[2750],[2722],{"nctId":2770,"briefTitle":2771,"status":136,"phases":2772,"primaryCompletion":2773,"completion":2773,"start":2747,"enrollment":327,"conditions":2774,"interventions":2775},"NCT00151749","WelChol® and Insulin in Treating Patients With Type 2 Diabetes",[97],"2005-12",[2750],[2722],{"trials":2777,"activeCount":105},[2778],{"nctId":1383,"briefTitle":1384,"status":136,"phases":2779,"completion":1386,"start":1387,"enrollment":1388,"conditions":2780,"interventions":2781},[98],[42],[1391,1322,1392],{"trials":2783,"activeCount":105},[],{"intervention":2785,"totalTrials":1406,"cells":2786},"Amlodipine",{"EARLY_PHASE1":2787,"PHASE1":2789,"PHASE2":2791,"PHASE3":2793,"PHASE4":2837,"NA":2857},{"trials":2788,"activeCount":105},[],{"trials":2790,"activeCount":105},[],{"trials":2792,"activeCount":105},[],{"trials":2794,"activeCount":105},[2795,2805,2816,2827],{"nctId":2796,"briefTitle":2797,"status":136,"phases":2798,"completion":2799,"start":2800,"enrollment":2801,"conditions":2802,"interventions":2803},"NCT00185133","Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension",[97],"2007-01","2005-05",1900,[25],[2804,2785],"Olmesartan medoxomil",{"nctId":2806,"briefTitle":2807,"status":136,"phases":2808,"primaryCompletion":2809,"completion":2810,"start":2811,"enrollment":2812,"conditions":2813,"interventions":2814},"NCT00649389","Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension",[97],"2009-04","2009-12","2008-05",2500,[25],[2804,2785,2815],"Hydrochlorothiazide",{"nctId":2817,"briefTitle":2818,"status":136,"phases":2819,"primaryCompletion":547,"completion":2820,"start":2821,"enrollment":2482,"conditions":2822,"interventions":2824},"NCT00891267","Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome",[97],"2011-05","2008-10",[2823,25],"Metabolic Syndrome",[2825,2826,2785],"Olmesartan medoxomil tablets low dose","Olmesartan medoxomil tablets high dose",{"nctId":2828,"briefTitle":2829,"status":136,"phases":2830,"primaryCompletion":2831,"completion":2831,"start":2832,"enrollment":2833,"conditions":2834,"interventions":2835},"NCT00527514","Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension",[97],"2008-04","2007-09",185,[25],[2785,2836],"Olmesartan medoxomil plus amlodipine",{"trials":2838,"activeCount":105},[2839,2849],{"nctId":2840,"briefTitle":2841,"status":136,"phases":2842,"primaryCompletion":2843,"completion":2843,"start":2844,"enrollment":156,"conditions":2845,"interventions":2846},"NCT00185120","Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker",[98],"2006-09","2005-09",[25],[2804,2847,2848,2785],"Hydroclorothiazide","Benazepril",{"nctId":2850,"briefTitle":2851,"status":136,"phases":2852,"primaryCompletion":2809,"completion":593,"start":2811,"enrollment":2853,"conditions":2854,"interventions":2855},"NCT00654745","18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics",[98],207,[2750,25],[2785,2856,2815],"amlodipine \u002F olmesartan medoxomil combination",{"trials":2858,"activeCount":105},[],{"intervention":2860,"totalTrials":722,"cells":2861},"Clopidogrel",{"EARLY_PHASE1":2862,"PHASE1":2864,"PHASE2":2875,"PHASE3":2889,"PHASE4":2904,"NA":2925},{"trials":2863,"activeCount":105},[],{"trials":2865,"activeCount":105},[2866],{"nctId":2867,"briefTitle":2868,"status":136,"phases":2869,"primaryCompletion":662,"completion":662,"start":2870,"enrollment":26,"conditions":2871,"interventions":2873},"NCT02560688","Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects",[95],"2015-12",[2872],"Drug Interaction",[2874,2860],"DS-1040b",{"trials":2876,"activeCount":105},[2877],{"nctId":2878,"briefTitle":2879,"status":136,"phases":2880,"primaryCompletion":2881,"completion":2881,"start":2882,"enrollment":2883,"conditions":2884,"interventions":2886},"NCT01802775","Edoxaban in Peripheral Arterial Disease",[96],"2014-12-03","2013-02-06",203,[2885],"Peripheral Arterial Disease",[2887,2860,2888],"edoxaban","Aspirin",{"trials":2890,"activeCount":105},[2891],{"nctId":2892,"briefTitle":2893,"status":136,"phases":2894,"primaryCompletion":2895,"completion":2895,"start":2896,"enrollment":2897,"conditions":2898,"interventions":2899},"NCT02866175","Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention",[97],"2019-06-06","2017-02-24",1506,[28],[2900,2860,2901,2902,2903],"Edoxaban","Prasugrel","Ticagrelor","Vitamin K antagonist",{"trials":2905,"activeCount":105},[2906,2915],{"nctId":2907,"briefTitle":2908,"status":136,"phases":2909,"primaryCompletion":2910,"completion":2910,"start":1196,"enrollment":2911,"conditions":2912,"interventions":2914},"NCT01260584","The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease",[98],"2011-09",110,[2913],"Coronary Artery Disease",[2901,2860],{"nctId":2916,"briefTitle":2917,"status":136,"phases":2918,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2922,"conditions":2923,"interventions":2924},"NCT01014624","Prasugrel\u002FClopidogrel Maintenance Dose Washout Study",[98],"2010-05","2010-06","2010-02",56,[2913],[2901,2860],{"trials":2926,"activeCount":105},[],{"intervention":2901,"totalTrials":344,"cells":2928},{"EARLY_PHASE1":2929,"PHASE1":2931,"PHASE2":2933,"PHASE3":2935,"PHASE4":2941,"NA":2960},{"trials":2930,"activeCount":105},[],{"trials":2932,"activeCount":105},[],{"trials":2934,"activeCount":105},[],{"trials":2936,"activeCount":105},[2937],{"nctId":2892,"briefTitle":2893,"status":136,"phases":2938,"primaryCompletion":2895,"completion":2895,"start":2896,"enrollment":2897,"conditions":2939,"interventions":2940},[97],[28],[2900,2860,2901,2902,2903],{"trials":2942,"activeCount":105},[2943,2947,2951],{"nctId":2907,"briefTitle":2908,"status":136,"phases":2944,"primaryCompletion":2910,"completion":2910,"start":1196,"enrollment":2911,"conditions":2945,"interventions":2946},[98],[2913],[2901,2860],{"nctId":2916,"briefTitle":2917,"status":136,"phases":2948,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2922,"conditions":2949,"interventions":2950},[98],[2913],[2901,2860],{"nctId":2952,"briefTitle":2953,"status":136,"phases":2954,"primaryCompletion":896,"completion":896,"start":2955,"enrollment":2956,"conditions":2957,"interventions":2959},"NCT03672097","Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)",[98],"2018-10-16",204,[2958],"Acute Coronary Syndrome (ACS)",[2901],{"trials":2961,"activeCount":105},[],{"intervention":2963,"totalTrials":344,"cells":2964},"losartan potassium",{"EARLY_PHASE1":2965,"PHASE1":2967,"PHASE2":2969,"PHASE3":2971,"PHASE4":2993,"NA":3014},{"trials":2966,"activeCount":105},[],{"trials":2968,"activeCount":105},[],{"trials":2970,"activeCount":105},[],{"trials":2972,"activeCount":105},[2973,2983],{"nctId":2974,"briefTitle":2975,"status":136,"phases":2976,"primaryCompletion":2977,"completion":2978,"start":2979,"enrollment":2264,"conditions":2980,"interventions":2981},"NCT00857285","Olmesartan Medoxomil Versus Losartan in Patients With Hypertension",[97],"2003-08","2003-09","2002-05",[34],[2982,2963],"olmesartan medoxomil",{"nctId":2984,"briefTitle":2985,"status":136,"phases":2986,"primaryCompletion":2987,"completion":2988,"start":2989,"enrollment":2990,"conditions":2991,"interventions":2992},"NCT00856271","Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension",[97],"2005-02","2005-04","2004-08",287,[34],[2982,2963],{"trials":2994,"activeCount":105},[2995,3004],{"nctId":2996,"briefTitle":2997,"status":136,"phases":2998,"primaryCompletion":2999,"completion":2999,"start":3000,"enrollment":3001,"conditions":3002,"interventions":3003},"NCT00949884","Olmesartan Comparison to Losartan in Hypertensive Subjects",[98],"2010-01","2009-08",941,[25],[2982,2963],{"nctId":3005,"briefTitle":3006,"status":136,"phases":3007,"completion":3008,"start":1653,"enrollment":2482,"conditions":3009,"interventions":3011},"NCT00185094","A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin",[98],"2005-07",[25,3010,2823],"Insulin Resistance",[2804,3012,3013],"Losartan potassium","Atenolol",{"trials":3015,"activeCount":105},[],{"intervention":2815,"totalTrials":344,"cells":3017},{"EARLY_PHASE1":3018,"PHASE1":3020,"PHASE2":3022,"PHASE3":3024,"PHASE4":3030,"NA":3056},{"trials":3019,"activeCount":105},[],{"trials":3021,"activeCount":105},[],{"trials":3023,"activeCount":105},[],{"trials":3025,"activeCount":105},[3026],{"nctId":2806,"briefTitle":2807,"status":136,"phases":3027,"primaryCompletion":2809,"completion":2810,"start":2811,"enrollment":2812,"conditions":3028,"interventions":3029},[97],[25],[2804,2785,2815],{"trials":3031,"activeCount":105},[3032,3041,3045],{"nctId":3033,"briefTitle":3034,"status":136,"phases":3035,"completion":3036,"start":3037,"enrollment":2911,"conditions":3038,"interventions":3039},"NCT00185068","An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension",[98],"2004-10","2004-03",[25],[2804,3040,2815],"Olmesartan medoxomil\u002Fhydrochlorothiazide",{"nctId":2850,"briefTitle":2851,"status":136,"phases":3042,"primaryCompletion":2809,"completion":593,"start":2811,"enrollment":2853,"conditions":3043,"interventions":3044},[98],[2750,25],[2785,2856,2815],{"nctId":3046,"briefTitle":3047,"status":136,"phases":3048,"primaryCompletion":3000,"completion":3049,"start":3050,"enrollment":3051,"conditions":3052,"interventions":3053},"NCT00791258","A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure",[98],"2009-09","2008-11",999,[25],[3054,3055],"amlodipine and olmesartan medoxomil","hydrochlorothiazide",{"trials":3057,"activeCount":105},[],{"intervention":3040,"totalTrials":997,"cells":3059},{"EARLY_PHASE1":3060,"PHASE1":3062,"PHASE2":3064,"PHASE3":3066,"PHASE4":3080,"NA":3094},{"trials":3061,"activeCount":105},[],{"trials":3063,"activeCount":105},[],{"trials":3065,"activeCount":105},[],{"trials":3067,"activeCount":105},[3068],{"nctId":3069,"briefTitle":3070,"status":136,"phases":3071,"primaryCompletion":3072,"completion":2811,"start":3073,"enrollment":3074,"conditions":3075,"interventions":3076},"NCT00430508","Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension",[97],"2008-03","2007-02",972,[34],[3077,3078,3079,3079],"olmesartan medoxomil (OM)\u002Fhydrochlorothiazide (HCTZ) tablets and placebo","olmesartan medoxomil (OM)\u002Fhydrochlorothiazide (HCTZ)","olmesartan medoxomil\u002Fhydrochlorothiazide",{"trials":3081,"activeCount":105},[3082,3090],{"nctId":3083,"briefTitle":3084,"status":136,"phases":3085,"primaryCompletion":2831,"completion":2831,"start":3086,"enrollment":3087,"conditions":3088,"interventions":3089},"NCT00412932","An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension",[98],"2006-12",178,[25],[2804,3040],{"nctId":3033,"briefTitle":3034,"status":136,"phases":3091,"completion":3036,"start":3037,"enrollment":2911,"conditions":3092,"interventions":3093},[98],[25],[2804,3040,2815],{"trials":3095,"activeCount":105},[],{"intervention":3097,"totalTrials":997,"cells":3098},"olmesartan medoxomil + hydrochlorothiazide, if necessary",{"EARLY_PHASE1":3099,"PHASE1":3101,"PHASE2":3103,"PHASE3":3105,"PHASE4":3127,"NA":3137},{"trials":3100,"activeCount":105},[],{"trials":3102,"activeCount":105},[],{"trials":3104,"activeCount":105},[],{"trials":3106,"activeCount":105},[3107,3117],{"nctId":3108,"briefTitle":3109,"status":136,"phases":3110,"primaryCompletion":2988,"completion":3111,"start":3112,"enrollment":3113,"conditions":3114,"interventions":3115},"NCT00751751","Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly",[97],"2005-06","2003-06",441,[34],[3097,3116],"losartan + hydrochlorothiazide, if necessary",{"nctId":3118,"briefTitle":3119,"status":136,"phases":3120,"primaryCompletion":3036,"completion":2987,"start":3121,"enrollment":3122,"conditions":3123,"interventions":3125},"NCT00751829","Isolated Systolic Hypertension in the Elderly and Very Elderly",[97],"2003-07",417,[3124],"Isolated Systolic Hypertension",[3097,3126],"nitrendipine + hydrochlorothiazide, if necessary",{"trials":3128,"activeCount":105},[3129],{"nctId":3130,"briefTitle":3131,"status":136,"phases":3132,"primaryCompletion":3133,"completion":3133,"start":3086,"enrollment":3134,"conditions":3135,"interventions":3136},"NCT00430638","A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension",[98],"2007-10",278,[25],[3097],{"trials":3138,"activeCount":105},[],{"intervention":3013,"totalTrials":146,"cells":3140},{"EARLY_PHASE1":3141,"PHASE1":3143,"PHASE2":3145,"PHASE3":3147,"PHASE4":3149,"NA":3164},{"trials":3142,"activeCount":105},[],{"trials":3144,"activeCount":105},[],{"trials":3146,"activeCount":105},[],{"trials":3148,"activeCount":105},[],{"trials":3150,"activeCount":105},[3151,3160],{"nctId":3152,"briefTitle":3153,"status":175,"phases":3154,"primaryCompletion":3155,"completion":3155,"start":2919,"enrollment":3156,"conditions":3157,"interventions":3159},"NCT01132768","The Confirmatory Olmesartan Plaque Regression Study",[98],"2011-06",114,[34,3158],"Carotid Plaque",[3013,2982],{"nctId":3005,"briefTitle":3006,"status":136,"phases":3161,"completion":3008,"start":1653,"enrollment":2482,"conditions":3162,"interventions":3163},[98],[25,3010,2823],[2804,3012,3013],{"trials":3165,"activeCount":105},[],{"intervention":3167,"totalTrials":146,"cells":3168},"colesevelam HCl",{"EARLY_PHASE1":3169,"PHASE1":3171,"PHASE2":3173,"PHASE3":3175,"PHASE4":3189,"NA":3200},{"trials":3170,"activeCount":105},[],{"trials":3172,"activeCount":105},[],{"trials":3174,"activeCount":105},[],{"trials":3176,"activeCount":105},[3177],{"nctId":3178,"briefTitle":3179,"status":136,"phases":3180,"primaryCompletion":2831,"completion":2831,"start":3181,"enrollment":3182,"conditions":3183,"interventions":3185},"NCT00484419","Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin",[97],"2007-05",169,[2750,3184],"Hyperlipidemia",[3186,3187,3188],"Colesevelam HCl","rosiglitazone maleate","sitagliptin phosphate",{"trials":3190,"activeCount":105},[3191],{"nctId":3192,"briefTitle":3193,"status":136,"phases":3194,"primaryCompletion":3195,"completion":3195,"start":3196,"enrollment":3197,"conditions":3198,"interventions":3199},"NCT00145574","Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol",[98],"2007-12","2005-11",194,[42],[3167],{"trials":3201,"activeCount":105},[],{"intervention":3203,"totalTrials":395,"cells":3204},"Perindopril + amlodipine + if necessary, hydrochlorothiazide",{"EARLY_PHASE1":3205,"PHASE1":3207,"PHASE2":3209,"PHASE3":3211,"PHASE4":3213,"NA":3226},{"trials":3206,"activeCount":105},[],{"trials":3208,"activeCount":105},[],{"trials":3210,"activeCount":105},[],{"trials":3212,"activeCount":105},[],{"trials":3214,"activeCount":105},[3215],{"nctId":3216,"briefTitle":3217,"status":136,"phases":3218,"primaryCompletion":3219,"completion":3220,"start":3221,"enrollment":3222,"conditions":3223,"interventions":3224},"NCT01101009","Comparison of Sevikar® and the Combination of Perindopril\u002FAmlodipine on Central Blood Pressure",[98],"2012-11","2012-12","2010-04",486,[25],[3203,3225],"olmesartan\u002Famlodipine + hydrochlorothiazide, if necessary.",{"trials":3227,"activeCount":105},[],{"intervention":3225,"totalTrials":395,"cells":3229},{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3234,"PHASE3":3236,"PHASE4":3238,"NA":3244},{"trials":3231,"activeCount":105},[],{"trials":3233,"activeCount":105},[],{"trials":3235,"activeCount":105},[],{"trials":3237,"activeCount":105},[],{"trials":3239,"activeCount":105},[3240],{"nctId":3216,"briefTitle":3217,"status":136,"phases":3241,"primaryCompletion":3219,"completion":3220,"start":3221,"enrollment":3222,"conditions":3242,"interventions":3243},[98],[25],[3203,3225],{"trials":3245,"activeCount":105},[],{"intervention":3247,"totalTrials":395,"cells":3248},"colesevelam HCl tablets and fenofibrate",{"EARLY_PHASE1":3249,"PHASE1":3251,"PHASE2":3253,"PHASE3":3255,"PHASE4":3257,"NA":3269},{"trials":3250,"activeCount":105},[],{"trials":3252,"activeCount":105},[],{"trials":3254,"activeCount":105},[],{"trials":3256,"activeCount":105},[],{"trials":3258,"activeCount":105},[3259],{"nctId":3260,"briefTitle":3261,"status":136,"phases":3262,"primaryCompletion":2978,"completion":3037,"start":3263,"enrollment":3264,"conditions":3265,"interventions":3267},"NCT00754039","Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol",[98],"2003-02",129,[42,3266],"Hyperlipidemia, Familial Combined",[3247,3268,3268],"fenofibrate tablets and Welchol placebo",{"trials":3270,"activeCount":105},[],{"intervention":3268,"totalTrials":395,"cells":3272},{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3277,"PHASE3":3279,"PHASE4":3281,"NA":3287},{"trials":3274,"activeCount":105},[],{"trials":3276,"activeCount":105},[],{"trials":3278,"activeCount":105},[],{"trials":3280,"activeCount":105},[],{"trials":3282,"activeCount":105},[3283],{"nctId":3260,"briefTitle":3261,"status":136,"phases":3284,"primaryCompletion":2978,"completion":3037,"start":3263,"enrollment":3264,"conditions":3285,"interventions":3286},[98],[42,3266],[3247,3268,3268],{"trials":3288,"activeCount":105},[],{"intervention":3290,"totalTrials":395,"cells":3291},"Sitafloxacin",{"EARLY_PHASE1":3292,"PHASE1":3294,"PHASE2":3296,"PHASE3":3298,"PHASE4":3300,"NA":3313},{"trials":3293,"activeCount":105},[],{"trials":3295,"activeCount":105},[],{"trials":3297,"activeCount":105},[],{"trials":3299,"activeCount":105},[],{"trials":3301,"activeCount":105},[3302],{"nctId":3303,"briefTitle":3304,"status":136,"phases":3305,"primaryCompletion":3306,"completion":3306,"start":3307,"enrollment":3308,"conditions":3309,"interventions":3311},"NCT05400369","A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease",[98],"2024-09-25","2022-08-10",140,[3310],"COPD Exacerbation Acute",[3290,3312],"Moxifloxacin Hydrochloride",{"trials":3314,"activeCount":105},[],{"intervention":3312,"totalTrials":395,"cells":3316},{"EARLY_PHASE1":3317,"PHASE1":3319,"PHASE2":3321,"PHASE3":3323,"PHASE4":3325,"NA":3331},{"trials":3318,"activeCount":105},[],{"trials":3320,"activeCount":105},[],{"trials":3322,"activeCount":105},[],{"trials":3324,"activeCount":105},[],{"trials":3326,"activeCount":105},[3327],{"nctId":3303,"briefTitle":3304,"status":136,"phases":3328,"primaryCompletion":3306,"completion":3306,"start":3307,"enrollment":3308,"conditions":3329,"interventions":3330},[98],[3310],[3290,3312],{"trials":3332,"activeCount":105},[],{"intervention":3334,"totalTrials":395,"cells":3335},"olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary",{"EARLY_PHASE1":3336,"PHASE1":3338,"PHASE2":3340,"PHASE3":3342,"PHASE4":3344,"NA":3355},{"trials":3337,"activeCount":105},[],{"trials":3339,"activeCount":105},[],{"trials":3341,"activeCount":105},[],{"trials":3343,"activeCount":105},[],{"trials":3345,"activeCount":105},[3346],{"nctId":3347,"briefTitle":3348,"status":136,"phases":3349,"primaryCompletion":3350,"completion":3351,"start":2756,"enrollment":3352,"conditions":3353,"interventions":3354},"NCT00890591","Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension",[98],"2007-06","2007-08",144,[34],[3334],{"trials":3356,"activeCount":105},[],{"intervention":3358,"totalTrials":395,"cells":3359},"High-dose colesevelam",{"EARLY_PHASE1":3360,"PHASE1":3362,"PHASE2":3364,"PHASE3":3366,"PHASE4":3368,"NA":3381},{"trials":3361,"activeCount":105},[],{"trials":3363,"activeCount":105},[],{"trials":3365,"activeCount":105},[],{"trials":3367,"activeCount":105},[],{"trials":3369,"activeCount":105},[3370],{"nctId":3371,"briefTitle":3372,"status":136,"phases":3373,"primaryCompletion":3374,"completion":3375,"start":3376,"enrollment":3377,"conditions":3378,"interventions":3379},"NCT01258075","Colesevelam for Children With Type 2 Diabetes",[98],"2019-11-01","2020-04-21","2011-02-24",236,[31],[3358,3380],"Low-dose colesevelam",{"trials":3382,"activeCount":105},[],{"intervention":3380,"totalTrials":395,"cells":3384},{"EARLY_PHASE1":3385,"PHASE1":3387,"PHASE2":3389,"PHASE3":3391,"PHASE4":3393,"NA":3399},{"trials":3386,"activeCount":105},[],{"trials":3388,"activeCount":105},[],{"trials":3390,"activeCount":105},[],{"trials":3392,"activeCount":105},[],{"trials":3394,"activeCount":105},[3395],{"nctId":3371,"briefTitle":3372,"status":136,"phases":3396,"primaryCompletion":3374,"completion":3375,"start":3376,"enrollment":3377,"conditions":3397,"interventions":3398},[98],[31],[3358,3380],{"trials":3400,"activeCount":105},[],{"intervention":3402,"totalTrials":395,"cells":3403},"Prasugrel Loading Dose",{"EARLY_PHASE1":3404,"PHASE1":3406,"PHASE2":3408,"PHASE3":3410,"PHASE4":3412,"NA":3424},{"trials":3405,"activeCount":105},[],{"trials":3407,"activeCount":105},[],{"trials":3409,"activeCount":105},[],{"trials":3411,"activeCount":105},[],{"trials":3413,"activeCount":105},[3414],{"nctId":3415,"briefTitle":3416,"status":136,"phases":3417,"primaryCompletion":3418,"completion":3418,"start":3419,"enrollment":2911,"conditions":3420,"interventions":3421},"NCT01587651","Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease",[98],"2013-02","2012-03",[2913],[3402,3422,3423],"Prasugrel Maintenance Dose","Ticagrelor Maintenance Dose",{"trials":3425,"activeCount":105},[],{"intervention":3422,"totalTrials":395,"cells":3427},{"EARLY_PHASE1":3428,"PHASE1":3430,"PHASE2":3432,"PHASE3":3434,"PHASE4":3436,"NA":3442},{"trials":3429,"activeCount":105},[],{"trials":3431,"activeCount":105},[],{"trials":3433,"activeCount":105},[],{"trials":3435,"activeCount":105},[],{"trials":3437,"activeCount":105},[3438],{"nctId":3415,"briefTitle":3416,"status":136,"phases":3439,"primaryCompletion":3418,"completion":3418,"start":3419,"enrollment":2911,"conditions":3440,"interventions":3441},[98],[2913],[3402,3422,3423],{"trials":3443,"activeCount":105},[],{"intervention":3423,"totalTrials":395,"cells":3445},{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3450,"PHASE3":3452,"PHASE4":3454,"NA":3460},{"trials":3447,"activeCount":105},[],{"trials":3449,"activeCount":105},[],{"trials":3451,"activeCount":105},[],{"trials":3453,"activeCount":105},[],{"trials":3455,"activeCount":105},[3456],{"nctId":3415,"briefTitle":3416,"status":136,"phases":3457,"primaryCompletion":3418,"completion":3418,"start":3419,"enrollment":2911,"conditions":3458,"interventions":3459},[98],[2913],[3402,3422,3423],{"trials":3461,"activeCount":105},[],{"intervention":3463,"totalTrials":395,"cells":3464},"colesevelam HCl tablets, and atorvastatin",{"EARLY_PHASE1":3465,"PHASE1":3467,"PHASE2":3469,"PHASE3":3471,"PHASE4":3473,"NA":3483},{"trials":3466,"activeCount":105},[],{"trials":3468,"activeCount":105},[],{"trials":3470,"activeCount":105},[],{"trials":3472,"activeCount":105},[],{"trials":3474,"activeCount":105},[3475],{"nctId":3476,"briefTitle":3477,"status":136,"phases":3478,"primaryCompletion":3112,"completion":2988,"start":3479,"enrollment":918,"conditions":3480,"interventions":3481},"NCT00754507","A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.",[98],"2002-11",[42],[3463,3482],"colesevelam HCl placebo tablets and atorvastatin",{"trials":3484,"activeCount":105},[],{"intervention":3482,"totalTrials":395,"cells":3486},{"EARLY_PHASE1":3487,"PHASE1":3489,"PHASE2":3491,"PHASE3":3493,"PHASE4":3495,"NA":3501},{"trials":3488,"activeCount":105},[],{"trials":3490,"activeCount":105},[],{"trials":3492,"activeCount":105},[],{"trials":3494,"activeCount":105},[],{"trials":3496,"activeCount":105},[3497],{"nctId":3476,"briefTitle":3477,"status":136,"phases":3498,"primaryCompletion":3112,"completion":2988,"start":3479,"enrollment":918,"conditions":3499,"interventions":3500},[98],[42],[3463,3482],{"trials":3502,"activeCount":105},[],{"intervention":2847,"totalTrials":395,"cells":3504},{"EARLY_PHASE1":3505,"PHASE1":3507,"PHASE2":3509,"PHASE3":3511,"PHASE4":3513,"NA":3519},{"trials":3506,"activeCount":105},[],{"trials":3508,"activeCount":105},[],{"trials":3510,"activeCount":105},[],{"trials":3512,"activeCount":105},[],{"trials":3514,"activeCount":105},[3515],{"nctId":2840,"briefTitle":2841,"status":136,"phases":3516,"primaryCompletion":2843,"completion":2843,"start":2844,"enrollment":156,"conditions":3517,"interventions":3518},[98],[25],[2804,2847,2848,2785],{"trials":3520,"activeCount":105},[],{"intervention":2848,"totalTrials":395,"cells":3522},{"EARLY_PHASE1":3523,"PHASE1":3525,"PHASE2":3527,"PHASE3":3529,"PHASE4":3531,"NA":3537},{"trials":3524,"activeCount":105},[],{"trials":3526,"activeCount":105},[],{"trials":3528,"activeCount":105},[],{"trials":3530,"activeCount":105},[],{"trials":3532,"activeCount":105},[3533],{"nctId":2840,"briefTitle":2841,"status":136,"phases":3534,"primaryCompletion":2843,"completion":2843,"start":2844,"enrollment":156,"conditions":3535,"interventions":3536},[98],[25],[2804,2847,2848,2785],{"trials":3538,"activeCount":105},[],{"intervention":3540,"totalTrials":395,"cells":3541},"pravastatin tablets and Welchol",{"EARLY_PHASE1":3542,"PHASE1":3544,"PHASE2":3546,"PHASE3":3548,"PHASE4":3550,"NA":3560},{"trials":3543,"activeCount":105},[],{"trials":3545,"activeCount":105},[],{"trials":3547,"activeCount":105},[],{"trials":3549,"activeCount":105},[],{"trials":3551,"activeCount":105},[3552],{"nctId":3553,"briefTitle":3554,"status":136,"phases":3555,"primaryCompletion":3112,"completion":2988,"start":3479,"enrollment":3556,"conditions":3557,"interventions":3558},"NCT00755352","A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.",[98],67,[42],[3540,3559],"pravastatin tablets and Welchol placebo",{"trials":3561,"activeCount":105},[],{"intervention":3559,"totalTrials":395,"cells":3563},{"EARLY_PHASE1":3564,"PHASE1":3566,"PHASE2":3568,"PHASE3":3570,"PHASE4":3572,"NA":3578},{"trials":3565,"activeCount":105},[],{"trials":3567,"activeCount":105},[],{"trials":3569,"activeCount":105},[],{"trials":3571,"activeCount":105},[],{"trials":3573,"activeCount":105},[3574],{"nctId":3553,"briefTitle":3554,"status":136,"phases":3575,"primaryCompletion":3112,"completion":2988,"start":3479,"enrollment":3556,"conditions":3576,"interventions":3577},[98],[42],[3540,3559],{"trials":3579,"activeCount":105},[],{"intervention":2856,"totalTrials":395,"cells":3581},{"EARLY_PHASE1":3582,"PHASE1":3584,"PHASE2":3586,"PHASE3":3588,"PHASE4":3590,"NA":3596},{"trials":3583,"activeCount":105},[],{"trials":3585,"activeCount":105},[],{"trials":3587,"activeCount":105},[],{"trials":3589,"activeCount":105},[],{"trials":3591,"activeCount":105},[3592],{"nctId":2850,"briefTitle":2851,"status":136,"phases":3593,"primaryCompletion":2809,"completion":593,"start":2811,"enrollment":2853,"conditions":3594,"interventions":3595},[98],[2750,25],[2785,2856,2815],{"trials":3597,"activeCount":105},[],{"intervention":3599,"totalTrials":395,"cells":3600},"colesevelam HCl tablets, and simvastatin",{"EARLY_PHASE1":3601,"PHASE1":3603,"PHASE2":3605,"PHASE3":3607,"PHASE4":3609,"NA":3619},{"trials":3602,"activeCount":105},[],{"trials":3604,"activeCount":105},[],{"trials":3606,"activeCount":105},[],{"trials":3608,"activeCount":105},[],{"trials":3610,"activeCount":105},[3611],{"nctId":3612,"briefTitle":3613,"status":136,"phases":3614,"primaryCompletion":3112,"completion":2988,"start":3479,"enrollment":3615,"conditions":3616,"interventions":3617},"NCT00753779","A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.",[98],72,[42],[3599,3618],"simvastatin tablets and colesevelam HCl placebo",{"trials":3620,"activeCount":105},[],{"intervention":3618,"totalTrials":395,"cells":3622},{"EARLY_PHASE1":3623,"PHASE1":3625,"PHASE2":3627,"PHASE3":3629,"PHASE4":3631,"NA":3637},{"trials":3624,"activeCount":105},[],{"trials":3626,"activeCount":105},[],{"trials":3628,"activeCount":105},[],{"trials":3630,"activeCount":105},[],{"trials":3632,"activeCount":105},[3633],{"nctId":3612,"briefTitle":3613,"status":136,"phases":3634,"primaryCompletion":3112,"completion":2988,"start":3479,"enrollment":3615,"conditions":3635,"interventions":3636},[98],[42],[3599,3618],{"trials":3638,"activeCount":105},[],{"intervention":3640,"totalTrials":395,"cells":3641},"Irbesartan",{"EARLY_PHASE1":3642,"PHASE1":3644,"PHASE2":3646,"PHASE3":3648,"PHASE4":3650,"NA":3661},{"trials":3643,"activeCount":105},[],{"trials":3645,"activeCount":105},[],{"trials":3647,"activeCount":105},[],{"trials":3649,"activeCount":105},[],{"trials":3651,"activeCount":105},[3652],{"nctId":3653,"briefTitle":3654,"status":136,"phases":3655,"completion":2987,"start":3656,"enrollment":22,"conditions":3657,"interventions":3659},"NCT00185055","The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects",[98],"2004-11",[3658],"Healthy",[2804,3640,3660],"Valsartan",{"trials":3662,"activeCount":105},[],{"intervention":3660,"totalTrials":395,"cells":3664},{"EARLY_PHASE1":3665,"PHASE1":3667,"PHASE2":3669,"PHASE3":3671,"PHASE4":3673,"NA":3679},{"trials":3666,"activeCount":105},[],{"trials":3668,"activeCount":105},[],{"trials":3670,"activeCount":105},[],{"trials":3672,"activeCount":105},[],{"trials":3674,"activeCount":105},[3675],{"nctId":3653,"briefTitle":3654,"status":136,"phases":3676,"completion":2987,"start":3656,"enrollment":22,"conditions":3677,"interventions":3678},[98],[3658],[2804,3640,3660],{"trials":3680,"activeCount":105},[],{"intervention":3682,"totalTrials":395,"cells":3683},"olmesartan medoxomil and a CCB",{"EARLY_PHASE1":3684,"PHASE1":3686,"PHASE2":3688,"PHASE3":3690,"PHASE4":3692,"NA":3702},{"trials":3685,"activeCount":105},[],{"trials":3687,"activeCount":105},[],{"trials":3689,"activeCount":105},[],{"trials":3691,"activeCount":105},[],{"trials":3693,"activeCount":105},[3694],{"nctId":3695,"briefTitle":3696,"status":136,"phases":3697,"primaryCompletion":3008,"completion":3196,"start":2987,"enrollment":3698,"conditions":3699,"interventions":3700},"NCT00858702","Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension",[98],105,[25],[3682,3701],"olmesartan medoxomil and a diuretic",{"trials":3703,"activeCount":105},[],{"intervention":3701,"totalTrials":395,"cells":3705},{"EARLY_PHASE1":3706,"PHASE1":3708,"PHASE2":3710,"PHASE3":3712,"PHASE4":3714,"NA":3720},{"trials":3707,"activeCount":105},[],{"trials":3709,"activeCount":105},[],{"trials":3711,"activeCount":105},[],{"trials":3713,"activeCount":105},[],{"trials":3715,"activeCount":105},[3716],{"nctId":3695,"briefTitle":3696,"status":136,"phases":3717,"primaryCompletion":3008,"completion":3196,"start":2987,"enrollment":3698,"conditions":3718,"interventions":3719},[98],[25],[3682,3701],{"trials":3721,"activeCount":105},[],{"intervention":1392,"totalTrials":395,"cells":3723},{"EARLY_PHASE1":3724,"PHASE1":3726,"PHASE2":3728,"PHASE3":3730,"PHASE4":3732,"NA":3738},{"trials":3725,"activeCount":105},[],{"trials":3727,"activeCount":105},[],{"trials":3729,"activeCount":105},[],{"trials":3731,"activeCount":105},[],{"trials":3733,"activeCount":105},[3734],{"nctId":1383,"briefTitle":1384,"status":136,"phases":3735,"completion":1386,"start":1387,"enrollment":1388,"conditions":3736,"interventions":3737},[98],[42],[1391,1322,1392],{"trials":3739,"activeCount":105},[],{"intervention":3054,"totalTrials":395,"cells":3741},{"EARLY_PHASE1":3742,"PHASE1":3744,"PHASE2":3746,"PHASE3":3748,"PHASE4":3750,"NA":3756},{"trials":3743,"activeCount":105},[],{"trials":3745,"activeCount":105},[],{"trials":3747,"activeCount":105},[],{"trials":3749,"activeCount":105},[],{"trials":3751,"activeCount":105},[3752],{"nctId":3046,"briefTitle":3047,"status":136,"phases":3753,"primaryCompletion":3000,"completion":3049,"start":3050,"enrollment":3051,"conditions":3754,"interventions":3755},[98],[25],[3054,3055],{"trials":3757,"activeCount":105},[],{"intervention":3759,"totalTrials":395,"cells":3760},"Bempedoic acid 180 mg",{"EARLY_PHASE1":3761,"PHASE1":3763,"PHASE2":3765,"PHASE3":3767,"PHASE4":3769,"NA":3781},{"trials":3762,"activeCount":105},[],{"trials":3764,"activeCount":105},[],{"trials":3766,"activeCount":105},[],{"trials":3768,"activeCount":105},[],{"trials":3770,"activeCount":105},[3771],{"nctId":3772,"briefTitle":3773,"status":136,"phases":3774,"primaryCompletion":3775,"completion":3775,"start":3776,"enrollment":3777,"conditions":3778,"interventions":3780},"NCT06925100","A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan",[98],"2025-10-15","2025-04-01",180,[3779],"Primary Hypercholesterolemia or Mixed Hyperlipidemia",[3759],{"trials":3782,"activeCount":105},[],{"intervention":3784,"totalTrials":395,"cells":3785},"Olmesartan medoxomil plus Hydrochlorothiazide",{"EARLY_PHASE1":3786,"PHASE1":3788,"PHASE2":3790,"PHASE3":3792,"PHASE4":3794,"NA":3804},{"trials":3787,"activeCount":105},[],{"trials":3789,"activeCount":105},[],{"trials":3791,"activeCount":105},[],{"trials":3793,"activeCount":105},[],{"trials":3795,"activeCount":105},[3796],{"nctId":3797,"briefTitle":3798,"status":136,"phases":3799,"primaryCompletion":3800,"completion":3195,"start":3801,"enrollment":358,"conditions":3802,"interventions":3803},"NCT00403481","An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes",[98],"2007-11","2006-11",[25],[2982,3784],{"trials":3805,"activeCount":105},[],{"intervention":3807,"totalTrials":395,"cells":3808},"olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure",{"EARLY_PHASE1":3809,"PHASE1":3811,"PHASE2":3813,"PHASE3":3815,"PHASE4":3817,"NA":3826},{"trials":3810,"activeCount":105},[],{"trials":3812,"activeCount":105},[],{"trials":3814,"activeCount":105},[],{"trials":3816,"activeCount":105},[],{"trials":3818,"activeCount":105},[3819],{"nctId":3820,"briefTitle":3821,"status":136,"phases":3822,"primaryCompletion":3008,"completion":3008,"start":3479,"enrollment":2344,"conditions":3823,"interventions":3824},"NCT00772499","Vascular Improvement With Olmesartan Medoxomil Study",[98],[25],[3807,3825],"atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure",{"trials":3827,"activeCount":105},[],{"intervention":3825,"totalTrials":395,"cells":3829},{"EARLY_PHASE1":3830,"PHASE1":3832,"PHASE2":3834,"PHASE3":3836,"PHASE4":3838,"NA":3844},{"trials":3831,"activeCount":105},[],{"trials":3833,"activeCount":105},[],{"trials":3835,"activeCount":105},[],{"trials":3837,"activeCount":105},[],{"trials":3839,"activeCount":105},[3840],{"nctId":3820,"briefTitle":3821,"status":136,"phases":3841,"primaryCompletion":3008,"completion":3008,"start":3479,"enrollment":2344,"conditions":3842,"interventions":3843},[98],[25],[3807,3825],{"trials":3845,"activeCount":105},[],{"intervention":3847,"totalTrials":2373,"cells":3848},"exatecan mesylate",{"EARLY_PHASE1":3849,"PHASE1":3851,"PHASE2":3873,"PHASE3":3949,"PHASE4":3959,"NA":3961},{"trials":3850,"activeCount":105},[],{"trials":3852,"activeCount":105},[3853,3861],{"nctId":3854,"briefTitle":3855,"status":136,"phases":3856,"primaryCompletion":2988,"completion":2988,"start":3857,"conditions":3858,"interventions":3860},"NCT00004047","Chemotherapy in Treating Patients Who Have Hematologic Cancer",[95],"1999-06",[740,3859],"Myelodysplastic Syndromes",[3847],{"nctId":3862,"briefTitle":3863,"status":136,"phases":3864,"primaryCompletion":3865,"completion":3865,"start":3866,"conditions":3867,"interventions":3871},"NCT00004212","DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas",[95],"2004-04","1999-09",[3868,3869,3870],"Brain and Central Nervous System Tumors","Lymphoma","Unspecified Childhood Solid Tumor, Protocol Specific",[3872,3847],"filgrastim",{"trials":3874,"activeCount":105},[3875,3882,3889,3896,3902,3910,3917,3923,3932,3942],{"nctId":3876,"briefTitle":3877,"status":136,"phases":3878,"primaryCompletion":2988,"completion":2988,"start":3866,"conditions":3879,"interventions":3881},"NCT00004108","DX-8951f in Treating Patients With Liver Cancer",[96],[3880],"Liver Cancer",[3847],{"nctId":3883,"briefTitle":3884,"status":136,"phases":3885,"primaryCompletion":3886,"completion":3886,"start":3857,"conditions":3887,"interventions":3888},"NCT00004046","Chemotherapy in Treating Women With Metastatic Breast Cancer",[96],"2002-04",[44],[3847],{"nctId":3890,"briefTitle":3891,"status":136,"phases":3892,"primaryCompletion":3893,"completion":3893,"start":3857,"conditions":3894,"interventions":3895},"NCT00004045","Chemotherapy in Treating Patients With Prostate Cancer",[96],"2001-08",[2000],[3847],{"nctId":3897,"briefTitle":3898,"status":136,"phases":3899,"primaryCompletion":2988,"completion":2988,"start":3857,"enrollment":931,"conditions":3900,"interventions":3901},"NCT00003951","DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas",[96],[1238],[3847],{"nctId":3903,"briefTitle":3904,"status":136,"phases":3905,"primaryCompletion":3906,"completion":3906,"start":3907,"conditions":3908,"interventions":3909},"NCT00055939","Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma",[96],"2006-04","2003-01",[2589],[3847],{"nctId":3911,"briefTitle":3912,"status":136,"phases":3913,"primaryCompletion":2978,"completion":2978,"start":3914,"conditions":3915,"interventions":3916},"NCT00017212","DX-8951f in Treating Patients With Metastatic Stomach Cancer",[96],"2001-04",[1998,270],[3847],{"nctId":3918,"briefTitle":3919,"status":136,"phases":3920,"primaryCompletion":3906,"completion":3906,"start":3907,"conditions":3921,"interventions":3922},"NCT00055952","Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor",[96],[2589],[3847],{"nctId":3924,"briefTitle":3925,"status":136,"phases":3926,"primaryCompletion":2988,"completion":2988,"start":3927,"conditions":3928,"interventions":3931},"NCT00005938","DX-8951f in Treating Patients With Biliary Cancer",[96],"2000-03",[3929,3930,3880],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer",[3847],{"nctId":3933,"briefTitle":3934,"status":136,"phases":3935,"primaryCompletion":3936,"completion":3936,"start":3937,"conditions":3938,"interventions":3941},"NCT00004060","Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer",[96],"2000-09","1999-07",[3939,194,3940],"Fallopian Tube Cancer","Primary Peritoneal Cavity Cancer",[3847],{"nctId":3943,"briefTitle":3944,"status":136,"phases":3945,"primaryCompletion":2978,"completion":2978,"start":3946,"conditions":3947,"interventions":3948},"NCT00004866","DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix",[96],"2000-01",[1997],[3847],{"trials":3950,"activeCount":105},[3951],{"nctId":3952,"briefTitle":3953,"status":136,"phases":3954,"primaryCompletion":2988,"completion":2988,"start":3955,"conditions":3956,"interventions":3957},"NCT00023972","Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",[97],"2001-07",[1238],[3847,3958],"gemcitabine hydrochloride",{"trials":3960,"activeCount":105},[],{"trials":3962,"activeCount":105},[],{"intervention":3964,"totalTrials":284,"cells":3965},"Tivantinib",{"EARLY_PHASE1":3966,"PHASE1":3968,"PHASE2":4013,"PHASE3":4036,"PHASE4":4060,"NA":4062},{"trials":3967,"activeCount":105},[],{"trials":3969,"activeCount":105},[3970,3980,3994,4004],{"nctId":3971,"briefTitle":3972,"status":136,"phases":3973,"primaryCompletion":3974,"completion":3974,"start":3975,"enrollment":604,"conditions":3976,"interventions":3977},"NCT01149720","Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors",[95],"2011-03","2010-07",[541],[3978,3978,3979],"Tivantinib (ARQ 197)","Tivantinib (ARQ 197) Capsule D,",{"nctId":3981,"briefTitle":3982,"status":136,"phases":3983,"primaryCompletion":3984,"completion":3985,"start":583,"enrollment":2329,"conditions":3986,"interventions":3987},"NCT01517399","Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects",[95],"2013-08","2013-09",[541],[3988,3989,3990,3991,3992,3993],"tivantinib","omeprazole","s-warfarin","caffeine","digoxin","midazolam",{"nctId":3995,"briefTitle":3996,"status":136,"phases":3997,"primaryCompletion":3998,"completion":3999,"start":4000,"enrollment":4001,"conditions":4002,"interventions":4003},"NCT01699061","Effect of Tivantinib on the QTC Interval in Cancer Subjects",[95],"2013-01","2013-05","2012-07",38,[541],[3964],{"nctId":4005,"briefTitle":4006,"status":136,"phases":4007,"primaryCompletion":2870,"completion":4008,"start":4009,"enrollment":563,"conditions":4010,"interventions":4012},"NCT02150733","Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment",[95],"2016-07","2014-04",[860,2399,4011],"Cancer",[3964,3964,3964,3964],{"trials":4014,"activeCount":105},[4015,4026],{"nctId":4016,"briefTitle":4017,"status":136,"phases":4018,"primaryCompletion":4019,"completion":4020,"start":4021,"enrollment":4022,"conditions":4023,"interventions":4024},"NCT01075048","ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer",[95,96],"2012-10-12","2015-02-20","2010-01-26",131,[1153],[3964,668,4025],"Irinotecan",{"nctId":4027,"briefTitle":4028,"status":175,"phases":4029,"primaryCompletion":4030,"completion":4030,"start":4031,"enrollment":4032,"conditions":4033,"interventions":4035},"NCT01055067","ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors",[96],"2011-11-30","2010-02-02",27,[4034],"Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)",[3964],{"trials":4037,"activeCount":105},[4038,4049],{"nctId":4039,"briefTitle":4040,"status":175,"phases":4041,"primaryCompletion":4042,"completion":4042,"start":4043,"enrollment":4044,"conditions":4045,"interventions":4047},"NCT01244191","Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer",[97],"2012-12-15","2011-01-11",1048,[4046],"Non Squamous, Non-small-cell Lung Cancer",[3964,4048],"Erlotinib",{"nctId":4050,"briefTitle":4051,"status":136,"phases":4052,"primaryCompletion":4053,"completion":4054,"start":4055,"enrollment":4056,"conditions":4057,"interventions":4059},"NCT01755767","Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy",[97],"2017-03-28","2017-07-31","2012-12-27",383,[4058],"Hepatocellular Carcinoma",[3964],{"trials":4061,"activeCount":105},[],{"trials":4063,"activeCount":105},[],{"intervention":4065,"totalTrials":1406,"cells":4066},"DU-176b",{"EARLY_PHASE1":4067,"PHASE1":4069,"PHASE2":4071,"PHASE3":4112,"PHASE4":4132,"NA":4134},{"trials":4068,"activeCount":105},[],{"trials":4070,"activeCount":105},[],{"trials":4072,"activeCount":105},[4073,4083,4093,4102],{"nctId":4074,"briefTitle":4075,"status":136,"phases":4076,"primaryCompletion":4077,"completion":4078,"start":2735,"enrollment":4079,"conditions":4080,"interventions":4081},"NCT00829933","Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation",[96],"2008-07","2008-09",536,[28],[4065,4082],"Warfarin potassium",{"nctId":4084,"briefTitle":4085,"status":136,"phases":4086,"primaryCompletion":2821,"completion":4087,"start":3133,"enrollment":4088,"conditions":4089,"interventions":4091},"NCT00806624","DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation",[96],"2009-11",234,[28,4090],"Stroke",[4065,4065,4092],"Warfarin",{"nctId":4094,"briefTitle":4095,"status":136,"phases":4096,"primaryCompletion":2832,"completion":4077,"start":2746,"enrollment":4097,"conditions":4098,"interventions":4101},"NCT01203072","A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty",[96],523,[39,4099,4100],"Deep Vein Thrombosis","Total Knee Arthroplasty",[4065,4065,4065,4065],{"nctId":4103,"briefTitle":4104,"status":136,"phases":4105,"primaryCompletion":2773,"completion":2773,"start":4106,"enrollment":4107,"conditions":4108,"interventions":4111},"NCT00107900","Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement",[96],"2005-01",606,[4109,4110],"Arthroplasty, Replacement, Hip","Thrombosis",[4065],{"trials":4113,"activeCount":105},[4114,4124],{"nctId":4115,"briefTitle":4116,"status":136,"phases":4117,"primaryCompletion":4118,"completion":4118,"start":4119,"enrollment":4120,"conditions":4121,"interventions":4122},"NCT02801669","Study of DU-176b Aged 80 Years or Older",[97],"2019-12-27","2016-08-05",984,[28],[4123],"Du-176b",{"nctId":4125,"briefTitle":4126,"status":136,"phases":4127,"primaryCompletion":3000,"completion":2921,"start":2821,"enrollment":4128,"conditions":4129,"interventions":4130},"NCT01181141","Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery",[97],92,[39],[4065,4131],"Enoxaparin sodium 20mg",{"trials":4133,"activeCount":105},[],{"trials":4135,"activeCount":105},[],{"intervention":4137,"totalTrials":1406,"cells":4138},"warfarin",{"EARLY_PHASE1":4139,"PHASE1":4141,"PHASE2":4143,"PHASE3":4170,"PHASE4":4202,"NA":4204},{"trials":4140,"activeCount":105},[],{"trials":4142,"activeCount":105},[],{"trials":4144,"activeCount":105},[4145,4157,4161],{"nctId":4146,"briefTitle":4147,"status":136,"phases":4148,"primaryCompletion":4149,"completion":4150,"start":572,"enrollment":4151,"conditions":4152,"interventions":4154},"NCT01662908","A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin\u002FWarfarin in Subjects With Symptomatic Deep-Vein Thrombosis",[96],"2014-01","2014-03",85,[4099,4153],"Venous Thrombosis",[4155,4156,4137],"edoxaban tosylate","enoxaparin\u002Funfractionated heparin",{"nctId":4084,"briefTitle":4085,"status":136,"phases":4158,"primaryCompletion":2821,"completion":4087,"start":3133,"enrollment":4088,"conditions":4159,"interventions":4160},[96],[28,4090],[4065,4065,4092],{"nctId":4162,"briefTitle":4163,"status":136,"phases":4164,"primaryCompletion":4165,"completion":4165,"start":3350,"enrollment":4166,"conditions":4167,"interventions":4169},"NCT00504556","A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation",[96],"2008-06",1146,[28,4168],"Thromboembolism",[2900,2900,2900,2900,4137],{"trials":4171,"activeCount":105},[4172,4182,4194],{"nctId":4173,"briefTitle":4174,"status":136,"phases":4175,"primaryCompletion":4176,"completion":4176,"start":4177,"enrollment":4178,"conditions":4179,"interventions":4180},"NCT02072434","Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)",[97],"2016-02-03","2014-03-25",2199,[28],[2900,4092,4181],"Enoxaparin",{"nctId":4183,"briefTitle":4184,"status":136,"phases":4185,"primaryCompletion":4186,"completion":4186,"start":4187,"enrollment":4188,"conditions":4189,"interventions":4192},"NCT00986154","Comparative Investigation of Low Molecular Weight (LMW) Heparin\u002FEdoxaban Tosylate (DU176b) Versus (LMW) Heparin\u002FWarfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and\u002For Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).",[97],"2013-04","2009-10",8292,[39,4190,4191,4168,4153],"Deep Vein Thrombosis (DVT)","Pulmonary Embolism (PE)",[4155,4193,4137],"low molecular weight heparin\u002Funfractionated heparin",{"nctId":4195,"briefTitle":4196,"status":136,"phases":4197,"primaryCompletion":4186,"completion":3999,"start":3050,"enrollment":4198,"conditions":4199,"interventions":4201},"NCT00781391","Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation",[97],21105,[4090,28,4200],"Embolism",[4137,2900,2900],{"trials":4203,"activeCount":105},[],{"trials":4205,"activeCount":105},[],{"intervention":4207,"totalTrials":1406,"cells":4208},"Pregabalin",{"EARLY_PHASE1":4209,"PHASE1":4211,"PHASE2":4213,"PHASE3":4247,"PHASE4":4276,"NA":4278},{"trials":4210,"activeCount":105},[],{"trials":4212,"activeCount":105},[],{"trials":4214,"activeCount":105},[4215,4227,4235],{"nctId":4216,"briefTitle":4217,"status":136,"phases":4218,"primaryCompletion":4219,"completion":4219,"start":4220,"enrollment":4221,"conditions":4222,"interventions":4224},"NCT01496365","Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy",[96],"2012-09-07","2011-11-28",452,[4223],"Diabetic Peripheral Neuropathy",[4225,4226],"DS-5565","pregabalin",{"nctId":4228,"briefTitle":4229,"status":136,"phases":4230,"primaryCompletion":1195,"completion":1195,"start":571,"enrollment":4231,"conditions":4232,"interventions":4234},"NCT01504412","Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral Neuropathy",[96],450,[4233,4223],"Pain",[4225,4225,4225,4207],{"nctId":4236,"briefTitle":4237,"status":1192,"phases":4238,"primaryCompletion":4239,"completion":4240,"start":4241,"enrollment":105,"conditions":4242,"interventions":4245},"NCT02673866","Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)",[96],"2017-01","2017-02","2016-02",[4243,4244],"Neuropathic Pain","Diabetes",[4246,4226],"DS-1971a",{"trials":4248,"activeCount":105},[4249,4259,4268],{"nctId":4250,"briefTitle":4251,"status":136,"phases":4252,"primaryCompletion":4253,"completion":4253,"start":4254,"enrollment":4255,"conditions":4256,"interventions":4258},"NCT02187159","Treatment of Pain Associated With Fibromyalgia",[97],"2016-07-07","2014-11",1270,[4257],"Pain Associated With Fibromyalgia",[4225,4207],{"nctId":4260,"briefTitle":4251,"status":136,"phases":4261,"primaryCompletion":4262,"completion":4263,"start":4264,"enrollment":4265,"conditions":4266,"interventions":4267},"NCT02187471",[97],"2017-01-06","2017-01-12","2015-01-16",1301,[4257],[4225,4207],{"nctId":4269,"briefTitle":4251,"status":136,"phases":4270,"primaryCompletion":4271,"completion":4271,"start":4272,"enrollment":4273,"conditions":4274,"interventions":4275},"NCT02146430",[97],"2016-07-14","2014-10-27",1293,[4257],[4225,4207],{"trials":4277,"activeCount":105},[],{"trials":4279,"activeCount":105},[],{"intervention":4048,"totalTrials":722,"cells":4281},{"EARLY_PHASE1":4282,"PHASE1":4284,"PHASE2":4292,"PHASE3":4314,"PHASE4":4327,"NA":4329},{"trials":4283,"activeCount":105},[],{"trials":4285,"activeCount":105},[4286],{"nctId":4287,"briefTitle":4288,"status":136,"phases":4289,"primaryCompletion":583,"completion":583,"start":2920,"enrollment":32,"conditions":4290,"interventions":4291},"NCT01199068","CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb\u002FIV Non-small Cell Lung Cancer (NSCLC)",[95],[552],[554,4048],{"trials":4293,"activeCount":105},[4294,4305],{"nctId":4295,"briefTitle":4296,"status":136,"phases":4297,"primaryCompletion":4298,"completion":4299,"start":4300,"enrollment":4301,"conditions":4302,"interventions":4304},"NCT01211483","Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer",[95,96],"2013-10","2013-11-23","2010-09",222,[4303],"NSCLC (Advanced Non-small Cell Lung Cancer)",[566,4048],{"nctId":4306,"briefTitle":4307,"status":136,"phases":4308,"primaryCompletion":4186,"completion":4186,"start":549,"enrollment":4309,"conditions":4310,"interventions":4312},"NCT01101334","Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer",[96],90,[4311],"Advanced Non-small Cell Lung Cancer (NSCLC)",[554,4313],"erlotinib",{"trials":4315,"activeCount":105},[4316,4320],{"nctId":4039,"briefTitle":4040,"status":175,"phases":4317,"primaryCompletion":4042,"completion":4042,"start":4043,"enrollment":4044,"conditions":4318,"interventions":4319},[97],[4046],[3964,4048],{"nctId":4321,"briefTitle":4322,"status":175,"phases":4323,"primaryCompletion":4324,"completion":4324,"start":4150,"enrollment":653,"conditions":4325,"interventions":4326},"NCT02134015","Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)",[97],"2016-11-11",[392,36],[667,4048],{"trials":4328,"activeCount":105},[],{"trials":4330,"activeCount":105},[],{"intervention":667,"totalTrials":344,"cells":4332},{"EARLY_PHASE1":4333,"PHASE1":4335,"PHASE2":4349,"PHASE3":4355,"PHASE4":4361,"NA":4363},{"trials":4334,"activeCount":105},[],{"trials":4336,"activeCount":105},[4337,4345],{"nctId":4338,"briefTitle":4339,"status":136,"phases":4340,"primaryCompletion":4298,"completion":4009,"start":1195,"enrollment":4341,"conditions":4342,"interventions":4343},"NCT01957280","Study to Assess Pharmacokinetics, Immunogenicity and Safety\u002FTolerability of Patritumab (U3-1287)",[95],17,[541],[4344],"patritumab",{"nctId":659,"briefTitle":660,"status":136,"phases":4346,"primaryCompletion":662,"completion":663,"start":664,"enrollment":32,"conditions":4347,"interventions":4348},[95],[379],[667,668,414,413],{"trials":4350,"activeCount":105},[4351],{"nctId":676,"briefTitle":677,"status":175,"phases":4352,"primaryCompletion":679,"completion":680,"start":681,"enrollment":682,"conditions":4353,"interventions":4354},[96],[684],[667,668,414,413],{"trials":4356,"activeCount":105},[4357],{"nctId":4321,"briefTitle":4322,"status":175,"phases":4358,"primaryCompletion":4324,"completion":4324,"start":4150,"enrollment":653,"conditions":4359,"interventions":4360},[97],[392,36],[667,4048],{"trials":4362,"activeCount":105},[],{"trials":4364,"activeCount":105},[],{"intervention":4366,"totalTrials":344,"cells":4367},"Pioglitazone",{"EARLY_PHASE1":4368,"PHASE1":4370,"PHASE2":4372,"PHASE3":4385,"PHASE4":4411,"NA":4413},{"trials":4369,"activeCount":105},[],{"trials":4371,"activeCount":105},[],{"trials":4373,"activeCount":105},[4374],{"nctId":4375,"briefTitle":4376,"status":136,"phases":4377,"completion":4378,"start":1652,"enrollment":2757,"conditions":4379,"interventions":4381},"NCT00290940","Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917",[96],"2007-04",[4380],"Diabetes Mellitus, Type 2",[4382,4383,4384],"CS-917","metformin hydrochloride","pioglitazone",{"trials":4386,"activeCount":105},[4387,4395,4405],{"nctId":4388,"briefTitle":4389,"status":136,"phases":4390,"primaryCompletion":4000,"completion":4000,"start":2809,"enrollment":4391,"conditions":4392,"interventions":4393},"NCT00789750","Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus",[97],562,[31],[4394,4366],"Colesevelam",{"nctId":4396,"briefTitle":4397,"status":136,"phases":4398,"primaryCompletion":4399,"completion":4399,"start":4400,"enrollment":4401,"conditions":4402,"interventions":4403},"NCT00484198","Study of Rivoglitazone in Type 2 Diabetes Mellitus",[97],"2009-02-12","2007-04-23",1912,[31],[4366,4404,4404],"Rivoglitazone",{"nctId":4406,"briefTitle":4407,"status":136,"phases":4408,"primaryCompletion":2773,"completion":2773,"start":2765,"enrollment":3113,"conditions":4409,"interventions":4410},"NCT00143520","Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes",[96,97],[2750],[4404,4366],{"trials":4412,"activeCount":105},[],{"trials":4414,"activeCount":105},[],{"intervention":4394,"totalTrials":997,"cells":4416},{"EARLY_PHASE1":4417,"PHASE1":4419,"PHASE2":4421,"PHASE3":4431,"PHASE4":4449,"NA":4451},{"trials":4418,"activeCount":105},[],{"trials":4420,"activeCount":105},[],{"trials":4422,"activeCount":105},[4423],{"nctId":4424,"briefTitle":4425,"status":136,"phases":4426,"primaryCompletion":584,"completion":584,"start":3111,"enrollment":4427,"conditions":4428,"interventions":4429},"NCT00147745","Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes",[96],36,[2750],[4394,4430],"Insulin glargine",{"trials":4432,"activeCount":105},[4433,4445],{"nctId":4434,"briefTitle":4435,"status":136,"phases":4436,"primaryCompletion":2809,"completion":4437,"start":3800,"enrollment":4438,"conditions":4439,"interventions":4441},"NCT00570739","Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.",[97],"2009-05",502,[31,42,4440],"Pre-diabetes",[4442,4443,4444,4394],"Metformin HCl and Colesevelam Placebo","Metformin HCl tablets and Colesevelam","Colesevelam placebo",{"nctId":4388,"briefTitle":4389,"status":136,"phases":4446,"primaryCompletion":4000,"completion":4000,"start":2809,"enrollment":4391,"conditions":4447,"interventions":4448},[97],[31],[4394,4366],{"trials":4450,"activeCount":105},[],{"trials":4452,"activeCount":105},[],{"intervention":4454,"totalTrials":997,"cells":4455},"Rivoglitazone HCl",{"EARLY_PHASE1":4456,"PHASE1":4458,"PHASE2":4460,"PHASE3":4477,"PHASE4":4490,"NA":4492},{"trials":4457,"activeCount":105},[],{"trials":4459,"activeCount":105},[],{"trials":4461,"activeCount":105},[4462,4469],{"nctId":4463,"briefTitle":4464,"status":136,"phases":4465,"primaryCompletion":3072,"completion":3072,"start":2764,"enrollment":203,"conditions":4466,"interventions":4467},"NCT00575471","Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes",[96],[2750],[4454,4468,4468],"rivoglitazone HCl",{"nctId":4470,"briefTitle":4471,"status":136,"phases":4472,"primaryCompletion":4165,"completion":4473,"start":3351,"enrollment":2587,"conditions":4474,"interventions":4475},"NCT00575874","Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes",[96],"2009-01",[2750],[4454,4468,4468,4476],"pioglitazone HCl",{"trials":4478,"activeCount":105},[4479],{"nctId":4480,"briefTitle":4481,"status":175,"phases":4482,"primaryCompletion":4483,"completion":4483,"start":4484,"enrollment":4485,"conditions":4486,"interventions":4487},"NCT00571519","Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus",[97],"2008-05-23","2007-11-14",94,[31],[4454,4468,4468,4476,4476,4488,4489],"pioglitazone HCl 45 mg","metformin",{"trials":4491,"activeCount":105},[],{"trials":4493,"activeCount":105},[],{"intervention":4495,"totalTrials":146,"cells":4496},"DU-176b 15mg",{"EARLY_PHASE1":4497,"PHASE1":4499,"PHASE2":4501,"PHASE3":4513,"PHASE4":4524,"NA":4526},{"trials":4498,"activeCount":105},[],{"trials":4500,"activeCount":105},[],{"trials":4502,"activeCount":105},[4503],{"nctId":4504,"briefTitle":4505,"status":136,"phases":4506,"primaryCompletion":573,"completion":593,"start":4077,"enrollment":4507,"conditions":4508,"interventions":4510},"NCT01203098","A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty",[96],264,[39,4168,4110,4509,4099,4109],"Embolism and Thrombosis",[4495,4511,4512],"DU-176b 30mg","Enoxaparin sodium 20 mg",{"trials":4514,"activeCount":105},[4515],{"nctId":4516,"briefTitle":4517,"status":136,"phases":4518,"primaryCompletion":3998,"completion":3998,"start":562,"enrollment":4519,"conditions":4520,"interventions":4522},"NCT01857622","Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment",[97],93,[4521],"Non-valvular Atrial Fibrillation",[4495,4511,4523],"DU-176b 60mg",{"trials":4525,"activeCount":105},[],{"trials":4527,"activeCount":105},[],{"intervention":4511,"totalTrials":146,"cells":4529},{"EARLY_PHASE1":4530,"PHASE1":4532,"PHASE2":4534,"PHASE3":4540,"PHASE4":4546,"NA":4548},{"trials":4531,"activeCount":105},[],{"trials":4533,"activeCount":105},[],{"trials":4535,"activeCount":105},[4536],{"nctId":4504,"briefTitle":4505,"status":136,"phases":4537,"primaryCompletion":573,"completion":593,"start":4077,"enrollment":4507,"conditions":4538,"interventions":4539},[96],[39,4168,4110,4509,4099,4109],[4495,4511,4512],{"trials":4541,"activeCount":105},[4542],{"nctId":4516,"briefTitle":4517,"status":136,"phases":4543,"primaryCompletion":3998,"completion":3998,"start":562,"enrollment":4519,"conditions":4544,"interventions":4545},[97],[4521],[4495,4511,4523],{"trials":4547,"activeCount":105},[],{"trials":4549,"activeCount":105},[],{"intervention":4181,"totalTrials":146,"cells":4551},{"EARLY_PHASE1":4552,"PHASE1":4554,"PHASE2":4556,"PHASE3":4569,"PHASE4":4575,"NA":4577},{"trials":4553,"activeCount":105},[],{"trials":4555,"activeCount":105},[],{"trials":4557,"activeCount":105},[4558],{"nctId":4559,"briefTitle":4560,"status":136,"phases":4561,"primaryCompletion":4562,"completion":4562,"start":4563,"enrollment":4564,"conditions":4565,"interventions":4568},"NCT02923115","Study to Assess the Safety, Pharmacokinetics\u002FDynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism",[95,96],"2019-08-05","2016-06-23",134,[4566,4567],"Pulmonary Embolism","Thrombotic Disease",[2874,4181],{"trials":4570,"activeCount":105},[4571],{"nctId":4173,"briefTitle":4174,"status":136,"phases":4572,"primaryCompletion":4176,"completion":4176,"start":4177,"enrollment":4178,"conditions":4573,"interventions":4574},[97],[28],[2900,4092,4181],{"trials":4576,"activeCount":105},[],{"trials":4578,"activeCount":105},[],{"intervention":4155,"totalTrials":146,"cells":4580},{"EARLY_PHASE1":4581,"PHASE1":4583,"PHASE2":4585,"PHASE3":4591,"PHASE4":4597,"NA":4599},{"trials":4582,"activeCount":105},[],{"trials":4584,"activeCount":105},[],{"trials":4586,"activeCount":105},[4587],{"nctId":4146,"briefTitle":4147,"status":136,"phases":4588,"primaryCompletion":4149,"completion":4150,"start":572,"enrollment":4151,"conditions":4589,"interventions":4590},[96],[4099,4153],[4155,4156,4137],{"trials":4592,"activeCount":105},[4593],{"nctId":4183,"briefTitle":4184,"status":136,"phases":4594,"primaryCompletion":4186,"completion":4186,"start":4187,"enrollment":4188,"conditions":4595,"interventions":4596},[97],[39,4190,4191,4168,4153],[4155,4193,4137],{"trials":4598,"activeCount":105},[],{"trials":4600,"activeCount":105},[],{"intervention":4602,"totalTrials":146,"cells":4603},"Eplerenone",{"EARLY_PHASE1":4604,"PHASE1":4606,"PHASE2":4608,"PHASE3":4621,"PHASE4":4632,"NA":4634},{"trials":4605,"activeCount":105},[],{"trials":4607,"activeCount":105},[],{"trials":4609,"activeCount":105},[4610],{"nctId":4611,"briefTitle":4612,"status":136,"phases":4613,"primaryCompletion":4614,"completion":2090,"start":4615,"enrollment":4616,"conditions":4617,"interventions":4618},"NCT02345044","A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects",[96],"2015-08","2015-01",426,[34],[4619,4620],"CS-3150","eplerenone",{"trials":4622,"activeCount":105},[4623],{"nctId":4624,"briefTitle":4625,"status":136,"phases":4626,"primaryCompletion":4627,"completion":4627,"start":4628,"enrollment":4629,"conditions":4630,"interventions":4631},"NCT02890173","Study of CS-3150 in Patients With Essential Hypertension",[97],"2017-07-11","2016-09",1001,[34],[4619,4602],{"trials":4633,"activeCount":105},[],{"trials":4635,"activeCount":105},[],{"intervention":4476,"totalTrials":146,"cells":4637},{"EARLY_PHASE1":4638,"PHASE1":4640,"PHASE2":4642,"PHASE3":4648,"PHASE4":4654,"NA":4656},{"trials":4639,"activeCount":105},[],{"trials":4641,"activeCount":105},[],{"trials":4643,"activeCount":105},[4644],{"nctId":4470,"briefTitle":4471,"status":136,"phases":4645,"primaryCompletion":4165,"completion":4473,"start":3351,"enrollment":2587,"conditions":4646,"interventions":4647},[96],[2750],[4454,4468,4468,4476],{"trials":4649,"activeCount":105},[4650],{"nctId":4480,"briefTitle":4481,"status":175,"phases":4651,"primaryCompletion":4483,"completion":4483,"start":4484,"enrollment":4485,"conditions":4652,"interventions":4653},[97],[31],[4454,4468,4468,4476,4476,4488,4489],{"trials":4655,"activeCount":105},[],{"trials":4657,"activeCount":105},[],{"intervention":4489,"totalTrials":146,"cells":4659},{"EARLY_PHASE1":4660,"PHASE1":4662,"PHASE2":4674,"PHASE3":4676,"PHASE4":4682,"NA":4684},{"trials":4661,"activeCount":105},[],{"trials":4663,"activeCount":105},[4664],{"nctId":4665,"briefTitle":4666,"status":136,"phases":4667,"primaryCompletion":4668,"completion":4668,"start":3985,"enrollment":4669,"conditions":4670,"interventions":4671},"NCT01956305","Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study",[95],"2014-06",48,[31],[4672,4673],"DS-7309","Metformin",{"trials":4675,"activeCount":105},[],{"trials":4677,"activeCount":105},[4678],{"nctId":4480,"briefTitle":4481,"status":175,"phases":4679,"primaryCompletion":4483,"completion":4483,"start":4484,"enrollment":4485,"conditions":4680,"interventions":4681},[97],[31],[4454,4468,4468,4476,4476,4488,4489],{"trials":4683,"activeCount":105},[],{"trials":4685,"activeCount":105},[],{"intervention":4687,"totalTrials":146,"cells":4688},"Standard of Care",{"EARLY_PHASE1":4689,"PHASE1":4691,"PHASE2":4693,"PHASE3":4695,"PHASE4":4716,"NA":4718},{"trials":4690,"activeCount":105},[],{"trials":4692,"activeCount":105},[],{"trials":4694,"activeCount":105},[],{"trials":4696,"activeCount":105},[4697,4707],{"nctId":4698,"briefTitle":4699,"status":136,"phases":4700,"primaryCompletion":4701,"completion":4701,"start":4702,"enrollment":4703,"conditions":4704,"interventions":4706},"NCT03395639","Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease",[97],"2021-12-03","2018-05-15",168,[4705],"Cardiac Disease",[2900,4687],{"nctId":4708,"briefTitle":4709,"status":136,"phases":4710,"primaryCompletion":4711,"completion":4711,"start":1109,"enrollment":4712,"conditions":4713,"interventions":4715},"NCT02798471","Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)",[97],"2022-05-24",290,[4714,4566,4190],"Venous Thromboembolism (VTE)",[2900,4687],{"trials":4717,"activeCount":105},[],{"trials":4719,"activeCount":105},[],{"intervention":4721,"totalTrials":146,"cells":4722},"VKA-Based Regimen",{"EARLY_PHASE1":4723,"PHASE1":4725,"PHASE2":4727,"PHASE3":4729,"PHASE4":4750,"NA":4752},{"trials":4724,"activeCount":105},[],{"trials":4726,"activeCount":105},[],{"trials":4728,"activeCount":105},[],{"trials":4730,"activeCount":105},[4731,4740],{"nctId":4732,"briefTitle":4733,"status":136,"phases":4734,"primaryCompletion":4735,"completion":4735,"start":4736,"enrollment":4737,"conditions":4738,"interventions":4739},"NCT02942576","Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation",[97],"2018-09-24","2017-03-21",632,[28],[2900,4721,4721,4721,4721],{"nctId":4741,"briefTitle":4742,"status":136,"phases":4743,"primaryCompletion":4744,"completion":4744,"start":4736,"enrollment":4745,"conditions":4746,"interventions":4747},"NCT02943785","Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)",[97],"2021-02-28",1426,[28],[4748,4749],"Edoxaban-based Regimen","VKA-based Regimen",{"trials":4751,"activeCount":105},[],{"trials":4753,"activeCount":105},[],{"intervention":4755,"totalTrials":146,"cells":4756},"Mirogabalin",{"EARLY_PHASE1":4757,"PHASE1":4759,"PHASE2":4761,"PHASE3":4763,"PHASE4":4785,"NA":4787},{"trials":4758,"activeCount":105},[],{"trials":4760,"activeCount":105},[],{"trials":4762,"activeCount":105},[],{"trials":4764,"activeCount":105},[4765,4776],{"nctId":4766,"briefTitle":4767,"status":136,"phases":4768,"primaryCompletion":4769,"completion":4770,"start":4771,"enrollment":4772,"conditions":4773,"interventions":4775},"NCT04094662","A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain",[97],"2022-01-17","2022-01-24","2019-09-18",393,[4774],"Diabetic Peripheral Neuropathic Pain",[4755],{"nctId":4777,"briefTitle":4778,"status":136,"phases":4779,"primaryCompletion":4780,"completion":4780,"start":4781,"enrollment":2748,"conditions":4782,"interventions":4784},"NCT03901352","Study of Mirogabalin for Central Neuropathic Pain",[97],"2020-12-28","2019-03-12",[4783],"Central Neuropathic Pain",[4755],{"trials":4786,"activeCount":105},[],{"trials":4788,"activeCount":105},[],{"intervention":4790,"totalTrials":146,"cells":4791},"enoxaparin sodium",{"EARLY_PHASE1":4792,"PHASE1":4794,"PHASE2":4796,"PHASE3":4798,"PHASE4":4816,"NA":4818},{"trials":4793,"activeCount":105},[],{"trials":4795,"activeCount":105},[],{"trials":4797,"activeCount":105},[],{"trials":4799,"activeCount":105},[4800,4808],{"nctId":4801,"briefTitle":4802,"status":136,"phases":4803,"primaryCompletion":3049,"completion":2921,"start":4804,"enrollment":4805,"conditions":4806,"interventions":4807},"NCT01181102","A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty",[97],"2009-03",716,[39],[2887,4790],{"nctId":4809,"briefTitle":4810,"status":136,"phases":4811,"primaryCompletion":2999,"completion":549,"start":4437,"enrollment":4812,"conditions":4813,"interventions":4815},"NCT01181167","A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty",[97],610,[4814,39],"Prevention",[2887,4790],{"trials":4817,"activeCount":105},[],{"trials":4819,"activeCount":105},[],{"intervention":4404,"totalTrials":146,"cells":4821},{"EARLY_PHASE1":4822,"PHASE1":4824,"PHASE2":4826,"PHASE3":4828,"PHASE4":4838,"NA":4840},{"trials":4823,"activeCount":105},[],{"trials":4825,"activeCount":105},[],{"trials":4827,"activeCount":105},[],{"trials":4829,"activeCount":105},[4830,4834],{"nctId":4396,"briefTitle":4397,"status":136,"phases":4831,"primaryCompletion":4399,"completion":4399,"start":4400,"enrollment":4401,"conditions":4832,"interventions":4833},[97],[31],[4366,4404,4404],{"nctId":4406,"briefTitle":4407,"status":136,"phases":4835,"primaryCompletion":2773,"completion":2773,"start":2765,"enrollment":3113,"conditions":4836,"interventions":4837},[96,97],[2750],[4404,4366],{"trials":4839,"activeCount":105},[],{"trials":4841,"activeCount":105},[],{"intervention":4843,"totalTrials":395,"cells":4844},"CS-8958",{"EARLY_PHASE1":4845,"PHASE1":4847,"PHASE2":4849,"PHASE3":4851,"PHASE4":4862,"NA":4864},{"trials":4846,"activeCount":105},[],{"trials":4848,"activeCount":105},[],{"trials":4850,"activeCount":105},[],{"trials":4852,"activeCount":105},[4853],{"nctId":4854,"briefTitle":4855,"status":136,"phases":4856,"primaryCompletion":4804,"completion":593,"start":3050,"enrollment":4857,"conditions":4858,"interventions":4860},"NCT00803595","A Multinational Phase III Study of CS-8958 (MARVEL)",[97],1002,[4859],"Influenza, Human",[4843,4843,4861],"oseltamivir phosphate",{"trials":4863,"activeCount":105},[],{"trials":4865,"activeCount":105},[],{"intervention":4861,"totalTrials":395,"cells":4867},{"EARLY_PHASE1":4868,"PHASE1":4870,"PHASE2":4872,"PHASE3":4874,"PHASE4":4880,"NA":4882},{"trials":4869,"activeCount":105},[],{"trials":4871,"activeCount":105},[],{"trials":4873,"activeCount":105},[],{"trials":4875,"activeCount":105},[4876],{"nctId":4854,"briefTitle":4855,"status":136,"phases":4877,"primaryCompletion":4804,"completion":593,"start":3050,"enrollment":4857,"conditions":4878,"interventions":4879},[97],[4859],[4843,4843,4861],{"trials":4881,"activeCount":105},[],{"trials":4883,"activeCount":105},[],{"intervention":4885,"totalTrials":395,"cells":4886},"Sodium hyaluronate",{"EARLY_PHASE1":4887,"PHASE1":4889,"PHASE2":4891,"PHASE3":4893,"PHASE4":4902,"NA":4904},{"trials":4888,"activeCount":105},[],{"trials":4890,"activeCount":105},[],{"trials":4892,"activeCount":105},[],{"trials":4894,"activeCount":105},[4895],{"nctId":4896,"briefTitle":4897,"status":175,"phases":4898,"primaryCompletion":2735,"completion":2735,"start":4106,"enrollment":4151,"conditions":4899,"interventions":4901},"NCT00330135","The Efficacy Study of Sodium Hyaluronate to Treat Symptomatic Hip Osteoarthritis",[97],[4900],"Symptomatic Hip Osteoarthritis",[4885],{"trials":4903,"activeCount":105},[],{"trials":4905,"activeCount":105},[],{"intervention":4907,"totalTrials":395,"cells":4908},"CS8635 20\u002F5\u002F12.5mg and placebo",{"EARLY_PHASE1":4909,"PHASE1":4911,"PHASE2":4913,"PHASE3":4915,"PHASE4":4926,"NA":4928},{"trials":4910,"activeCount":105},[],{"trials":4912,"activeCount":105},[],{"trials":4914,"activeCount":105},[],{"trials":4916,"activeCount":105},[4917],{"nctId":4918,"briefTitle":4919,"status":136,"phases":4920,"primaryCompletion":4921,"completion":4921,"start":4186,"enrollment":4922,"conditions":4923,"interventions":4924},"NCT01838850","Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy",[97],"2014-08",344,[34],[4907,4925],"Olmetec® Plus 20\u002F12.5mg and placebo",{"trials":4927,"activeCount":105},[],{"trials":4929,"activeCount":105},[],{"intervention":4925,"totalTrials":395,"cells":4931},{"EARLY_PHASE1":4932,"PHASE1":4934,"PHASE2":4936,"PHASE3":4938,"PHASE4":4944,"NA":4946},{"trials":4933,"activeCount":105},[],{"trials":4935,"activeCount":105},[],{"trials":4937,"activeCount":105},[],{"trials":4939,"activeCount":105},[4940],{"nctId":4918,"briefTitle":4919,"status":136,"phases":4941,"primaryCompletion":4921,"completion":4921,"start":4186,"enrollment":4922,"conditions":4942,"interventions":4943},[97],[34],[4907,4925],{"trials":4945,"activeCount":105},[],{"trials":4947,"activeCount":105},[],{"intervention":3958,"totalTrials":395,"cells":4949},{"EARLY_PHASE1":4950,"PHASE1":4952,"PHASE2":4954,"PHASE3":4956,"PHASE4":4962,"NA":4964},{"trials":4951,"activeCount":105},[],{"trials":4953,"activeCount":105},[],{"trials":4955,"activeCount":105},[],{"trials":4957,"activeCount":105},[4958],{"nctId":3952,"briefTitle":3953,"status":136,"phases":4959,"primaryCompletion":2988,"completion":2988,"start":3955,"conditions":4960,"interventions":4961},[97],[1238],[3847,3958],{"trials":4963,"activeCount":105},[],{"trials":4965,"activeCount":105},[],{"intervention":4442,"totalTrials":395,"cells":4967},{"EARLY_PHASE1":4968,"PHASE1":4970,"PHASE2":4972,"PHASE3":4974,"PHASE4":4980,"NA":4982},{"trials":4969,"activeCount":105},[],{"trials":4971,"activeCount":105},[],{"trials":4973,"activeCount":105},[],{"trials":4975,"activeCount":105},[4976],{"nctId":4434,"briefTitle":4435,"status":136,"phases":4977,"primaryCompletion":2809,"completion":4437,"start":3800,"enrollment":4438,"conditions":4978,"interventions":4979},[97],[31,42,4440],[4442,4443,4444,4394],{"trials":4981,"activeCount":105},[],{"trials":4983,"activeCount":105},[],{"intervention":4443,"totalTrials":395,"cells":4985},{"EARLY_PHASE1":4986,"PHASE1":4988,"PHASE2":4990,"PHASE3":4992,"PHASE4":4998,"NA":5000},{"trials":4987,"activeCount":105},[],{"trials":4989,"activeCount":105},[],{"trials":4991,"activeCount":105},[],{"trials":4993,"activeCount":105},[4994],{"nctId":4434,"briefTitle":4435,"status":136,"phases":4995,"primaryCompletion":2809,"completion":4437,"start":3800,"enrollment":4438,"conditions":4996,"interventions":4997},[97],[31,42,4440],[4442,4443,4444,4394],{"trials":4999,"activeCount":105},[],{"trials":5001,"activeCount":105},[],{"intervention":4444,"totalTrials":395,"cells":5003},{"EARLY_PHASE1":5004,"PHASE1":5006,"PHASE2":5008,"PHASE3":5010,"PHASE4":5016,"NA":5018},{"trials":5005,"activeCount":105},[],{"trials":5007,"activeCount":105},[],{"trials":5009,"activeCount":105},[],{"trials":5011,"activeCount":105},[5012],{"nctId":4434,"briefTitle":4435,"status":136,"phases":5013,"primaryCompletion":2809,"completion":4437,"start":3800,"enrollment":4438,"conditions":5014,"interventions":5015},[97],[31,42,4440],[4442,4443,4444,4394],{"trials":5017,"activeCount":105},[],{"trials":5019,"activeCount":105},[],{"intervention":3116,"totalTrials":395,"cells":5021},{"EARLY_PHASE1":5022,"PHASE1":5024,"PHASE2":5026,"PHASE3":5028,"PHASE4":5034,"NA":5036},{"trials":5023,"activeCount":105},[],{"trials":5025,"activeCount":105},[],{"trials":5027,"activeCount":105},[],{"trials":5029,"activeCount":105},[5030],{"nctId":3108,"briefTitle":3109,"status":136,"phases":5031,"primaryCompletion":2988,"completion":3111,"start":3112,"enrollment":3113,"conditions":5032,"interventions":5033},[97],[34],[3097,3116],{"trials":5035,"activeCount":105},[],{"trials":5037,"activeCount":105},[],{"intervention":5039,"totalTrials":395,"cells":5040},"Dalteparin",{"EARLY_PHASE1":5041,"PHASE1":5043,"PHASE2":5045,"PHASE3":5047,"PHASE4":5059,"NA":5061},{"trials":5042,"activeCount":105},[],{"trials":5044,"activeCount":105},[],{"trials":5046,"activeCount":105},[],{"trials":5048,"activeCount":105},[5049],{"nctId":5050,"briefTitle":5051,"status":136,"phases":5052,"primaryCompletion":5053,"completion":5053,"start":5054,"enrollment":5055,"conditions":5056,"interventions":5057},"NCT02073682","Cancer Venous Thromboembolism (VTE)",[97],"2017-09-15","2015-07-16",1046,[4714,4190,4191,4011],[2900,5039,5058],"Low molecular weight heparin",{"trials":5060,"activeCount":105},[],{"trials":5062,"activeCount":105},[],{"intervention":5058,"totalTrials":395,"cells":5064},{"EARLY_PHASE1":5065,"PHASE1":5067,"PHASE2":5069,"PHASE3":5071,"PHASE4":5077,"NA":5079},{"trials":5066,"activeCount":105},[],{"trials":5068,"activeCount":105},[],{"trials":5070,"activeCount":105},[],{"trials":5072,"activeCount":105},[5073],{"nctId":5050,"briefTitle":5051,"status":136,"phases":5074,"primaryCompletion":5053,"completion":5053,"start":5054,"enrollment":5055,"conditions":5075,"interventions":5076},[97],[4714,4190,4191,4011],[2900,5039,5058],{"trials":5078,"activeCount":105},[],{"trials":5080,"activeCount":105},[],{"intervention":3126,"totalTrials":395,"cells":5082},{"EARLY_PHASE1":5083,"PHASE1":5085,"PHASE2":5087,"PHASE3":5089,"PHASE4":5095,"NA":5097},{"trials":5084,"activeCount":105},[],{"trials":5086,"activeCount":105},[],{"trials":5088,"activeCount":105},[],{"trials":5090,"activeCount":105},[5091],{"nctId":3118,"briefTitle":3119,"status":136,"phases":5092,"primaryCompletion":3036,"completion":2987,"start":3121,"enrollment":3122,"conditions":5093,"interventions":5094},[97],[3124],[3097,3126],{"trials":5096,"activeCount":105},[],{"trials":5098,"activeCount":105},[],{"intervention":5100,"totalTrials":395,"cells":5101},"olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo",{"EARLY_PHASE1":5102,"PHASE1":5104,"PHASE2":5106,"PHASE3":5108,"PHASE4":5121,"NA":5123},{"trials":5103,"activeCount":105},[],{"trials":5105,"activeCount":105},[],{"trials":5107,"activeCount":105},[],{"trials":5109,"activeCount":105},[5110],{"nctId":5111,"briefTitle":5112,"status":136,"phases":5113,"primaryCompletion":5114,"completion":3974,"start":593,"enrollment":5115,"conditions":5116,"interventions":5117},"NCT00923091","Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension",[97],"2011-01",2689,[34],[5100,5118,5119,5119,5119,5120,5120,5120],"Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo","olmesartan medoxomil + amlodipine + hydroclororthiazide","olmesartan medoxomil + amlodipine",{"trials":5122,"activeCount":105},[],{"trials":5124,"activeCount":105},[],{"intervention":5118,"totalTrials":395,"cells":5126},{"EARLY_PHASE1":5127,"PHASE1":5129,"PHASE2":5131,"PHASE3":5133,"PHASE4":5139,"NA":5141},{"trials":5128,"activeCount":105},[],{"trials":5130,"activeCount":105},[],{"trials":5132,"activeCount":105},[],{"trials":5134,"activeCount":105},[5135],{"nctId":5111,"briefTitle":5112,"status":136,"phases":5136,"primaryCompletion":5114,"completion":3974,"start":593,"enrollment":5115,"conditions":5137,"interventions":5138},[97],[34],[5100,5118,5119,5119,5119,5120,5120,5120],{"trials":5140,"activeCount":105},[],{"trials":5142,"activeCount":105},[],{"intervention":5119,"totalTrials":395,"cells":5144},{"EARLY_PHASE1":5145,"PHASE1":5147,"PHASE2":5149,"PHASE3":5151,"PHASE4":5157,"NA":5159},{"trials":5146,"activeCount":105},[],{"trials":5148,"activeCount":105},[],{"trials":5150,"activeCount":105},[],{"trials":5152,"activeCount":105},[5153],{"nctId":5111,"briefTitle":5112,"status":136,"phases":5154,"primaryCompletion":5114,"completion":3974,"start":593,"enrollment":5115,"conditions":5155,"interventions":5156},[97],[34],[5100,5118,5119,5119,5119,5120,5120,5120],{"trials":5158,"activeCount":105},[],{"trials":5160,"activeCount":105},[],{"intervention":5120,"totalTrials":395,"cells":5162},{"EARLY_PHASE1":5163,"PHASE1":5165,"PHASE2":5167,"PHASE3":5169,"PHASE4":5175,"NA":5177},{"trials":5164,"activeCount":105},[],{"trials":5166,"activeCount":105},[],{"trials":5168,"activeCount":105},[],{"trials":5170,"activeCount":105},[5171],{"nctId":5111,"briefTitle":5112,"status":136,"phases":5172,"primaryCompletion":5114,"completion":3974,"start":593,"enrollment":5115,"conditions":5173,"interventions":5174},[97],[34],[5100,5118,5119,5119,5119,5120,5120,5120],{"trials":5176,"activeCount":105},[],{"trials":5178,"activeCount":105},[],{"intervention":5180,"totalTrials":395,"cells":5181},"olmesartan medoxomil (OM)\u002F hydrochlorothiazide (HCTZ) 20mg\u002F25mg",{"EARLY_PHASE1":5182,"PHASE1":5184,"PHASE2":5186,"PHASE3":5188,"PHASE4":5198,"NA":5200},{"trials":5183,"activeCount":105},[],{"trials":5185,"activeCount":105},[],{"trials":5187,"activeCount":105},[],{"trials":5189,"activeCount":105},[5190],{"nctId":5191,"briefTitle":5192,"status":136,"phases":5193,"primaryCompletion":2811,"completion":2821,"start":3073,"enrollment":5194,"conditions":5195,"interventions":5196},"NCT00430950","Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension",[97],1011,[34],[5197,5180],"olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ)",{"trials":5199,"activeCount":105},[],{"trials":5201,"activeCount":105},[],{"intervention":5203,"totalTrials":395,"cells":5204},"Welchol",{"EARLY_PHASE1":5205,"PHASE1":5207,"PHASE2":5209,"PHASE3":5211,"PHASE4":5220,"NA":5222},{"trials":5206,"activeCount":105},[],{"trials":5208,"activeCount":105},[],{"trials":5210,"activeCount":105},[],{"trials":5212,"activeCount":105},[5213],{"nctId":5214,"briefTitle":5215,"status":136,"phases":5216,"primaryCompletion":583,"completion":583,"start":4473,"enrollment":5217,"conditions":5218,"interventions":5219},"NCT00789737","Welchol as Monotherapy for Type 2 Diabetes Mellitus",[97],357,[31],[5203],{"trials":5221,"activeCount":105},[],{"trials":5223,"activeCount":105},[],{"intervention":5225,"totalTrials":395,"cells":5226},"olmesartan medoxomil + candesartan cilexetil placebo",{"EARLY_PHASE1":5227,"PHASE1":5229,"PHASE2":5231,"PHASE3":5233,"PHASE4":5244,"NA":5246},{"trials":5228,"activeCount":105},[],{"trials":5230,"activeCount":105},[],{"trials":5232,"activeCount":105},[],{"trials":5234,"activeCount":105},[5235],{"nctId":5236,"briefTitle":5237,"status":175,"phases":5238,"primaryCompletion":4087,"completion":4087,"start":4165,"enrollment":2757,"conditions":5239,"interventions":5242},"NCT00679484","Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24",[97],[5240,5241],"Chronic Heart Failure","High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level",[5225,5243],"olmesartan medoxomil placebo + candesartan cilexetil",{"trials":5245,"activeCount":105},[],{"trials":5247,"activeCount":105},[],{"intervention":5243,"totalTrials":395,"cells":5249},{"EARLY_PHASE1":5250,"PHASE1":5252,"PHASE2":5254,"PHASE3":5256,"PHASE4":5262,"NA":5264},{"trials":5251,"activeCount":105},[],{"trials":5253,"activeCount":105},[],{"trials":5255,"activeCount":105},[],{"trials":5257,"activeCount":105},[5258],{"nctId":5236,"briefTitle":5237,"status":175,"phases":5259,"primaryCompletion":4087,"completion":4087,"start":4165,"enrollment":2757,"conditions":5260,"interventions":5261},[97],[5240,5241],[5225,5243],{"trials":5263,"activeCount":105},[],{"trials":5265,"activeCount":105},[],{"intervention":5267,"totalTrials":395,"cells":5268},"ofloxacin otic solution 0.3%",{"EARLY_PHASE1":5269,"PHASE1":5271,"PHASE2":5273,"PHASE3":5275,"PHASE4":5286,"NA":5288},{"trials":5270,"activeCount":105},[],{"trials":5272,"activeCount":105},[],{"trials":5274,"activeCount":105},[],{"trials":5276,"activeCount":105},[5277],{"nctId":5278,"briefTitle":5279,"status":136,"phases":5280,"primaryCompletion":5281,"completion":5281,"start":3479,"enrollment":5282,"conditions":5283,"interventions":5285},"NCT00781521","Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media in Children",[97],"2003-04",96,[5284],"Otitis Media",[5267],{"trials":5287,"activeCount":105},[],{"trials":5289,"activeCount":105},[],{"intervention":5291,"totalTrials":395,"cells":5292},"Pactimibe sulfate",{"EARLY_PHASE1":5293,"PHASE1":5295,"PHASE2":5297,"PHASE3":5299,"PHASE4":5311,"NA":5313},{"trials":5294,"activeCount":105},[],{"trials":5296,"activeCount":105},[],{"trials":5298,"activeCount":105},[],{"trials":5300,"activeCount":105},[5301],{"nctId":5302,"briefTitle":5303,"status":175,"phases":5304,"primaryCompletion":5305,"completion":5305,"start":1653,"enrollment":5306,"conditions":5307,"interventions":5310},"NCT00151788","Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.",[96,97],"2006-03",796,[5308,5309],"Atherosclerosis","Heterozygous Familial Hypercholesterolemia",[5291],{"trials":5312,"activeCount":105},[],{"trials":5314,"activeCount":105},[],{"intervention":4488,"totalTrials":395,"cells":5316},{"EARLY_PHASE1":5317,"PHASE1":5319,"PHASE2":5321,"PHASE3":5323,"PHASE4":5329,"NA":5331},{"trials":5318,"activeCount":105},[],{"trials":5320,"activeCount":105},[],{"trials":5322,"activeCount":105},[],{"trials":5324,"activeCount":105},[5325],{"nctId":4480,"briefTitle":4481,"status":175,"phases":5326,"primaryCompletion":4483,"completion":4483,"start":4484,"enrollment":4485,"conditions":5327,"interventions":5328},[97],[31],[4454,4468,4468,4476,4476,4488,4489],{"trials":5330,"activeCount":105},[],{"trials":5332,"activeCount":105},[],{"intervention":5334,"totalTrials":395,"cells":5335},"Transdermal Patch",{"EARLY_PHASE1":5336,"PHASE1":5338,"PHASE2":5340,"PHASE3":5342,"PHASE4":5354,"NA":5356},{"trials":5337,"activeCount":105},[],{"trials":5339,"activeCount":105},[],{"trials":5341,"activeCount":105},[],{"trials":5343,"activeCount":105},[5344],{"nctId":5345,"briefTitle":5346,"status":136,"phases":5347,"primaryCompletion":5348,"completion":5348,"start":2090,"enrollment":5349,"conditions":5350,"interventions":5352},"NCT02616068","Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma",[97],"2016-12",242,[5351,4233],"Trauma",[5334,5353],"Loxoprofen sodium",{"trials":5355,"activeCount":105},[],{"trials":5357,"activeCount":105},[],{"intervention":5353,"totalTrials":395,"cells":5359},{"EARLY_PHASE1":5360,"PHASE1":5362,"PHASE2":5364,"PHASE3":5366,"PHASE4":5372,"NA":5374},{"trials":5361,"activeCount":105},[],{"trials":5363,"activeCount":105},[],{"trials":5365,"activeCount":105},[],{"trials":5367,"activeCount":105},[5368],{"nctId":5345,"briefTitle":5346,"status":136,"phases":5369,"primaryCompletion":5348,"completion":5348,"start":2090,"enrollment":5349,"conditions":5370,"interventions":5371},[97],[5351,4233],[5334,5353],{"trials":5373,"activeCount":105},[],{"trials":5375,"activeCount":105},[],{"intervention":5377,"totalTrials":395,"cells":5378},"15mg DU-176b",{"EARLY_PHASE1":5379,"PHASE1":5381,"PHASE2":5383,"PHASE3":5385,"PHASE4":5396,"NA":5398},{"trials":5380,"activeCount":105},[],{"trials":5382,"activeCount":105},[],{"trials":5384,"activeCount":105},[],{"trials":5386,"activeCount":105},[5387],{"nctId":5388,"briefTitle":5389,"status":136,"phases":5390,"primaryCompletion":3220,"completion":3220,"start":3419,"enrollment":5391,"conditions":5392,"interventions":5393},"NCT01857583","Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs",[97],80,[39],[5377,5394,5395],"30mg DU-176b","Fondaparinux",{"trials":5397,"activeCount":105},[],{"trials":5399,"activeCount":105},[],{"intervention":5394,"totalTrials":395,"cells":5401},{"EARLY_PHASE1":5402,"PHASE1":5404,"PHASE2":5406,"PHASE3":5408,"PHASE4":5414,"NA":5416},{"trials":5403,"activeCount":105},[],{"trials":5405,"activeCount":105},[],{"trials":5407,"activeCount":105},[],{"trials":5409,"activeCount":105},[5410],{"nctId":5388,"briefTitle":5389,"status":136,"phases":5411,"primaryCompletion":3220,"completion":3220,"start":3419,"enrollment":5391,"conditions":5412,"interventions":5413},[97],[39],[5377,5394,5395],{"trials":5415,"activeCount":105},[],{"trials":5417,"activeCount":105},[],{"intervention":5395,"totalTrials":395,"cells":5419},{"EARLY_PHASE1":5420,"PHASE1":5422,"PHASE2":5424,"PHASE3":5426,"PHASE4":5432,"NA":5434},{"trials":5421,"activeCount":105},[],{"trials":5423,"activeCount":105},[],{"trials":5425,"activeCount":105},[],{"trials":5427,"activeCount":105},[5428],{"nctId":5388,"briefTitle":5389,"status":136,"phases":5429,"primaryCompletion":3220,"completion":3220,"start":3419,"enrollment":5391,"conditions":5430,"interventions":5431},[97],[39],[5377,5394,5395],{"trials":5433,"activeCount":105},[],{"trials":5435,"activeCount":105},[],{"intervention":225,"totalTrials":395,"cells":5437},{"EARLY_PHASE1":5438,"PHASE1":5440,"PHASE2":5442,"PHASE3":5444,"PHASE4":5450,"NA":5452},{"trials":5439,"activeCount":105},[],{"trials":5441,"activeCount":105},[],{"trials":5443,"activeCount":105},[],{"trials":5445,"activeCount":105},[5446],{"nctId":215,"briefTitle":216,"status":136,"phases":5447,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":5448,"interventions":5449},[97],[44],[55,224,225,226],{"trials":5451,"activeCount":105},[],{"trials":5453,"activeCount":105},[],{"intervention":2825,"totalTrials":395,"cells":5455},{"EARLY_PHASE1":5456,"PHASE1":5458,"PHASE2":5460,"PHASE3":5462,"PHASE4":5468,"NA":5470},{"trials":5457,"activeCount":105},[],{"trials":5459,"activeCount":105},[],{"trials":5461,"activeCount":105},[],{"trials":5463,"activeCount":105},[5464],{"nctId":2817,"briefTitle":2818,"status":136,"phases":5465,"primaryCompletion":547,"completion":2820,"start":2821,"enrollment":2482,"conditions":5466,"interventions":5467},[97],[2823,25],[2825,2826,2785],{"trials":5469,"activeCount":105},[],{"trials":5471,"activeCount":105},[],{"intervention":2826,"totalTrials":395,"cells":5473},{"EARLY_PHASE1":5474,"PHASE1":5476,"PHASE2":5478,"PHASE3":5480,"PHASE4":5486,"NA":5488},{"trials":5475,"activeCount":105},[],{"trials":5477,"activeCount":105},[],{"trials":5479,"activeCount":105},[],{"trials":5481,"activeCount":105},[5482],{"nctId":2817,"briefTitle":2818,"status":136,"phases":5483,"primaryCompletion":547,"completion":2820,"start":2821,"enrollment":2482,"conditions":5484,"interventions":5485},[97],[2823,25],[2825,2826,2785],{"trials":5487,"activeCount":105},[],{"trials":5489,"activeCount":105},[],{"intervention":4131,"totalTrials":395,"cells":5491},{"EARLY_PHASE1":5492,"PHASE1":5494,"PHASE2":5496,"PHASE3":5498,"PHASE4":5504,"NA":5506},{"trials":5493,"activeCount":105},[],{"trials":5495,"activeCount":105},[],{"trials":5497,"activeCount":105},[],{"trials":5499,"activeCount":105},[5500],{"nctId":4125,"briefTitle":4126,"status":136,"phases":5501,"primaryCompletion":3000,"completion":2921,"start":2821,"enrollment":4128,"conditions":5502,"interventions":5503},[97],[39],[4065,4131],{"trials":5505,"activeCount":105},[],{"trials":5507,"activeCount":105},[],{"intervention":4748,"totalTrials":395,"cells":5509},{"EARLY_PHASE1":5510,"PHASE1":5512,"PHASE2":5514,"PHASE3":5516,"PHASE4":5522,"NA":5524},{"trials":5511,"activeCount":105},[],{"trials":5513,"activeCount":105},[],{"trials":5515,"activeCount":105},[],{"trials":5517,"activeCount":105},[5518],{"nctId":4741,"briefTitle":4742,"status":136,"phases":5519,"primaryCompletion":4744,"completion":4744,"start":4736,"enrollment":4745,"conditions":5520,"interventions":5521},[97],[28],[4748,4749],{"trials":5523,"activeCount":105},[],{"trials":5525,"activeCount":105},[],{"intervention":3077,"totalTrials":395,"cells":5527},{"EARLY_PHASE1":5528,"PHASE1":5530,"PHASE2":5532,"PHASE3":5534,"PHASE4":5540,"NA":5542},{"trials":5529,"activeCount":105},[],{"trials":5531,"activeCount":105},[],{"trials":5533,"activeCount":105},[],{"trials":5535,"activeCount":105},[5536],{"nctId":3069,"briefTitle":3070,"status":136,"phases":5537,"primaryCompletion":3072,"completion":2811,"start":3073,"enrollment":3074,"conditions":5538,"interventions":5539},[97],[34],[3077,3078,3079,3079],{"trials":5541,"activeCount":105},[],{"trials":5543,"activeCount":105},[],{"intervention":956,"totalTrials":395,"cells":5545},{"EARLY_PHASE1":5546,"PHASE1":5548,"PHASE2":5550,"PHASE3":5552,"PHASE4":5558,"NA":5560},{"trials":5547,"activeCount":105},[],{"trials":5549,"activeCount":105},[],{"trials":5551,"activeCount":105},[],{"trials":5553,"activeCount":105},[5554],{"nctId":946,"briefTitle":947,"status":136,"phases":5555,"primaryCompletion":949,"completion":950,"start":951,"enrollment":952,"conditions":5556,"interventions":5557},[97],[954],[742,956],{"trials":5559,"activeCount":105},[],{"trials":5561,"activeCount":105},[],{"intervention":5563,"totalTrials":395,"cells":5564},"olmesartan medoxomil + hydrochlorothiazide",{"EARLY_PHASE1":5565,"PHASE1":5567,"PHASE2":5569,"PHASE3":5571,"PHASE4":5580,"NA":5582},{"trials":5566,"activeCount":105},[],{"trials":5568,"activeCount":105},[],{"trials":5570,"activeCount":105},[],{"trials":5572,"activeCount":105},[5573],{"nctId":5574,"briefTitle":5575,"status":136,"phases":5576,"primaryCompletion":2764,"completion":3351,"start":2756,"enrollment":5577,"conditions":5578,"interventions":5579},"NCT00872586","Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg \u002F Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension",[97],304,[34],[5563,2982],{"trials":5581,"activeCount":105},[],{"trials":5583,"activeCount":105},[],{"intervention":5585,"totalTrials":395,"cells":5586},"Olmesartan medoxomil 40 mg - Amlodipine 10 mg",{"EARLY_PHASE1":5587,"PHASE1":5589,"PHASE2":5591,"PHASE3":5593,"PHASE4":5607,"NA":5609},{"trials":5588,"activeCount":105},[],{"trials":5590,"activeCount":105},[],{"trials":5592,"activeCount":105},[],{"trials":5594,"activeCount":105},[5595],{"nctId":5596,"briefTitle":5597,"status":136,"phases":5598,"primaryCompletion":4300,"completion":5599,"start":2809,"enrollment":5600,"conditions":5601,"interventions":5602},"NCT00902538","Hydrochlorothiazide as add-on to Olmesartan\u002FAmlodipine in Hypertension",[97],"2010-10",2204,[34],[5585,5603,5604,5605,5605,5606],"Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg","Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg","OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg","OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg",{"trials":5608,"activeCount":105},[],{"trials":5610,"activeCount":105},[],{"intervention":5603,"totalTrials":395,"cells":5612},{"EARLY_PHASE1":5613,"PHASE1":5615,"PHASE2":5617,"PHASE3":5619,"PHASE4":5625,"NA":5627},{"trials":5614,"activeCount":105},[],{"trials":5616,"activeCount":105},[],{"trials":5618,"activeCount":105},[],{"trials":5620,"activeCount":105},[5621],{"nctId":5596,"briefTitle":5597,"status":136,"phases":5622,"primaryCompletion":4300,"completion":5599,"start":2809,"enrollment":5600,"conditions":5623,"interventions":5624},[97],[34],[5585,5603,5604,5605,5605,5606],{"trials":5626,"activeCount":105},[],{"trials":5628,"activeCount":105},[],{"intervention":5604,"totalTrials":395,"cells":5630},{"EARLY_PHASE1":5631,"PHASE1":5633,"PHASE2":5635,"PHASE3":5637,"PHASE4":5643,"NA":5645},{"trials":5632,"activeCount":105},[],{"trials":5634,"activeCount":105},[],{"trials":5636,"activeCount":105},[],{"trials":5638,"activeCount":105},[5639],{"nctId":5596,"briefTitle":5597,"status":136,"phases":5640,"primaryCompletion":4300,"completion":5599,"start":2809,"enrollment":5600,"conditions":5641,"interventions":5642},[97],[34],[5585,5603,5604,5605,5605,5606],{"trials":5644,"activeCount":105},[],{"trials":5646,"activeCount":105},[],{"intervention":5605,"totalTrials":395,"cells":5648},{"EARLY_PHASE1":5649,"PHASE1":5651,"PHASE2":5653,"PHASE3":5655,"PHASE4":5661,"NA":5663},{"trials":5650,"activeCount":105},[],{"trials":5652,"activeCount":105},[],{"trials":5654,"activeCount":105},[],{"trials":5656,"activeCount":105},[5657],{"nctId":5596,"briefTitle":5597,"status":136,"phases":5658,"primaryCompletion":4300,"completion":5599,"start":2809,"enrollment":5600,"conditions":5659,"interventions":5660},[97],[34],[5585,5603,5604,5605,5605,5606],{"trials":5662,"activeCount":105},[],{"trials":5664,"activeCount":105},[],{"intervention":5606,"totalTrials":395,"cells":5666},{"EARLY_PHASE1":5667,"PHASE1":5669,"PHASE2":5671,"PHASE3":5673,"PHASE4":5679,"NA":5681},{"trials":5668,"activeCount":105},[],{"trials":5670,"activeCount":105},[],{"trials":5672,"activeCount":105},[],{"trials":5674,"activeCount":105},[5675],{"nctId":5596,"briefTitle":5597,"status":136,"phases":5676,"primaryCompletion":4300,"completion":5599,"start":2809,"enrollment":5600,"conditions":5677,"interventions":5678},[97],[34],[5585,5603,5604,5605,5605,5606],{"trials":5680,"activeCount":105},[],{"trials":5682,"activeCount":105},[],{"intervention":2902,"totalTrials":395,"cells":5684},{"EARLY_PHASE1":5685,"PHASE1":5687,"PHASE2":5689,"PHASE3":5691,"PHASE4":5697,"NA":5699},{"trials":5686,"activeCount":105},[],{"trials":5688,"activeCount":105},[],{"trials":5690,"activeCount":105},[],{"trials":5692,"activeCount":105},[5693],{"nctId":2892,"briefTitle":2893,"status":136,"phases":5694,"primaryCompletion":2895,"completion":2895,"start":2896,"enrollment":2897,"conditions":5695,"interventions":5696},[97],[28],[2900,2860,2901,2902,2903],{"trials":5698,"activeCount":105},[],{"trials":5700,"activeCount":105},[],{"intervention":2903,"totalTrials":395,"cells":5702},{"EARLY_PHASE1":5703,"PHASE1":5705,"PHASE2":5707,"PHASE3":5709,"PHASE4":5715,"NA":5717},{"trials":5704,"activeCount":105},[],{"trials":5706,"activeCount":105},[],{"trials":5708,"activeCount":105},[],{"trials":5710,"activeCount":105},[5711],{"nctId":2892,"briefTitle":2893,"status":136,"phases":5712,"primaryCompletion":2895,"completion":2895,"start":2896,"enrollment":2897,"conditions":5713,"interventions":5714},[97],[28],[2900,2860,2901,2902,2903],{"trials":5716,"activeCount":105},[],{"trials":5718,"activeCount":105},[],{"intervention":4523,"totalTrials":395,"cells":5720},{"EARLY_PHASE1":5721,"PHASE1":5723,"PHASE2":5725,"PHASE3":5727,"PHASE4":5733,"NA":5735},{"trials":5722,"activeCount":105},[],{"trials":5724,"activeCount":105},[],{"trials":5726,"activeCount":105},[],{"trials":5728,"activeCount":105},[5729],{"nctId":4516,"briefTitle":4517,"status":136,"phases":5730,"primaryCompletion":3998,"completion":3998,"start":562,"enrollment":4519,"conditions":5731,"interventions":5732},[97],[4521],[4495,4511,4523],{"trials":5734,"activeCount":105},[],{"trials":5736,"activeCount":105},[],{"intervention":3187,"totalTrials":395,"cells":5738},{"EARLY_PHASE1":5739,"PHASE1":5741,"PHASE2":5743,"PHASE3":5745,"PHASE4":5751,"NA":5753},{"trials":5740,"activeCount":105},[],{"trials":5742,"activeCount":105},[],{"trials":5744,"activeCount":105},[],{"trials":5746,"activeCount":105},[5747],{"nctId":3178,"briefTitle":3179,"status":136,"phases":5748,"primaryCompletion":2831,"completion":2831,"start":3181,"enrollment":3182,"conditions":5749,"interventions":5750},[97],[2750,3184],[3186,3187,3188],{"trials":5752,"activeCount":105},[],{"trials":5754,"activeCount":105},[],{"intervention":3188,"totalTrials":395,"cells":5756},{"EARLY_PHASE1":5757,"PHASE1":5759,"PHASE2":5761,"PHASE3":5763,"PHASE4":5769,"NA":5771},{"trials":5758,"activeCount":105},[],{"trials":5760,"activeCount":105},[],{"trials":5762,"activeCount":105},[],{"trials":5764,"activeCount":105},[5765],{"nctId":3178,"briefTitle":3179,"status":136,"phases":5766,"primaryCompletion":2831,"completion":2831,"start":3181,"enrollment":3182,"conditions":5767,"interventions":5768},[97],[2750,3184],[3186,3187,3188],{"trials":5770,"activeCount":105},[],{"trials":5772,"activeCount":105},[],{"intervention":5774,"totalTrials":395,"cells":5775},"Alendronate sodium hydrate",{"EARLY_PHASE1":5776,"PHASE1":5778,"PHASE2":5780,"PHASE3":5782,"PHASE4":5794,"NA":5796},{"trials":5777,"activeCount":105},[],{"trials":5779,"activeCount":105},[],{"trials":5781,"activeCount":105},[],{"trials":5783,"activeCount":105},[5784],{"nctId":5785,"briefTitle":5786,"status":136,"phases":5787,"primaryCompletion":5788,"completion":4000,"start":2811,"enrollment":5789,"conditions":5790,"interventions":5792},"NCT00680953","Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis",[97],"2012-06",1262,[5791],"Osteoporosis",[5793,5774],"Denosumab",{"trials":5795,"activeCount":105},[],{"trials":5797,"activeCount":105},[],{"intervention":4193,"totalTrials":395,"cells":5799},{"EARLY_PHASE1":5800,"PHASE1":5802,"PHASE2":5804,"PHASE3":5806,"PHASE4":5812,"NA":5814},{"trials":5801,"activeCount":105},[],{"trials":5803,"activeCount":105},[],{"trials":5805,"activeCount":105},[],{"trials":5807,"activeCount":105},[5808],{"nctId":4183,"briefTitle":4184,"status":136,"phases":5809,"primaryCompletion":4186,"completion":4186,"start":4187,"enrollment":4188,"conditions":5810,"interventions":5811},[97],[39,4190,4191,4168,4153],[4155,4193,4137],{"trials":5813,"activeCount":105},[],{"trials":5815,"activeCount":105},[],{"intervention":2836,"totalTrials":395,"cells":5817},{"EARLY_PHASE1":5818,"PHASE1":5820,"PHASE2":5822,"PHASE3":5824,"PHASE4":5830,"NA":5832},{"trials":5819,"activeCount":105},[],{"trials":5821,"activeCount":105},[],{"trials":5823,"activeCount":105},[],{"trials":5825,"activeCount":105},[5826],{"nctId":2828,"briefTitle":2829,"status":136,"phases":5827,"primaryCompletion":2831,"completion":2831,"start":2832,"enrollment":2833,"conditions":5828,"interventions":5829},[97],[25],[2785,2836],{"trials":5831,"activeCount":105},[],{"trials":5833,"activeCount":105},[],{"intervention":5835,"totalTrials":395,"cells":5836},"cevimeline hydrochloride",{"EARLY_PHASE1":5837,"PHASE1":5839,"PHASE2":5841,"PHASE3":5843,"PHASE4":5855,"NA":5857},{"trials":5838,"activeCount":105},[],{"trials":5840,"activeCount":105},[],{"trials":5842,"activeCount":105},[],{"trials":5844,"activeCount":105},[5845],{"nctId":5846,"briefTitle":5847,"status":136,"phases":5848,"primaryCompletion":5849,"completion":5849,"start":5850,"conditions":5851,"interventions":5854},"NCT00017511","Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer",[97],"2003-03","2001-06",[1995,5852,5853],"Oral Complications","Radiation Toxicity",[5835],{"trials":5856,"activeCount":105},[],{"trials":5858,"activeCount":105},[],{"intervention":554,"totalTrials":435,"cells":5860},{"EARLY_PHASE1":5861,"PHASE1":5863,"PHASE2":5886,"PHASE3":5906,"PHASE4":5908,"NA":5910},{"trials":5862,"activeCount":105},[],{"trials":5864,"activeCount":105},[5865,5869,5873,5880],{"nctId":4287,"briefTitle":4288,"status":136,"phases":5866,"primaryCompletion":583,"completion":583,"start":2920,"enrollment":32,"conditions":5867,"interventions":5868},[95],[552],[554,4048],{"nctId":544,"briefTitle":545,"status":136,"phases":5870,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":5871,"interventions":5872},[95],[552],[554,413,249],{"nctId":5874,"briefTitle":5875,"status":136,"phases":5876,"primaryCompletion":2921,"completion":2921,"start":3801,"enrollment":897,"conditions":5877,"interventions":5879},"NCT00408434","Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer",[95],[5878],"Neoplasm",[554],{"nctId":5881,"briefTitle":5882,"status":136,"phases":5883,"primaryCompletion":3974,"completion":2910,"start":4804,"enrollment":146,"conditions":5884,"interventions":5885},"NCT00881569","Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017",[95],[311],[554],{"trials":5887,"activeCount":105},[5888,5898,5902],{"nctId":5889,"briefTitle":5890,"status":175,"phases":5891,"primaryCompletion":5892,"completion":5892,"start":5893,"enrollment":5894,"conditions":5895,"interventions":5897},"NCT00986440","Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy",[96],"2012-10-29","2009-07-31",84,[5896],"Colorectal Cancer",[554],{"nctId":580,"briefTitle":581,"status":175,"phases":5899,"primaryCompletion":583,"completion":583,"start":584,"enrollment":585,"conditions":5900,"interventions":5901},[95,96],[587],[554,249],{"nctId":4306,"briefTitle":4307,"status":136,"phases":5903,"primaryCompletion":4186,"completion":4186,"start":549,"enrollment":4309,"conditions":5904,"interventions":5905},[96],[4311],[554,4313],{"trials":5907,"activeCount":105},[],{"trials":5909,"activeCount":105},[],{"trials":5911,"activeCount":105},[],{"intervention":4246,"totalTrials":1406,"cells":5913},{"EARLY_PHASE1":5914,"PHASE1":5916,"PHASE2":5958,"PHASE3":5964,"PHASE4":5966,"NA":5968},{"trials":5915,"activeCount":105},[],{"trials":5917,"activeCount":105},[5918,5925,5932,5939,5951],{"nctId":5919,"briefTitle":5920,"status":136,"phases":5921,"primaryCompletion":2870,"completion":2870,"start":5922,"enrollment":1945,"conditions":5923,"interventions":5924},"NCT02564861","Multiple Dose Study of D1971a in Healthy Volunteers",[95],"2015-09",[3658],[4246],{"nctId":5926,"briefTitle":5927,"status":136,"phases":5928,"primaryCompletion":4254,"completion":4254,"start":5929,"enrollment":4669,"conditions":5930,"interventions":5931},"NCT02261376","Effects of Age, Gender & Race on the Pharmacokinetics (PK)of DS-1971a",[95],"2014-09",[3658],[4246],{"nctId":5933,"briefTitle":5934,"status":136,"phases":5935,"primaryCompletion":4615,"completion":4615,"start":4254,"enrollment":29,"conditions":5936,"interventions":5937},"NCT02266940","Relative Bioavailability DS-1971a Suspension and Tablets and Food Effect on DS-1971a Tablets",[95],[3658],[5938,4246],"DS-1971a suspension",{"nctId":5940,"briefTitle":5941,"status":136,"phases":5942,"primaryCompletion":5943,"completion":5943,"start":5944,"enrollment":29,"conditions":5945,"interventions":5946},"NCT02473627","A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS",[95],"2015-07","2015-05",[3658],[4246,5947,5948,5949,5950,1065],"midazolam hydrochloride","Omeprazole","Pioglitazone hydrochloride","Buproprion",{"nctId":5952,"briefTitle":5953,"status":136,"phases":5954,"primaryCompletion":4254,"completion":4254,"start":5955,"enrollment":897,"conditions":5956,"interventions":5957},"NCT02190058","Multiple Dose Study of DS-1971a",[95],"2014-07",[3658],[4246],{"trials":5959,"activeCount":105},[5960],{"nctId":4236,"briefTitle":4237,"status":1192,"phases":5961,"primaryCompletion":4239,"completion":4240,"start":4241,"enrollment":105,"conditions":5962,"interventions":5963},[96],[4243,4244],[4246,4226],{"trials":5965,"activeCount":105},[],{"trials":5967,"activeCount":105},[],{"trials":5969,"activeCount":105},[],{"intervention":597,"totalTrials":1406,"cells":5971},{"EARLY_PHASE1":5972,"PHASE1":5974,"PHASE2":5992,"PHASE3":6014,"PHASE4":6016,"NA":6018},{"trials":5973,"activeCount":105},[],{"trials":5975,"activeCount":105},[5976,5983],{"nctId":5977,"briefTitle":5978,"status":136,"phases":5979,"enrollment":1102,"conditions":5980,"interventions":5982},"NCT00320827","Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)",[95],[5981,3869],"Malignancies",[597],{"nctId":5984,"briefTitle":5985,"status":136,"phases":5986,"primaryCompletion":5987,"completion":3984,"start":2919,"enrollment":5988,"conditions":5989,"interventions":5990},"NCT01124630","Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments",[95],"2013-07",21,[1153],[597,5991],"FOLFIRI",{"trials":5993,"activeCount":105},[5994,6002,6006,6010],{"nctId":5995,"briefTitle":5996,"status":175,"phases":5997,"primaryCompletion":583,"completion":583,"start":5998,"enrollment":284,"conditions":5999,"interventions":6000},"NCT00969033","CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin",[96],"2009-07",[1153],[597,6001],"irinotecan",{"nctId":590,"briefTitle":591,"status":136,"phases":6003,"primaryCompletion":548,"completion":583,"start":593,"enrollment":594,"conditions":6004,"interventions":6005},[96],[36],[597,249,413],{"nctId":599,"briefTitle":600,"status":136,"phases":6007,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":6008,"interventions":6009},[96],[606,607],[597,249,413],{"nctId":1232,"briefTitle":1233,"status":136,"phases":6011,"primaryCompletion":1235,"completion":1235,"start":1236,"enrollment":918,"conditions":6012,"interventions":6013},[96],[1238],[597,1240],{"trials":6015,"activeCount":105},[],{"trials":6017,"activeCount":105},[],{"trials":6019,"activeCount":105},[],{"intervention":2062,"totalTrials":722,"cells":6021},{"EARLY_PHASE1":6022,"PHASE1":6024,"PHASE2":6055,"PHASE3":6063,"PHASE4":6065,"NA":6067},{"trials":6023,"activeCount":105},[],{"trials":6025,"activeCount":105},[6026,6034,6042,6051],{"nctId":6027,"briefTitle":6028,"status":136,"phases":6029,"primaryCompletion":6030,"completion":6030,"start":6031,"enrollment":2373,"conditions":6032,"interventions":6033},"NCT01468467","A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)",[95],"2015-03","2012-04",[933],[2062],{"nctId":6035,"briefTitle":6036,"status":136,"phases":6037,"primaryCompletion":4804,"completion":2810,"start":2799,"enrollment":115,"conditions":6038,"interventions":6041},"NCT00462761","A Phase I Study of AC220 in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia Regardless of FLT3 Status",[95],[752,740,6039,954,6040],"Myelodysplastic Syndrome","MDS",[2062],{"nctId":6043,"briefTitle":6044,"status":136,"phases":6045,"primaryCompletion":6046,"completion":6046,"start":4241,"enrollment":4341,"conditions":6047,"interventions":6050},"NCT02675478","Phase 1 Study of Quizartinib",[95],"2018-11-13",[6048,6049],"Relapsed AML","Refractory AML",[2062],{"nctId":2055,"briefTitle":2056,"status":136,"phases":6052,"primaryCompletion":2058,"completion":2058,"start":2059,"enrollment":585,"conditions":6053,"interventions":6054},[95],[933],[2062,2063,2064],{"trials":6056,"activeCount":105},[6057],{"nctId":6058,"briefTitle":6059,"status":136,"phases":6060,"primaryCompletion":6030,"completion":6030,"start":6031,"enrollment":115,"conditions":6061,"interventions":6062},"NCT01565668","Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia",[96],[933],[2062],{"trials":6064,"activeCount":105},[],{"trials":6066,"activeCount":105},[],{"trials":6068,"activeCount":105},[],{"intervention":2874,"totalTrials":722,"cells":6070},{"EARLY_PHASE1":6071,"PHASE1":6073,"PHASE2":6093,"PHASE3":6107,"PHASE4":6109,"NA":6111},{"trials":6072,"activeCount":105},[],{"trials":6074,"activeCount":105},[6075,6079,6087],{"nctId":2867,"briefTitle":2868,"status":136,"phases":6076,"primaryCompletion":662,"completion":662,"start":2870,"enrollment":26,"conditions":6077,"interventions":6078},[95],[2872],[2874,2860],{"nctId":6080,"briefTitle":6081,"status":136,"phases":6082,"primaryCompletion":6083,"completion":6083,"start":4149,"enrollment":29,"conditions":6084,"interventions":6086},"NCT02071004","DS1040b\u002FAspirin Drug\u002FDrug Interaction Study",[95],"2014-02",[6085],"Acute Ischemic Stroke",[2874,2888],{"nctId":6088,"briefTitle":6089,"status":136,"phases":6090,"primaryCompletion":663,"completion":663,"start":4241,"enrollment":4669,"conditions":6091,"interventions":6092},"NCT02647307","Study of the Effects of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of DS-1040b",[95],[3658],[2874],{"trials":6094,"activeCount":105},[6095,6099],{"nctId":4559,"briefTitle":4560,"status":136,"phases":6096,"primaryCompletion":4562,"completion":4562,"start":4563,"enrollment":4564,"conditions":6097,"interventions":6098},[95,96],[4566,4567],[2874,4181],{"nctId":6100,"briefTitle":6101,"status":136,"phases":6102,"primaryCompletion":6103,"completion":6103,"start":5922,"enrollment":6104,"conditions":6105,"interventions":6106},"NCT02586233","Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke",[95,96],"2019-08-13",106,[6085,4567],[2874],{"trials":6108,"activeCount":105},[],{"trials":6110,"activeCount":105},[],{"trials":6112,"activeCount":105},[],{"intervention":6114,"totalTrials":997,"cells":6115},"DS-2325a",{"EARLY_PHASE1":6116,"PHASE1":6118,"PHASE2":6138,"PHASE3":6147,"PHASE4":6149,"NA":6151},{"trials":6117,"activeCount":105},[],{"trials":6119,"activeCount":105},[6120,6130],{"nctId":6121,"briefTitle":6122,"status":136,"phases":6123,"primaryCompletion":6124,"completion":6124,"start":6125,"enrollment":6126,"conditions":6127,"interventions":6129},"NCT05388903","A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects",[95],"2023-01-26","2022-06-20",64,[6128],"Netherton Syndrome",[6114,6114],{"nctId":6131,"briefTitle":6132,"status":136,"phases":6133,"primaryCompletion":6134,"completion":6134,"start":6135,"enrollment":604,"conditions":6136,"interventions":6137},"NCT05583669","A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects",[95],"2023-05-11","2022-11-08",[6128],[6114],{"trials":6139,"activeCount":105},[6140],{"nctId":6141,"briefTitle":6142,"status":175,"phases":6143,"primaryCompletion":2306,"completion":2306,"start":6144,"enrollment":1092,"conditions":6145,"interventions":6146},"NCT05979831","A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome",[95,96],"2023-09-28",[6128],[6114],{"trials":6148,"activeCount":105},[],{"trials":6150,"activeCount":105},[],{"trials":6152,"activeCount":105},[],{"intervention":668,"totalTrials":997,"cells":6154},{"EARLY_PHASE1":6155,"PHASE1":6157,"PHASE2":6163,"PHASE3":6173,"PHASE4":6175,"NA":6177},{"trials":6156,"activeCount":105},[],{"trials":6158,"activeCount":105},[6159],{"nctId":659,"briefTitle":660,"status":136,"phases":6160,"primaryCompletion":662,"completion":663,"start":664,"enrollment":32,"conditions":6161,"interventions":6162},[95],[379],[667,668,414,413],{"trials":6164,"activeCount":105},[6165,6169],{"nctId":676,"briefTitle":677,"status":175,"phases":6166,"primaryCompletion":679,"completion":680,"start":681,"enrollment":682,"conditions":6167,"interventions":6168},[96],[684],[667,668,414,413],{"nctId":4016,"briefTitle":4017,"status":136,"phases":6170,"primaryCompletion":4019,"completion":4020,"start":4021,"enrollment":4022,"conditions":6171,"interventions":6172},[95,96],[1153],[3964,668,4025],{"trials":6174,"activeCount":105},[],{"trials":6176,"activeCount":105},[],{"trials":6178,"activeCount":105},[],{"intervention":6180,"totalTrials":146,"cells":6181},"VN-0200",{"EARLY_PHASE1":6182,"PHASE1":6184,"PHASE2":6194,"PHASE3":6206,"PHASE4":6208,"NA":6210},{"trials":6183,"activeCount":105},[],{"trials":6185,"activeCount":105},[6186],{"nctId":6187,"briefTitle":6188,"status":136,"phases":6189,"primaryCompletion":6190,"completion":6190,"start":1971,"enrollment":4669,"conditions":6191,"interventions":6193},"NCT04914520","Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects",[95],"2021-12-16",[6192],"Respiratory Syncytial Virus Infections",[6180],{"trials":6195,"activeCount":105},[6196],{"nctId":6197,"briefTitle":6198,"status":136,"phases":6199,"primaryCompletion":6200,"completion":6201,"start":6202,"enrollment":6203,"conditions":6204,"interventions":6205},"NCT05547087","A Dose Finding Study of VN-0200",[96],"2023-04-11","2024-02-15","2022-10-13",342,[6192],[6180],{"trials":6207,"activeCount":105},[],{"trials":6209,"activeCount":105},[],{"trials":6211,"activeCount":105},[],{"intervention":6213,"totalTrials":146,"cells":6214},"SUN13837",{"EARLY_PHASE1":6215,"PHASE1":6217,"PHASE2":6219,"PHASE3":6237,"PHASE4":6239,"NA":6241},{"trials":6216,"activeCount":105},[],{"trials":6218,"activeCount":105},[],{"trials":6220,"activeCount":105},[6221,6230],{"nctId":6222,"briefTitle":6223,"status":136,"phases":6224,"primaryCompletion":6225,"completion":6225,"start":6226,"enrollment":918,"conditions":6227,"interventions":6229},"NCT01502631","Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)",[96],"2014-09-21","2012-08-08",[6228],"Acute Spinal Cord Injury",[6213],{"nctId":6231,"briefTitle":6232,"status":1192,"phases":6233,"primaryCompletion":6234,"completion":6234,"start":5929,"enrollment":105,"conditions":6235,"interventions":6236},"NCT02258880","Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke",[96],"2016-05",[4090],[6213],{"trials":6238,"activeCount":105},[],{"trials":6240,"activeCount":105},[],{"trials":6242,"activeCount":105},[],{"intervention":566,"totalTrials":146,"cells":6244},{"EARLY_PHASE1":6245,"PHASE1":6247,"PHASE2":6249,"PHASE3":6259,"PHASE4":6261,"NA":6263},{"trials":6246,"activeCount":105},[],{"trials":6248,"activeCount":105},[],{"trials":6250,"activeCount":105},[6251,6255],{"nctId":4295,"briefTitle":4296,"status":136,"phases":6252,"primaryCompletion":4298,"completion":4299,"start":4300,"enrollment":4301,"conditions":6253,"interventions":6254},[95,96],[4303],[566,4048],{"nctId":558,"briefTitle":559,"status":175,"phases":6256,"primaryCompletion":561,"completion":561,"start":562,"enrollment":563,"conditions":6257,"interventions":6258},[95,96],[341],[566,226,249,566,226,249],{"trials":6260,"activeCount":105},[],{"trials":6262,"activeCount":105},[],{"trials":6264,"activeCount":105},[],{"intervention":6266,"totalTrials":146,"cells":6267},"Compound AC220",{"EARLY_PHASE1":6268,"PHASE1":6270,"PHASE2":6278,"PHASE3":6289,"PHASE4":6291,"NA":6293},{"trials":6269,"activeCount":105},[],{"trials":6271,"activeCount":105},[6272],{"nctId":6273,"briefTitle":6274,"status":136,"phases":6275,"primaryCompletion":562,"completion":562,"start":2999,"enrollment":1388,"conditions":6276,"interventions":6277},"NCT01049893","Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors",[95],[541],[6266],{"trials":6279,"activeCount":105},[6280],{"nctId":6281,"briefTitle":6282,"status":136,"phases":6283,"primaryCompletion":6284,"completion":6285,"start":4087,"enrollment":6286,"conditions":6287,"interventions":6288},"NCT00989261","Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)",[96],"2012-09-28","2014-12-31",333,[752],[6266],{"trials":6290,"activeCount":105},[],{"trials":6292,"activeCount":105},[],{"trials":6294,"activeCount":105},[],{"intervention":578,"totalTrials":146,"cells":6296},{"EARLY_PHASE1":6297,"PHASE1":6299,"PHASE2":6301,"PHASE3":6315,"PHASE4":6317,"NA":6319},{"trials":6298,"activeCount":105},[],{"trials":6300,"activeCount":105},[],{"trials":6302,"activeCount":105},[6303,6307],{"nctId":568,"briefTitle":569,"status":136,"phases":6304,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":6305,"interventions":6306},[96],[576],[578,249,413],{"nctId":6308,"briefTitle":6309,"status":136,"phases":6310,"primaryCompletion":4186,"completion":4186,"start":3049,"enrollment":2344,"conditions":6311,"interventions":6313},"NCT00967616","Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy",[96],[5896,6312],"Neoplasms, Colorectal",[578,6314],"irinotecan, leucovorin, and 5-fluorouracil",{"trials":6316,"activeCount":105},[],{"trials":6318,"activeCount":105},[],{"trials":6320,"activeCount":105},[],{"intervention":6322,"totalTrials":146,"cells":6323},"DS-7011a",{"EARLY_PHASE1":6324,"PHASE1":6326,"PHASE2":6338,"PHASE3":6348,"PHASE4":6350,"NA":6352},{"trials":6325,"activeCount":105},[],{"trials":6327,"activeCount":105},[6328],{"nctId":6329,"briefTitle":6330,"status":136,"phases":6331,"primaryCompletion":6332,"completion":6333,"start":6334,"enrollment":5391,"conditions":6335,"interventions":6337},"NCT05203692","A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects",[95],"2023-01-25","2023-03-22","2022-02-02",[6336],"Systemic Lupus Erythematosus",[6322],{"trials":6339,"activeCount":105},[6340],{"nctId":6341,"briefTitle":6342,"status":136,"phases":6343,"primaryCompletion":3776,"completion":3776,"start":6344,"enrollment":6345,"conditions":6346,"interventions":6347},"NCT05638802","A Study of DS-7011a in Patients With Systemic Lupus Erythematosus",[95,96],"2023-06-07",26,[6336],[6322],{"trials":6349,"activeCount":105},[],{"trials":6351,"activeCount":105},[],{"trials":6353,"activeCount":105},[],{"intervention":4025,"totalTrials":146,"cells":6355},{"EARLY_PHASE1":6356,"PHASE1":6358,"PHASE2":6360,"PHASE3":6370,"PHASE4":6372,"NA":6374},{"trials":6357,"activeCount":105},[],{"trials":6359,"activeCount":105},[],{"trials":6361,"activeCount":105},[6362,6366],{"nctId":4016,"briefTitle":4017,"status":136,"phases":6363,"primaryCompletion":4019,"completion":4020,"start":4021,"enrollment":4022,"conditions":6364,"interventions":6365},[95,96],[1153],[3964,668,4025],{"nctId":5995,"briefTitle":5996,"status":175,"phases":6367,"primaryCompletion":583,"completion":583,"start":5998,"enrollment":284,"conditions":6368,"interventions":6369},[96],[1153],[597,6001],{"trials":6371,"activeCount":105},[],{"trials":6373,"activeCount":105},[],{"trials":6375,"activeCount":105},[],{"intervention":1657,"totalTrials":146,"cells":6377},{"EARLY_PHASE1":6378,"PHASE1":6380,"PHASE2":6386,"PHASE3":6394,"PHASE4":6396,"NA":6398},{"trials":6379,"activeCount":105},[],{"trials":6381,"activeCount":105},[6382],{"nctId":1649,"briefTitle":1650,"status":136,"phases":6383,"primaryCompletion":1652,"completion":1652,"start":1653,"conditions":6384,"interventions":6385},[95],[1655],[1657,1658],{"trials":6387,"activeCount":105},[6388],{"nctId":6389,"briefTitle":6390,"status":136,"phases":6391,"primaryCompletion":2756,"completion":2756,"start":1653,"conditions":6392,"interventions":6393},"NCT00080834","DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma",[96],[5896],[1657],{"trials":6395,"activeCount":105},[],{"trials":6397,"activeCount":105},[],{"trials":6399,"activeCount":105},[],{"intervention":2888,"totalTrials":146,"cells":6401},{"EARLY_PHASE1":6402,"PHASE1":6404,"PHASE2":6410,"PHASE3":6416,"PHASE4":6418,"NA":6420},{"trials":6403,"activeCount":105},[],{"trials":6405,"activeCount":105},[6406],{"nctId":6080,"briefTitle":6081,"status":136,"phases":6407,"primaryCompletion":6083,"completion":6083,"start":4149,"enrollment":29,"conditions":6408,"interventions":6409},[95],[6085],[2874,2888],{"trials":6411,"activeCount":105},[6412],{"nctId":2878,"briefTitle":2879,"status":136,"phases":6413,"primaryCompletion":2881,"completion":2881,"start":2882,"enrollment":2883,"conditions":6414,"interventions":6415},[96],[2885],[2887,2860,2888],{"trials":6417,"activeCount":105},[],{"trials":6419,"activeCount":105},[],{"trials":6421,"activeCount":105},[],{"intervention":6423,"totalTrials":146,"cells":6424},"soblidotin",{"EARLY_PHASE1":6425,"PHASE1":6427,"PHASE2":6429,"PHASE3":6443,"PHASE4":6445,"NA":6447},{"trials":6426,"activeCount":105},[],{"trials":6428,"activeCount":105},[],{"trials":6430,"activeCount":105},[6431,6437],{"nctId":6432,"briefTitle":6433,"status":136,"phases":6434,"primaryCompletion":2773,"completion":2773,"start":5281,"conditions":6435,"interventions":6436},"NCT00064220","Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma",[96],[2589],[6423],{"nctId":6438,"briefTitle":6439,"status":136,"phases":6440,"primaryCompletion":2800,"completion":2800,"start":5281,"conditions":6441,"interventions":6442},"NCT00061854","Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[96],[392],[6423],{"trials":6444,"activeCount":105},[],{"trials":6446,"activeCount":105},[],{"trials":6448,"activeCount":105},[],{"intervention":4512,"totalTrials":395,"cells":6450},{"EARLY_PHASE1":6451,"PHASE1":6453,"PHASE2":6455,"PHASE3":6461,"PHASE4":6463,"NA":6465},{"trials":6452,"activeCount":105},[],{"trials":6454,"activeCount":105},[],{"trials":6456,"activeCount":105},[6457],{"nctId":4504,"briefTitle":4505,"status":136,"phases":6458,"primaryCompletion":573,"completion":593,"start":4077,"enrollment":4507,"conditions":6459,"interventions":6460},[96],[39,4168,4110,4509,4099,4109],[4495,4511,4512],{"trials":6462,"activeCount":105},[],{"trials":6464,"activeCount":105},[],{"trials":6466,"activeCount":105},[],{"intervention":6468,"totalTrials":395,"cells":6469},"DS-9231",{"EARLY_PHASE1":6470,"PHASE1":6472,"PHASE2":6474,"PHASE3":6484,"PHASE4":6486,"NA":6488},{"trials":6471,"activeCount":105},[],{"trials":6473,"activeCount":105},[],{"trials":6475,"activeCount":105},[6476],{"nctId":6477,"briefTitle":6478,"status":1192,"phases":6479,"primaryCompletion":6480,"completion":6480,"start":6481,"enrollment":105,"conditions":6482,"interventions":6483},"NCT03316729","DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)",[96],"2020-02","2018-01",[4566],[6468],{"trials":6485,"activeCount":105},[],{"trials":6487,"activeCount":105},[],{"trials":6489,"activeCount":105},[],{"intervention":4082,"totalTrials":395,"cells":6491},{"EARLY_PHASE1":6492,"PHASE1":6494,"PHASE2":6496,"PHASE3":6502,"PHASE4":6504,"NA":6506},{"trials":6493,"activeCount":105},[],{"trials":6495,"activeCount":105},[],{"trials":6497,"activeCount":105},[6498],{"nctId":4074,"briefTitle":4075,"status":136,"phases":6499,"primaryCompletion":4077,"completion":4078,"start":2735,"enrollment":4079,"conditions":6500,"interventions":6501},[96],[28],[4065,4082],{"trials":6503,"activeCount":105},[],{"trials":6505,"activeCount":105},[],{"trials":6507,"activeCount":105},[],{"intervention":6509,"totalTrials":395,"cells":6510},"piclozotan low dose",{"EARLY_PHASE1":6511,"PHASE1":6513,"PHASE2":6515,"PHASE3":6526,"PHASE4":6528,"NA":6530},{"trials":6512,"activeCount":105},[],{"trials":6514,"activeCount":105},[],{"trials":6516,"activeCount":105},[6517],{"nctId":6518,"briefTitle":6519,"status":175,"phases":6520,"primaryCompletion":2734,"completion":2799,"start":6521,"enrollment":6522,"conditions":6523,"interventions":6524},"NCT00272909","Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)",[96],"2004-09",43,[4090],[6509,6525],"piclozotan high dose",{"trials":6527,"activeCount":105},[],{"trials":6529,"activeCount":105},[],{"trials":6531,"activeCount":105},[],{"intervention":6525,"totalTrials":395,"cells":6533},{"EARLY_PHASE1":6534,"PHASE1":6536,"PHASE2":6538,"PHASE3":6544,"PHASE4":6546,"NA":6548},{"trials":6535,"activeCount":105},[],{"trials":6537,"activeCount":105},[],{"trials":6539,"activeCount":105},[6540],{"nctId":6518,"briefTitle":6519,"status":175,"phases":6541,"primaryCompletion":2734,"completion":2799,"start":6521,"enrollment":6522,"conditions":6542,"interventions":6543},[96],[4090],[6509,6525],{"trials":6545,"activeCount":105},[],{"trials":6547,"activeCount":105},[],{"trials":6549,"activeCount":105},[],{"intervention":6551,"totalTrials":395,"cells":6552},"Temozolomide",{"EARLY_PHASE1":6553,"PHASE1":6555,"PHASE2":6557,"PHASE3":6569,"PHASE4":6571,"NA":6573},{"trials":6554,"activeCount":105},[],{"trials":6556,"activeCount":105},[],{"trials":6558,"activeCount":105},[6559],{"nctId":6560,"briefTitle":6561,"status":136,"phases":6562,"primaryCompletion":6563,"completion":6564,"start":6565,"enrollment":918,"conditions":6566,"interventions":6568},"NCT01790503","A Phase 1b\u002F2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma",[95,96],"2017-11-03","2020-03-04","2013-07-18",[6567],"Patients With Newly Diagnosed Glioblastoma",[382,6551],{"trials":6570,"activeCount":105},[],{"trials":6572,"activeCount":105},[],{"trials":6574,"activeCount":105},[],{"intervention":4156,"totalTrials":395,"cells":6576},{"EARLY_PHASE1":6577,"PHASE1":6579,"PHASE2":6581,"PHASE3":6587,"PHASE4":6589,"NA":6591},{"trials":6578,"activeCount":105},[],{"trials":6580,"activeCount":105},[],{"trials":6582,"activeCount":105},[6583],{"nctId":4146,"briefTitle":4147,"status":136,"phases":6584,"primaryCompletion":4149,"completion":4150,"start":572,"enrollment":4151,"conditions":6585,"interventions":6586},[96],[4099,4153],[4155,4156,4137],{"trials":6588,"activeCount":105},[],{"trials":6590,"activeCount":105},[],{"trials":6592,"activeCount":105},[],{"intervention":6594,"totalTrials":395,"cells":6595},"DS-8500a 25 mg",{"EARLY_PHASE1":6596,"PHASE1":6598,"PHASE2":6600,"PHASE3":6611,"PHASE4":6613,"NA":6615},{"trials":6597,"activeCount":105},[],{"trials":6599,"activeCount":105},[],{"trials":6601,"activeCount":105},[6602],{"nctId":6603,"briefTitle":6604,"status":136,"phases":6605,"primaryCompletion":4628,"completion":6606,"start":6607,"enrollment":4151,"conditions":6608,"interventions":6609},"NCT02685345","A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin",[96],"2016-10","2016-01",[31],[6594,6610],"DS-8500a 75 mg",{"trials":6612,"activeCount":105},[],{"trials":6614,"activeCount":105},[],{"trials":6616,"activeCount":105},[],{"intervention":6610,"totalTrials":395,"cells":6618},{"EARLY_PHASE1":6619,"PHASE1":6621,"PHASE2":6623,"PHASE3":6629,"PHASE4":6631,"NA":6633},{"trials":6620,"activeCount":105},[],{"trials":6622,"activeCount":105},[],{"trials":6624,"activeCount":105},[6625],{"nctId":6603,"briefTitle":6604,"status":136,"phases":6626,"primaryCompletion":4628,"completion":6606,"start":6607,"enrollment":4151,"conditions":6627,"interventions":6628},[96],[31],[6594,6610],{"trials":6630,"activeCount":105},[],{"trials":6632,"activeCount":105},[],{"trials":6634,"activeCount":105},[],{"intervention":6636,"totalTrials":395,"cells":6637},"Carperitide",{"EARLY_PHASE1":6638,"PHASE1":6640,"PHASE2":6642,"PHASE3":6658,"PHASE4":6660,"NA":6662},{"trials":6639,"activeCount":105},[],{"trials":6641,"activeCount":105},[],{"trials":6643,"activeCount":105},[6644],{"nctId":6645,"briefTitle":6646,"status":136,"phases":6647,"primaryCompletion":6648,"completion":6648,"start":6649,"enrollment":6650,"conditions":6651,"interventions":6657},"NCT00259038","Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure",[96],"2006-02","2004-01",162,[6652,6653,6654,6655,6656],"Heart Failure, Congestive","Heart Decompensation","Left Ventricular Failure","Myocardiopathies","Systolic or Diastolic Left Ventricular Dysfunction",[6636],{"trials":6659,"activeCount":105},[],{"trials":6661,"activeCount":105},[],{"trials":6663,"activeCount":105},[],{"intervention":6314,"totalTrials":395,"cells":6665},{"EARLY_PHASE1":6666,"PHASE1":6668,"PHASE2":6670,"PHASE3":6676,"PHASE4":6678,"NA":6680},{"trials":6667,"activeCount":105},[],{"trials":6669,"activeCount":105},[],{"trials":6671,"activeCount":105},[6672],{"nctId":6308,"briefTitle":6309,"status":136,"phases":6673,"primaryCompletion":4186,"completion":4186,"start":3049,"enrollment":2344,"conditions":6674,"interventions":6675},[96],[5896,6312],[578,6314],{"trials":6677,"activeCount":105},[],{"trials":6679,"activeCount":105},[],{"trials":6681,"activeCount":105},[],{"intervention":6683,"totalTrials":395,"cells":6684},"piclozotan",{"EARLY_PHASE1":6685,"PHASE1":6687,"PHASE2":6689,"PHASE3":6701,"PHASE4":6703,"NA":6705},{"trials":6686,"activeCount":105},[],{"trials":6688,"activeCount":105},[],{"trials":6690,"activeCount":105},[6691],{"nctId":6692,"briefTitle":6693,"status":136,"phases":6694,"primaryCompletion":6695,"completion":6695,"start":6696,"enrollment":4032,"conditions":6697,"interventions":6699},"NCT00623363","Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease",[96],"2008-07-17","2007-07-13",[6698],"Parkinson's Disease",[6683,6700],"0.9% sodium chloride",{"trials":6702,"activeCount":105},[],{"trials":6704,"activeCount":105},[],{"trials":6706,"activeCount":105},[],{"intervention":6700,"totalTrials":395,"cells":6708},{"EARLY_PHASE1":6709,"PHASE1":6711,"PHASE2":6713,"PHASE3":6719,"PHASE4":6721,"NA":6723},{"trials":6710,"activeCount":105},[],{"trials":6712,"activeCount":105},[],{"trials":6714,"activeCount":105},[6715],{"nctId":6692,"briefTitle":6693,"status":136,"phases":6716,"primaryCompletion":6695,"completion":6695,"start":6696,"enrollment":4032,"conditions":6717,"interventions":6718},[96],[6698],[6683,6700],{"trials":6720,"activeCount":105},[],{"trials":6722,"activeCount":105},[],{"trials":6724,"activeCount":105},[],{"intervention":4382,"totalTrials":395,"cells":6726},{"EARLY_PHASE1":6727,"PHASE1":6729,"PHASE2":6731,"PHASE3":6737,"PHASE4":6739,"NA":6741},{"trials":6728,"activeCount":105},[],{"trials":6730,"activeCount":105},[],{"trials":6732,"activeCount":105},[6733],{"nctId":4375,"briefTitle":4376,"status":136,"phases":6734,"completion":4378,"start":1652,"enrollment":2757,"conditions":6735,"interventions":6736},[96],[4380],[4382,4383,4384],{"trials":6738,"activeCount":105},[],{"trials":6740,"activeCount":105},[],{"trials":6742,"activeCount":105},[],{"intervention":4383,"totalTrials":395,"cells":6744},{"EARLY_PHASE1":6745,"PHASE1":6747,"PHASE2":6749,"PHASE3":6755,"PHASE4":6757,"NA":6759},{"trials":6746,"activeCount":105},[],{"trials":6748,"activeCount":105},[],{"trials":6750,"activeCount":105},[6751],{"nctId":4375,"briefTitle":4376,"status":136,"phases":6752,"completion":4378,"start":1652,"enrollment":2757,"conditions":6753,"interventions":6754},[96],[4380],[4382,4383,4384],{"trials":6756,"activeCount":105},[],{"trials":6758,"activeCount":105},[],{"trials":6760,"activeCount":105},[],{"intervention":6762,"totalTrials":395,"cells":6763},"DS-5670a",{"EARLY_PHASE1":6764,"PHASE1":6766,"PHASE2":6768,"PHASE3":6779,"PHASE4":6781,"NA":6783},{"trials":6765,"activeCount":105},[],{"trials":6767,"activeCount":105},[],{"trials":6769,"activeCount":105},[6770],{"nctId":6771,"briefTitle":6772,"status":136,"phases":6773,"primaryCompletion":747,"completion":6774,"start":1091,"enrollment":6775,"conditions":6776,"interventions":6778},"NCT04821674","Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects",[95,96],"2022-07-14",142,[6777],"Covid19",[6762],{"trials":6780,"activeCount":105},[],{"trials":6782,"activeCount":105},[],{"trials":6784,"activeCount":105},[],{"intervention":6786,"totalTrials":395,"cells":6787},"SUN11031 20 μg\u002Fkg",{"EARLY_PHASE1":6788,"PHASE1":6790,"PHASE2":6792,"PHASE3":6805,"PHASE4":6807,"NA":6809},{"trials":6789,"activeCount":105},[],{"trials":6791,"activeCount":105},[],{"trials":6793,"activeCount":105},[6794],{"nctId":6795,"briefTitle":6796,"status":136,"phases":6797,"primaryCompletion":6798,"completion":6798,"start":6799,"enrollment":6800,"conditions":6801,"interventions":6803},"NCT00698828","SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)",[96],"2009-10-08","2008-05-15",227,[6802],"Cachexia",[6786,6804],"SUN11031 40 μg\u002Fkg",{"trials":6806,"activeCount":105},[],{"trials":6808,"activeCount":105},[],{"trials":6810,"activeCount":105},[],{"intervention":6804,"totalTrials":395,"cells":6812},{"EARLY_PHASE1":6813,"PHASE1":6815,"PHASE2":6817,"PHASE3":6823,"PHASE4":6825,"NA":6827},{"trials":6814,"activeCount":105},[],{"trials":6816,"activeCount":105},[],{"trials":6818,"activeCount":105},[6819],{"nctId":6795,"briefTitle":6796,"status":136,"phases":6820,"primaryCompletion":6798,"completion":6798,"start":6799,"enrollment":6800,"conditions":6821,"interventions":6822},[96],[6802],[6786,6804],{"trials":6824,"activeCount":105},[],{"trials":6826,"activeCount":105},[],{"trials":6828,"activeCount":105},[],{"intervention":6830,"totalTrials":395,"cells":6831},"Sitagliptin 100 mg",{"EARLY_PHASE1":6832,"PHASE1":6834,"PHASE2":6836,"PHASE3":6847,"PHASE4":6849,"NA":6851},{"trials":6833,"activeCount":105},[],{"trials":6835,"activeCount":105},[],{"trials":6837,"activeCount":105},[6838],{"nctId":6839,"briefTitle":6840,"status":136,"phases":6841,"primaryCompletion":6842,"completion":6842,"start":6607,"enrollment":6843,"conditions":6844,"interventions":6845},"NCT02647320","12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin",[96],"2017-01-31",298,[31],[6830,6846],"DS-8500a 25mg",{"trials":6848,"activeCount":105},[],{"trials":6850,"activeCount":105},[],{"trials":6852,"activeCount":105},[],{"intervention":6846,"totalTrials":395,"cells":6854},{"EARLY_PHASE1":6855,"PHASE1":6857,"PHASE2":6859,"PHASE3":6865,"PHASE4":6867,"NA":6869},{"trials":6856,"activeCount":105},[],{"trials":6858,"activeCount":105},[],{"trials":6860,"activeCount":105},[6861],{"nctId":6839,"briefTitle":6840,"status":136,"phases":6862,"primaryCompletion":6842,"completion":6842,"start":6607,"enrollment":6843,"conditions":6863,"interventions":6864},[96],[31],[6830,6846],{"trials":6866,"activeCount":105},[],{"trials":6868,"activeCount":105},[],{"trials":6870,"activeCount":105},[],{"intervention":6872,"totalTrials":395,"cells":6873},"DS-8201a 5.4 mg\u002Fkg Q3W",{"EARLY_PHASE1":6874,"PHASE1":6876,"PHASE2":6878,"PHASE3":6892,"PHASE4":6894,"NA":6896},{"trials":6875,"activeCount":105},[],{"trials":6877,"activeCount":105},[],{"trials":6879,"activeCount":105},[6880],{"nctId":6881,"briefTitle":6882,"status":136,"phases":6883,"primaryCompletion":6884,"completion":6885,"start":6886,"enrollment":6887,"conditions":6888,"interventions":6890},"NCT04744831","Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer",[96],"2022-11-01","2024-12-04","2021-03-05",122,[6889],"Advanced Colorectal Cancer",[6872,6891],"DS-8201a 6.4 mg\u002Fkg Q3W",{"trials":6893,"activeCount":105},[],{"trials":6895,"activeCount":105},[],{"trials":6897,"activeCount":105},[],{"intervention":6891,"totalTrials":395,"cells":6899},{"EARLY_PHASE1":6900,"PHASE1":6902,"PHASE2":6904,"PHASE3":6910,"PHASE4":6912,"NA":6914},{"trials":6901,"activeCount":105},[],{"trials":6903,"activeCount":105},[],{"trials":6905,"activeCount":105},[6906],{"nctId":6881,"briefTitle":6882,"status":136,"phases":6907,"primaryCompletion":6884,"completion":6885,"start":6886,"enrollment":6887,"conditions":6908,"interventions":6909},[96],[6889],[6872,6891],{"trials":6911,"activeCount":105},[],{"trials":6913,"activeCount":105},[],{"trials":6915,"activeCount":105},[],{"intervention":6917,"totalTrials":395,"cells":6918},"CS-1008 2 mg\u002Fkg",{"EARLY_PHASE1":6919,"PHASE1":6921,"PHASE2":6923,"PHASE3":6943,"PHASE4":6945,"NA":6947},{"trials":6920,"activeCount":105},[],{"trials":6922,"activeCount":105},[],{"trials":6924,"activeCount":105},[6925],{"nctId":6926,"briefTitle":6927,"status":136,"phases":6928,"primaryCompletion":6929,"completion":6930,"start":6931,"enrollment":6932,"conditions":6933,"interventions":6937},"NCT01033240","CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer",[96],"2012-07-13","2013-09-09","2010-07-09",172,[6934,3880,6935,6936],"Advanced Hepatocellular Carcinoma","Hepatic Cancer","Liver Neoplasms",[6917,6938,6939,6940,6941,6942],"Sorafenib","CS-1008 6\u002F2 mg\u002Fkg","CS-1008 6\u002F6 mg\u002Fkg","CS-1008 4 mg\u002Fkg","CS-1008 6 mg\u002Fkg",{"trials":6944,"activeCount":105},[],{"trials":6946,"activeCount":105},[],{"trials":6948,"activeCount":105},[],{"intervention":6938,"totalTrials":395,"cells":6950},{"EARLY_PHASE1":6951,"PHASE1":6953,"PHASE2":6955,"PHASE3":6961,"PHASE4":6963,"NA":6965},{"trials":6952,"activeCount":105},[],{"trials":6954,"activeCount":105},[],{"trials":6956,"activeCount":105},[6957],{"nctId":6926,"briefTitle":6927,"status":136,"phases":6958,"primaryCompletion":6929,"completion":6930,"start":6931,"enrollment":6932,"conditions":6959,"interventions":6960},[96],[6934,3880,6935,6936],[6917,6938,6939,6940,6941,6942],{"trials":6962,"activeCount":105},[],{"trials":6964,"activeCount":105},[],{"trials":6966,"activeCount":105},[],{"intervention":6939,"totalTrials":395,"cells":6968},{"EARLY_PHASE1":6969,"PHASE1":6971,"PHASE2":6973,"PHASE3":6979,"PHASE4":6981,"NA":6983},{"trials":6970,"activeCount":105},[],{"trials":6972,"activeCount":105},[],{"trials":6974,"activeCount":105},[6975],{"nctId":6926,"briefTitle":6927,"status":136,"phases":6976,"primaryCompletion":6929,"completion":6930,"start":6931,"enrollment":6932,"conditions":6977,"interventions":6978},[96],[6934,3880,6935,6936],[6917,6938,6939,6940,6941,6942],{"trials":6980,"activeCount":105},[],{"trials":6982,"activeCount":105},[],{"trials":6984,"activeCount":105},[],{"intervention":6940,"totalTrials":395,"cells":6986},{"EARLY_PHASE1":6987,"PHASE1":6989,"PHASE2":6991,"PHASE3":6997,"PHASE4":6999,"NA":7001},{"trials":6988,"activeCount":105},[],{"trials":6990,"activeCount":105},[],{"trials":6992,"activeCount":105},[6993],{"nctId":6926,"briefTitle":6927,"status":136,"phases":6994,"primaryCompletion":6929,"completion":6930,"start":6931,"enrollment":6932,"conditions":6995,"interventions":6996},[96],[6934,3880,6935,6936],[6917,6938,6939,6940,6941,6942],{"trials":6998,"activeCount":105},[],{"trials":7000,"activeCount":105},[],{"trials":7002,"activeCount":105},[],{"intervention":6941,"totalTrials":395,"cells":7004},{"EARLY_PHASE1":7005,"PHASE1":7007,"PHASE2":7009,"PHASE3":7015,"PHASE4":7017,"NA":7019},{"trials":7006,"activeCount":105},[],{"trials":7008,"activeCount":105},[],{"trials":7010,"activeCount":105},[7011],{"nctId":6926,"briefTitle":6927,"status":136,"phases":7012,"primaryCompletion":6929,"completion":6930,"start":6931,"enrollment":6932,"conditions":7013,"interventions":7014},[96],[6934,3880,6935,6936],[6917,6938,6939,6940,6941,6942],{"trials":7016,"activeCount":105},[],{"trials":7018,"activeCount":105},[],{"trials":7020,"activeCount":105},[],{"intervention":6942,"totalTrials":395,"cells":7022},{"EARLY_PHASE1":7023,"PHASE1":7025,"PHASE2":7027,"PHASE3":7033,"PHASE4":7035,"NA":7037},{"trials":7024,"activeCount":105},[],{"trials":7026,"activeCount":105},[],{"trials":7028,"activeCount":105},[7029],{"nctId":6926,"briefTitle":6927,"status":136,"phases":7030,"primaryCompletion":6929,"completion":6930,"start":6931,"enrollment":6932,"conditions":7031,"interventions":7032},[96],[6934,3880,6935,6936],[6917,6938,6939,6940,6941,6942],{"trials":7034,"activeCount":105},[],{"trials":7036,"activeCount":105},[],{"trials":7038,"activeCount":105},[],{"intervention":7040,"totalTrials":395,"cells":7041},"10mg DS-8500a",{"EARLY_PHASE1":7042,"PHASE1":7044,"PHASE2":7046,"PHASE3":7055,"PHASE4":7057,"NA":7059},{"trials":7043,"activeCount":105},[],{"trials":7045,"activeCount":105},[],{"trials":7047,"activeCount":105},[7048],{"nctId":7049,"briefTitle":7050,"status":136,"phases":7051,"primaryCompletion":4254,"completion":4615,"start":5955,"enrollment":2344,"conditions":7052,"interventions":7053},"NCT02222350","Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes",[96],[31],[7040,7054],"75mg DS-8500a",{"trials":7056,"activeCount":105},[],{"trials":7058,"activeCount":105},[],{"trials":7060,"activeCount":105},[],{"intervention":7054,"totalTrials":395,"cells":7062},{"EARLY_PHASE1":7063,"PHASE1":7065,"PHASE2":7067,"PHASE3":7073,"PHASE4":7075,"NA":7077},{"trials":7064,"activeCount":105},[],{"trials":7066,"activeCount":105},[],{"trials":7068,"activeCount":105},[7069],{"nctId":7049,"briefTitle":7050,"status":136,"phases":7070,"primaryCompletion":4254,"completion":4615,"start":5955,"enrollment":2344,"conditions":7071,"interventions":7072},[96],[31],[7040,7054],{"trials":7074,"activeCount":105},[],{"trials":7076,"activeCount":105},[],{"trials":7078,"activeCount":105},[],{"intervention":7080,"totalTrials":395,"cells":7081},"SUN13834",{"EARLY_PHASE1":7082,"PHASE1":7084,"PHASE2":7086,"PHASE3":7098,"PHASE4":7100,"NA":7102},{"trials":7083,"activeCount":105},[],{"trials":7085,"activeCount":105},[],{"trials":7087,"activeCount":105},[7088],{"nctId":7089,"briefTitle":7090,"status":136,"phases":7091,"primaryCompletion":7092,"completion":7092,"start":7093,"enrollment":7094,"conditions":7095,"interventions":7097},"NCT00717769","A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis",[96],"2009-04-09","2008-07-16",270,[7096],"Atopic Dermatitis",[7080],{"trials":7099,"activeCount":105},[],{"trials":7101,"activeCount":105},[],{"trials":7103,"activeCount":105},[],{"intervention":7105,"totalTrials":395,"cells":7106},"DS-1211b",{"EARLY_PHASE1":7107,"PHASE1":7109,"PHASE2":7111,"PHASE3":7122,"PHASE4":7124,"NA":7126},{"trials":7108,"activeCount":105},[],{"trials":7110,"activeCount":105},[],{"trials":7112,"activeCount":105},[7113],{"nctId":7114,"briefTitle":7115,"status":136,"phases":7116,"primaryCompletion":7117,"completion":7117,"start":7118,"enrollment":918,"conditions":7119,"interventions":7121},"NCT05569252","A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum",[96],"2023-11-21","2022-10-20",[7120],"Pseudoxanthoma Elasticum",[7105],{"trials":7123,"activeCount":105},[],{"trials":7125,"activeCount":105},[],{"trials":7127,"activeCount":105},[],{"intervention":7129,"totalTrials":395,"cells":7130},"5 mg ASB17061",{"EARLY_PHASE1":7131,"PHASE1":7133,"PHASE2":7135,"PHASE3":7148,"PHASE4":7150,"NA":7152},{"trials":7132,"activeCount":105},[],{"trials":7134,"activeCount":105},[],{"trials":7136,"activeCount":105},[7137],{"nctId":7138,"briefTitle":7139,"status":136,"phases":7140,"primaryCompletion":7141,"completion":7141,"start":7142,"enrollment":7143,"conditions":7144,"interventions":7145},"NCT01756898","Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis",[96],"2014-01-14","2012-11-28",370,[7096],[7129,7146,7147],"10 mg ASB17061","20 mg ASB17061",{"trials":7149,"activeCount":105},[],{"trials":7151,"activeCount":105},[],{"trials":7153,"activeCount":105},[],{"intervention":7146,"totalTrials":395,"cells":7155},{"EARLY_PHASE1":7156,"PHASE1":7158,"PHASE2":7160,"PHASE3":7166,"PHASE4":7168,"NA":7170},{"trials":7157,"activeCount":105},[],{"trials":7159,"activeCount":105},[],{"trials":7161,"activeCount":105},[7162],{"nctId":7138,"briefTitle":7139,"status":136,"phases":7163,"primaryCompletion":7141,"completion":7141,"start":7142,"enrollment":7143,"conditions":7164,"interventions":7165},[96],[7096],[7129,7146,7147],{"trials":7167,"activeCount":105},[],{"trials":7169,"activeCount":105},[],{"trials":7171,"activeCount":105},[],{"intervention":7147,"totalTrials":395,"cells":7173},{"EARLY_PHASE1":7174,"PHASE1":7176,"PHASE2":7178,"PHASE3":7184,"PHASE4":7186,"NA":7188},{"trials":7175,"activeCount":105},[],{"trials":7177,"activeCount":105},[],{"trials":7179,"activeCount":105},[7180],{"nctId":7138,"briefTitle":7139,"status":136,"phases":7181,"primaryCompletion":7141,"completion":7141,"start":7142,"enrollment":7143,"conditions":7182,"interventions":7183},[96],[7096],[7129,7146,7147],{"trials":7185,"activeCount":105},[],{"trials":7187,"activeCount":105},[],{"trials":7189,"activeCount":105},[],{"intervention":7191,"totalTrials":395,"cells":7192},"Pactimibe, CS-505",{"EARLY_PHASE1":7193,"PHASE1":7195,"PHASE2":7197,"PHASE3":7207,"PHASE4":7209,"NA":7211},{"trials":7194,"activeCount":105},[],{"trials":7196,"activeCount":105},[],{"trials":7198,"activeCount":105},[7199],{"nctId":7200,"briefTitle":7201,"status":136,"phases":7202,"completion":3008,"start":3479,"enrollment":7203,"conditions":7204,"interventions":7206},"NCT00185042","Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease",[96],534,[7205],"Coronary Heart Disease",[7191],{"trials":7208,"activeCount":105},[],{"trials":7210,"activeCount":105},[],{"trials":7212,"activeCount":105},[],{"intervention":1596,"totalTrials":395,"cells":7214},{"EARLY_PHASE1":7215,"PHASE1":7217,"PHASE2":7219,"PHASE3":7225,"PHASE4":7227,"NA":7229},{"trials":7216,"activeCount":105},[],{"trials":7218,"activeCount":105},[],{"trials":7220,"activeCount":105},[7221],{"nctId":1586,"briefTitle":1587,"status":136,"phases":7222,"primaryCompletion":1589,"completion":1590,"start":1591,"enrollment":1592,"conditions":7223,"interventions":7224},[96],[1594],[1515,1596],{"trials":7226,"activeCount":105},[],{"trials":7228,"activeCount":105},[],{"trials":7230,"activeCount":105},[],{"intervention":7232,"totalTrials":395,"cells":7233},"DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor",{"EARLY_PHASE1":7234,"PHASE1":7236,"PHASE2":7238,"PHASE3":7248,"PHASE4":7250,"NA":7252},{"trials":7235,"activeCount":105},[],{"trials":7237,"activeCount":105},[],{"trials":7239,"activeCount":105},[7240],{"nctId":7241,"briefTitle":7242,"status":136,"phases":7243,"primaryCompletion":3350,"completion":3350,"start":2736,"enrollment":7244,"conditions":7245,"interventions":7247},"NCT00398216","A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery",[96],903,[4110,7246],"Hip Replacement",[7232],{"trials":7249,"activeCount":105},[],{"trials":7251,"activeCount":105},[],{"trials":7253,"activeCount":105},[],{"intervention":4430,"totalTrials":395,"cells":7255},{"EARLY_PHASE1":7256,"PHASE1":7258,"PHASE2":7260,"PHASE3":7266,"PHASE4":7268,"NA":7270},{"trials":7257,"activeCount":105},[],{"trials":7259,"activeCount":105},[],{"trials":7261,"activeCount":105},[7262],{"nctId":4424,"briefTitle":4425,"status":136,"phases":7263,"primaryCompletion":584,"completion":584,"start":3111,"enrollment":4427,"conditions":7264,"interventions":7265},[96],[2750],[4394,4430],{"trials":7267,"activeCount":105},[],{"trials":7269,"activeCount":105},[],{"trials":7271,"activeCount":105},[],{"intervention":882,"totalTrials":722,"cells":7273},{"EARLY_PHASE1":7274,"PHASE1":7285,"PHASE2":7319,"PHASE3":7321,"PHASE4":7323,"NA":7325},{"trials":7275,"activeCount":105},[7276],{"nctId":7277,"briefTitle":7278,"status":136,"phases":7279,"primaryCompletion":7280,"completion":7280,"start":7281,"enrollment":4427,"conditions":7282,"interventions":7283},"NCT03614455","Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants",[94],"2018-10-01","2018-07-13",[831],[882,1551,7284],"Posaconazole",{"trials":7286,"activeCount":105},[7287,7291,7299,7309],{"nctId":875,"briefTitle":876,"status":175,"phases":7288,"primaryCompletion":878,"completion":878,"start":879,"enrollment":639,"conditions":7289,"interventions":7290},[95],[752],[742,882,882],{"nctId":7292,"briefTitle":7293,"status":136,"phases":7294,"primaryCompletion":7295,"completion":7295,"start":7296,"enrollment":818,"conditions":7297,"interventions":7298},"NCT03671564","Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)",[95],"2019-09-11","2018-08-23",[752],[882],{"nctId":7300,"briefTitle":7301,"status":136,"phases":7302,"primaryCompletion":7303,"completion":7304,"start":7305,"enrollment":7306,"conditions":7307,"interventions":7308},"NCT01877382","A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas",[95],"2020-10-08","2020-12-03","2013-07-11",107,[360,3869],[882,882],{"nctId":7310,"briefTitle":7311,"status":175,"phases":7312,"primaryCompletion":7313,"completion":7313,"start":7314,"enrollment":539,"conditions":7315,"interventions":7317},"NCT02319369","Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)",[95],"2020-08-21","2014-11-25",[7316,6039],"Acute Myelogenous Leukemia",[882,7318,882],"AZA",{"trials":7320,"activeCount":105},[],{"trials":7322,"activeCount":105},[],{"trials":7324,"activeCount":105},[],{"trials":7326,"activeCount":105},[],{"intervention":1551,"totalTrials":997,"cells":7328},{"EARLY_PHASE1":7329,"PHASE1":7335,"PHASE2":7347,"PHASE3":7349,"PHASE4":7351,"NA":7353},{"trials":7330,"activeCount":105},[7331],{"nctId":7277,"briefTitle":7278,"status":136,"phases":7332,"primaryCompletion":7280,"completion":7280,"start":7281,"enrollment":4427,"conditions":7333,"interventions":7334},[94],[831],[882,1551,7284],{"trials":7336,"activeCount":105},[7337,7343],{"nctId":7338,"briefTitle":7339,"status":136,"phases":7340,"primaryCompletion":663,"completion":663,"start":6234,"enrollment":6345,"conditions":7341,"interventions":7342},"NCT02790671","A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy Subjects",[95],[831],[1459,1551],{"nctId":1542,"briefTitle":1543,"status":136,"phases":7344,"primaryCompletion":1059,"completion":1545,"start":1546,"enrollment":1102,"conditions":7345,"interventions":7346},[95],[1548],[1515,1550,1551],{"trials":7348,"activeCount":105},[],{"trials":7350,"activeCount":105},[],{"trials":7352,"activeCount":105},[],{"trials":7354,"activeCount":105},[],{"intervention":2376,"totalTrials":146,"cells":7356},{"EARLY_PHASE1":7357,"PHASE1":7359,"PHASE2":7376,"PHASE3":7378,"PHASE4":7380,"NA":7382},{"trials":7358,"activeCount":105},[],{"trials":7360,"activeCount":105},[7361,7372],{"nctId":7362,"briefTitle":7363,"status":175,"phases":7364,"primaryCompletion":7365,"completion":7366,"start":7367,"enrollment":22,"conditions":7368,"interventions":7370},"NCT03599518","DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer",[95],"2020-04-22","2020-06-29","2018-09-21",[7369],"Non Small Cell Lung Cancer",[2376,7371],"Gefitinib",{"nctId":2368,"briefTitle":2369,"status":175,"phases":7373,"primaryCompletion":2371,"completion":2371,"start":2372,"enrollment":2373,"conditions":7374,"interventions":7375},[95],[2001],[2376,1976],{"trials":7377,"activeCount":105},[],{"trials":7379,"activeCount":105},[],{"trials":7381,"activeCount":105},[],{"trials":7383,"activeCount":105},[],{"intervention":1065,"totalTrials":146,"cells":7385},{"EARLY_PHASE1":7386,"PHASE1":7388,"PHASE2":7398,"PHASE3":7400,"PHASE4":7402,"NA":7404},{"trials":7387,"activeCount":105},[],{"trials":7389,"activeCount":105},[7390,7394],{"nctId":1056,"briefTitle":1057,"status":136,"phases":7391,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":897,"conditions":7392,"interventions":7393},[95],[1063],[1065,1066,60],{"nctId":5940,"briefTitle":5941,"status":136,"phases":7395,"primaryCompletion":5943,"completion":5943,"start":5944,"enrollment":29,"conditions":7396,"interventions":7397},[95],[3658],[4246,5947,5948,5949,5950,1065],{"trials":7399,"activeCount":105},[],{"trials":7401,"activeCount":105},[],{"trials":7403,"activeCount":105},[],{"trials":7405,"activeCount":105},[],{"intervention":1066,"totalTrials":146,"cells":7407},{"EARLY_PHASE1":7408,"PHASE1":7410,"PHASE2":7420,"PHASE3":7422,"PHASE4":7424,"NA":7426},{"trials":7409,"activeCount":105},[],{"trials":7411,"activeCount":105},[7412,7416],{"nctId":1056,"briefTitle":1057,"status":136,"phases":7413,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":897,"conditions":7414,"interventions":7415},[95],[1063],[1065,1066,60],{"nctId":3981,"briefTitle":3982,"status":136,"phases":7417,"primaryCompletion":3984,"completion":3985,"start":583,"enrollment":2329,"conditions":7418,"interventions":7419},[95],[541],[3988,3989,3990,3991,3992,3993],{"trials":7421,"activeCount":105},[],{"trials":7423,"activeCount":105},[],{"trials":7425,"activeCount":105},[],{"trials":7427,"activeCount":105},[],{"intervention":3989,"totalTrials":146,"cells":7429},{"EARLY_PHASE1":7430,"PHASE1":7432,"PHASE2":7442,"PHASE3":7444,"PHASE4":7446,"NA":7448},{"trials":7431,"activeCount":105},[],{"trials":7433,"activeCount":105},[7434,7438],{"nctId":3981,"briefTitle":3982,"status":136,"phases":7435,"primaryCompletion":3984,"completion":3985,"start":583,"enrollment":2329,"conditions":7436,"interventions":7437},[95],[541],[3988,3989,3990,3991,3992,3993],{"nctId":5940,"briefTitle":5941,"status":136,"phases":7439,"primaryCompletion":5943,"completion":5943,"start":5944,"enrollment":29,"conditions":7440,"interventions":7441},[95],[3658],[4246,5947,5948,5949,5950,1065],{"trials":7443,"activeCount":105},[],{"trials":7445,"activeCount":105},[],{"trials":7447,"activeCount":105},[],{"trials":7449,"activeCount":105},[],{"intervention":873,"totalTrials":146,"cells":7451},{"EARLY_PHASE1":7452,"PHASE1":7454,"PHASE2":7464,"PHASE3":7466,"PHASE4":7468,"NA":7470},{"trials":7453,"activeCount":105},[],{"trials":7455,"activeCount":105},[7456,7460],{"nctId":864,"briefTitle":865,"status":136,"phases":7457,"primaryCompletion":867,"completion":867,"start":868,"enrollment":435,"conditions":7458,"interventions":7459},[95],[752],[742,871,872,873],{"nctId":2055,"briefTitle":2056,"status":136,"phases":7461,"primaryCompletion":2058,"completion":2058,"start":2059,"enrollment":585,"conditions":7462,"interventions":7463},[95],[933],[2062,2063,2064],{"trials":7465,"activeCount":105},[],{"trials":7467,"activeCount":105},[],{"trials":7469,"activeCount":105},[],{"trials":7471,"activeCount":105},[],{"intervention":4672,"totalTrials":146,"cells":7473},{"EARLY_PHASE1":7474,"PHASE1":7476,"PHASE2":7489,"PHASE3":7491,"PHASE4":7493,"NA":7495},{"trials":7475,"activeCount":105},[],{"trials":7477,"activeCount":105},[7478,7485],{"nctId":7479,"briefTitle":7480,"status":136,"phases":7481,"primaryCompletion":2910,"completion":2910,"start":547,"enrollment":7482,"conditions":7483,"interventions":7484},"NCT01862939","A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus",[95],52,[31],[4672],{"nctId":4665,"briefTitle":4666,"status":136,"phases":7486,"primaryCompletion":4668,"completion":4668,"start":3985,"enrollment":4669,"conditions":7487,"interventions":7488},[95],[31],[4672,4673],{"trials":7490,"activeCount":105},[],{"trials":7492,"activeCount":105},[],{"trials":7494,"activeCount":105},[],{"trials":7496,"activeCount":105},[],{"intervention":7498,"totalTrials":395,"cells":7499},"DS-1093a",{"EARLY_PHASE1":7500,"PHASE1":7502,"PHASE2":7513,"PHASE3":7515,"PHASE4":7517,"NA":7519},{"trials":7501,"activeCount":105},[],{"trials":7503,"activeCount":105},[7504],{"nctId":7505,"briefTitle":7506,"status":136,"phases":7507,"primaryCompletion":5944,"completion":5944,"start":4254,"enrollment":7508,"conditions":7509,"interventions":7512},"NCT02299661","Pilot PK\u002FPD Study of DS-1093a in Patients With Chronic Kidney Disease",[95],31,[7510,7511],"Chronic Renal Disease","Renal Anemia",[7498],{"trials":7514,"activeCount":105},[],{"trials":7516,"activeCount":105},[],{"trials":7518,"activeCount":105},[],{"trials":7520,"activeCount":105},[],{"intervention":7522,"totalTrials":395,"cells":7523},"Moxifloxacin",{"EARLY_PHASE1":7524,"PHASE1":7526,"PHASE2":7538,"PHASE3":7540,"PHASE4":7542,"NA":7544},{"trials":7525,"activeCount":105},[],{"trials":7527,"activeCount":105},[7528],{"nctId":7529,"briefTitle":7530,"status":136,"phases":7531,"primaryCompletion":7532,"completion":7532,"start":7533,"enrollment":7534,"conditions":7535,"interventions":7537},"NCT04019652","The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers",[95],"2015-12-23","2015-11-19",55,[25,7536],"Mineralocorticoid Receptor Antagonist",[4619,7522],{"trials":7539,"activeCount":105},[],{"trials":7541,"activeCount":105},[],{"trials":7543,"activeCount":105},[],{"trials":7545,"activeCount":105},[],{"intervention":7547,"totalTrials":395,"cells":7548},"AC430",{"EARLY_PHASE1":7549,"PHASE1":7551,"PHASE2":7561,"PHASE3":7563,"PHASE4":7565,"NA":7567},{"trials":7550,"activeCount":105},[],{"trials":7552,"activeCount":105},[7553],{"nctId":7554,"briefTitle":7555,"status":136,"phases":7556,"primaryCompletion":3155,"completion":3155,"start":1196,"enrollment":7557,"conditions":7558,"interventions":7560},"NCT01287858","Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects",[95],88,[7559],"Rheumatoid Arthritis",[7547],{"trials":7562,"activeCount":105},[],{"trials":7564,"activeCount":105},[],{"trials":7566,"activeCount":105},[],{"trials":7568,"activeCount":105},[],{"intervention":7570,"totalTrials":395,"cells":7571},"DS-1971",{"EARLY_PHASE1":7572,"PHASE1":7574,"PHASE2":7584,"PHASE3":7586,"PHASE4":7588,"NA":7590},{"trials":7573,"activeCount":105},[],{"trials":7575,"activeCount":105},[7576],{"nctId":7577,"briefTitle":7578,"status":136,"phases":7579,"primaryCompletion":5955,"completion":5955,"start":4150,"enrollment":6126,"conditions":7580,"interventions":7583},"NCT02107885","Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants.",[95],[7581,7582,831],"Safety","Tolerability",[7570],{"trials":7585,"activeCount":105},[],{"trials":7587,"activeCount":105},[],{"trials":7589,"activeCount":105},[],{"trials":7591,"activeCount":105},[],{"intervention":1199,"totalTrials":395,"cells":7593},{"EARLY_PHASE1":7594,"PHASE1":7596,"PHASE2":7602,"PHASE3":7604,"PHASE4":7606,"NA":7608},{"trials":7595,"activeCount":105},[],{"trials":7597,"activeCount":105},[7598],{"nctId":1190,"briefTitle":1191,"status":1192,"phases":7599,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":105,"conditions":7600,"interventions":7601},[95],[541],[1199,511],{"trials":7603,"activeCount":105},[],{"trials":7605,"activeCount":105},[],{"trials":7607,"activeCount":105},[],{"trials":7609,"activeCount":105},[],{"intervention":7611,"totalTrials":395,"cells":7612},"CS-8080",{"EARLY_PHASE1":7613,"PHASE1":7615,"PHASE2":7623,"PHASE3":7625,"PHASE4":7627,"NA":7629},{"trials":7614,"activeCount":105},[],{"trials":7616,"activeCount":105},[7617],{"nctId":7618,"briefTitle":7619,"status":175,"phases":7620,"primaryCompletion":573,"completion":573,"start":3050,"enrollment":550,"conditions":7621,"interventions":7622},"NCT00796575","Effects of Multiple Doses of CS-8080 in Healthy Volunteers",[95],[3658],[7611,7611,7611],{"trials":7624,"activeCount":105},[],{"trials":7626,"activeCount":105},[],{"trials":7628,"activeCount":105},[],{"trials":7630,"activeCount":105},[],{"intervention":3979,"totalTrials":395,"cells":7632},{"EARLY_PHASE1":7633,"PHASE1":7635,"PHASE2":7641,"PHASE3":7643,"PHASE4":7645,"NA":7647},{"trials":7634,"activeCount":105},[],{"trials":7636,"activeCount":105},[7637],{"nctId":3971,"briefTitle":3972,"status":136,"phases":7638,"primaryCompletion":3974,"completion":3974,"start":3975,"enrollment":604,"conditions":7639,"interventions":7640},[95],[541],[3978,3978,3979],{"trials":7642,"activeCount":105},[],{"trials":7644,"activeCount":105},[],{"trials":7646,"activeCount":105},[],{"trials":7648,"activeCount":105},[],{"intervention":7650,"totalTrials":395,"cells":7651},"DS-6016a",{"EARLY_PHASE1":7652,"PHASE1":7654,"PHASE2":7665,"PHASE3":7667,"PHASE4":7669,"NA":7671},{"trials":7653,"activeCount":105},[],{"trials":7655,"activeCount":105},[7656],{"nctId":7657,"briefTitle":7658,"status":136,"phases":7659,"primaryCompletion":7660,"completion":7661,"start":878,"enrollment":4669,"conditions":7662,"interventions":7664},"NCT04818398","Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects",[95],"2021-12-24","2022-07-26",[7663],"Fibrodysplasia Ossificans Progressiva",[7650],{"trials":7666,"activeCount":105},[],{"trials":7668,"activeCount":105},[],{"trials":7670,"activeCount":105},[],{"trials":7672,"activeCount":105},[],{"intervention":7674,"totalTrials":395,"cells":7675},"DS-9606a",{"EARLY_PHASE1":7676,"PHASE1":7678,"PHASE2":7689,"PHASE3":7691,"PHASE4":7693,"NA":7695},{"trials":7677,"activeCount":105},[],{"trials":7679,"activeCount":105},[7680],{"nctId":7681,"briefTitle":7682,"status":175,"phases":7683,"primaryCompletion":7684,"completion":7684,"start":7685,"enrollment":7557,"conditions":7686,"interventions":7688},"NCT05394675","A Study of DS-9606a in Patients With Advanced Solid Tumors",[95],"2026-02-06","2022-05-31",[311,1034,7687],"Germ Cell Tumor",[7674],{"trials":7690,"activeCount":105},[],{"trials":7692,"activeCount":105},[],{"trials":7694,"activeCount":105},[],{"trials":7696,"activeCount":105},[],{"intervention":7698,"totalTrials":395,"cells":7699},"DS-7423",{"EARLY_PHASE1":7700,"PHASE1":7702,"PHASE2":7712,"PHASE3":7714,"PHASE4":7716,"NA":7718},{"trials":7701,"activeCount":105},[],{"trials":7703,"activeCount":105},[7704],{"nctId":7705,"briefTitle":7706,"status":136,"phases":7707,"primaryCompletion":7708,"completion":7708,"start":548,"enrollment":7709,"conditions":7710,"interventions":7711},"NCT01364844","Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors",[95],"2013-11",42,[2399,5896,259],[7698],{"trials":7713,"activeCount":105},[],{"trials":7715,"activeCount":105},[],{"trials":7717,"activeCount":105},[],{"trials":7719,"activeCount":105},[],{"intervention":7721,"totalTrials":395,"cells":7722},"CS8080",{"EARLY_PHASE1":7723,"PHASE1":7725,"PHASE2":7734,"PHASE3":7736,"PHASE4":7738,"NA":7740},{"trials":7724,"activeCount":105},[],{"trials":7726,"activeCount":105},[7727],{"nctId":7728,"briefTitle":7729,"status":136,"phases":7730,"primaryCompletion":7731,"start":584,"enrollment":3615,"conditions":7732,"interventions":7733},"NCT00613431","Effects of CS-8080 in Healthy Volunteers",[95],"2008-08",[3658],[7721],{"trials":7735,"activeCount":105},[],{"trials":7737,"activeCount":105},[],{"trials":7739,"activeCount":105},[],{"trials":7741,"activeCount":105},[],{"intervention":5938,"totalTrials":395,"cells":7743},{"EARLY_PHASE1":7744,"PHASE1":7746,"PHASE2":7752,"PHASE3":7754,"PHASE4":7756,"NA":7758},{"trials":7745,"activeCount":105},[],{"trials":7747,"activeCount":105},[7748],{"nctId":5933,"briefTitle":5934,"status":136,"phases":7749,"primaryCompletion":4615,"completion":4615,"start":4254,"enrollment":29,"conditions":7750,"interventions":7751},[95],[3658],[5938,4246],{"trials":7753,"activeCount":105},[],{"trials":7755,"activeCount":105},[],{"trials":7757,"activeCount":105},[],{"trials":7759,"activeCount":105},[],{"intervention":7761,"totalTrials":395,"cells":7762},"DS-7080a",{"EARLY_PHASE1":7763,"PHASE1":7765,"PHASE2":7777,"PHASE3":7779,"PHASE4":7781,"NA":7783},{"trials":7764,"activeCount":105},[],{"trials":7766,"activeCount":105},[7767],{"nctId":7768,"briefTitle":7769,"status":136,"phases":7770,"primaryCompletion":7771,"completion":7771,"start":5943,"enrollment":2922,"conditions":7772,"interventions":7775},"NCT02530918","Study of DS-7080a for the Treatment of Macular Degeneration",[95],"2018-01-02",[7773,7774],"Neovascular Age-Related Macular Degeneration","Diabetic Macular Edema",[7761,7776],"Ranibizumab",{"trials":7778,"activeCount":105},[],{"trials":7780,"activeCount":105},[],{"trials":7782,"activeCount":105},[],{"trials":7784,"activeCount":105},[],{"intervention":7776,"totalTrials":395,"cells":7786},{"EARLY_PHASE1":7787,"PHASE1":7789,"PHASE2":7795,"PHASE3":7797,"PHASE4":7799,"NA":7801},{"trials":7788,"activeCount":105},[],{"trials":7790,"activeCount":105},[7791],{"nctId":7768,"briefTitle":7769,"status":136,"phases":7792,"primaryCompletion":7771,"completion":7771,"start":5943,"enrollment":2922,"conditions":7793,"interventions":7794},[95],[7773,7774],[7761,7776],{"trials":7796,"activeCount":105},[],{"trials":7798,"activeCount":105},[],{"trials":7800,"activeCount":105},[],{"trials":7802,"activeCount":105},[],{"intervention":7371,"totalTrials":395,"cells":7804},{"EARLY_PHASE1":7805,"PHASE1":7807,"PHASE2":7813,"PHASE3":7815,"PHASE4":7817,"NA":7819},{"trials":7806,"activeCount":105},[],{"trials":7808,"activeCount":105},[7809],{"nctId":7362,"briefTitle":7363,"status":175,"phases":7810,"primaryCompletion":7365,"completion":7366,"start":7367,"enrollment":22,"conditions":7811,"interventions":7812},[95],[7369],[2376,7371],{"trials":7814,"activeCount":105},[],{"trials":7816,"activeCount":105},[],{"trials":7818,"activeCount":105},[],{"trials":7820,"activeCount":105},[],{"intervention":7822,"totalTrials":395,"cells":7823},"DS-2330b PIB",{"EARLY_PHASE1":7824,"PHASE1":7826,"PHASE2":7839,"PHASE3":7841,"PHASE4":7843,"NA":7845},{"trials":7825,"activeCount":105},[],{"trials":7827,"activeCount":105},[7828],{"nctId":7829,"briefTitle":7830,"status":136,"phases":7831,"primaryCompletion":7832,"completion":7832,"start":7833,"enrollment":1102,"conditions":7834,"interventions":7836},"NCT03305471","DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis",[95],"2019-01-03","2017-08-17",[7835],"Hyperphosphatemia",[7822,7837,7838],"Sevelamer","DS-2330b",{"trials":7840,"activeCount":105},[],{"trials":7842,"activeCount":105},[],{"trials":7844,"activeCount":105},[],{"trials":7846,"activeCount":105},[],{"intervention":7837,"totalTrials":395,"cells":7848},{"EARLY_PHASE1":7849,"PHASE1":7851,"PHASE2":7857,"PHASE3":7859,"PHASE4":7861,"NA":7863},{"trials":7850,"activeCount":105},[],{"trials":7852,"activeCount":105},[7853],{"nctId":7829,"briefTitle":7830,"status":136,"phases":7854,"primaryCompletion":7832,"completion":7832,"start":7833,"enrollment":1102,"conditions":7855,"interventions":7856},[95],[7835],[7822,7837,7838],{"trials":7858,"activeCount":105},[],{"trials":7860,"activeCount":105},[],{"trials":7862,"activeCount":105},[],{"trials":7864,"activeCount":105},[],{"intervention":7838,"totalTrials":395,"cells":7866},{"EARLY_PHASE1":7867,"PHASE1":7869,"PHASE2":7875,"PHASE3":7877,"PHASE4":7879,"NA":7881},{"trials":7868,"activeCount":105},[],{"trials":7870,"activeCount":105},[7871],{"nctId":7829,"briefTitle":7830,"status":136,"phases":7872,"primaryCompletion":7832,"completion":7832,"start":7833,"enrollment":1102,"conditions":7873,"interventions":7874},[95],[7835],[7822,7837,7838],{"trials":7876,"activeCount":105},[],{"trials":7878,"activeCount":105},[],{"trials":7880,"activeCount":105},[],{"trials":7882,"activeCount":105},[],{"intervention":7884,"totalTrials":395,"cells":7885},"14C-Quizartinib solution for",{"EARLY_PHASE1":7886,"PHASE1":7888,"PHASE2":7898,"PHASE3":7900,"PHASE4":7902,"NA":7904},{"trials":7887,"activeCount":105},[],{"trials":7889,"activeCount":105},[7890],{"nctId":7891,"briefTitle":7892,"status":136,"phases":7893,"primaryCompletion":1971,"completion":1971,"start":7894,"enrollment":284,"conditions":7895,"interventions":7896},"NCT04796831","A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects",[95],"2021-04-26",[829],[7897,7884],"Quizartinib dihydrochloride",{"trials":7899,"activeCount":105},[],{"trials":7901,"activeCount":105},[],{"trials":7903,"activeCount":105},[],{"trials":7905,"activeCount":105},[],{"intervention":7907,"totalTrials":395,"cells":7908},"DS-2741a",{"EARLY_PHASE1":7909,"PHASE1":7911,"PHASE2":7922,"PHASE3":7924,"PHASE4":7926,"NA":7928},{"trials":7910,"activeCount":105},[],{"trials":7912,"activeCount":105},[7913],{"nctId":7914,"briefTitle":7915,"status":175,"phases":7916,"primaryCompletion":7917,"completion":7918,"start":7919,"enrollment":284,"conditions":7920,"interventions":7921},"NCT04211415","Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis",[95],"2020-03-14","2020-12-18","2020-01-13",[7096],[7907],{"trials":7923,"activeCount":105},[],{"trials":7925,"activeCount":105},[],{"trials":7927,"activeCount":105},[],{"trials":7929,"activeCount":105},[],{"intervention":3990,"totalTrials":395,"cells":7931},{"EARLY_PHASE1":7932,"PHASE1":7934,"PHASE2":7940,"PHASE3":7942,"PHASE4":7944,"NA":7946},{"trials":7933,"activeCount":105},[],{"trials":7935,"activeCount":105},[7936],{"nctId":3981,"briefTitle":3982,"status":136,"phases":7937,"primaryCompletion":3984,"completion":3985,"start":583,"enrollment":2329,"conditions":7938,"interventions":7939},[95],[541],[3988,3989,3990,3991,3992,3993],{"trials":7941,"activeCount":105},[],{"trials":7943,"activeCount":105},[],{"trials":7945,"activeCount":105},[],{"trials":7947,"activeCount":105},[],{"intervention":3991,"totalTrials":395,"cells":7949},{"EARLY_PHASE1":7950,"PHASE1":7952,"PHASE2":7958,"PHASE3":7960,"PHASE4":7962,"NA":7964},{"trials":7951,"activeCount":105},[],{"trials":7953,"activeCount":105},[7954],{"nctId":3981,"briefTitle":3982,"status":136,"phases":7955,"primaryCompletion":3984,"completion":3985,"start":583,"enrollment":2329,"conditions":7956,"interventions":7957},[95],[541],[3988,3989,3990,3991,3992,3993],{"trials":7959,"activeCount":105},[],{"trials":7961,"activeCount":105},[],{"trials":7963,"activeCount":105},[],{"trials":7965,"activeCount":105},[],{"intervention":3992,"totalTrials":395,"cells":7967},{"EARLY_PHASE1":7968,"PHASE1":7970,"PHASE2":7976,"PHASE3":7978,"PHASE4":7980,"NA":7982},{"trials":7969,"activeCount":105},[],{"trials":7971,"activeCount":105},[7972],{"nctId":3981,"briefTitle":3982,"status":136,"phases":7973,"primaryCompletion":3984,"completion":3985,"start":583,"enrollment":2329,"conditions":7974,"interventions":7975},[95],[541],[3988,3989,3990,3991,3992,3993],{"trials":7977,"activeCount":105},[],{"trials":7979,"activeCount":105},[],{"trials":7981,"activeCount":105},[],{"trials":7983,"activeCount":105},[],{"intervention":872,"totalTrials":395,"cells":7985},{"EARLY_PHASE1":7986,"PHASE1":7988,"PHASE2":7994,"PHASE3":7996,"PHASE4":7998,"NA":8000},{"trials":7987,"activeCount":105},[],{"trials":7989,"activeCount":105},[7990],{"nctId":864,"briefTitle":865,"status":136,"phases":7991,"primaryCompletion":867,"completion":867,"start":868,"enrollment":435,"conditions":7992,"interventions":7993},[95],[752],[742,871,872,873],{"trials":7995,"activeCount":105},[],{"trials":7997,"activeCount":105},[],{"trials":7999,"activeCount":105},[],{"trials":8001,"activeCount":105},[],{"intervention":8003,"totalTrials":395,"cells":8004},"DS-1471a",{"EARLY_PHASE1":8005,"PHASE1":8007,"PHASE2":8017,"PHASE3":8019,"PHASE4":8021,"NA":8023},{"trials":8006,"activeCount":105},[],{"trials":8008,"activeCount":105},[8009],{"nctId":8010,"briefTitle":8011,"status":175,"phases":8012,"primaryCompletion":8013,"completion":8013,"start":8014,"enrollment":4341,"conditions":8015,"interventions":8016},"NCT06074705","A Study of DS-1471a In Subjects With Advanced Solid Tumors",[95],"2025-07-29","2023-08-04",[360],[8003],{"trials":8018,"activeCount":105},[],{"trials":8020,"activeCount":105},[],{"trials":8022,"activeCount":105},[],{"trials":8024,"activeCount":105},[],{"intervention":8026,"totalTrials":395,"cells":8027},"DS-6051b",{"EARLY_PHASE1":8028,"PHASE1":8030,"PHASE2":8042,"PHASE3":8044,"PHASE4":8046,"NA":8048},{"trials":8029,"activeCount":105},[],{"trials":8031,"activeCount":105},[8032],{"nctId":8033,"briefTitle":8034,"status":136,"phases":8035,"primaryCompletion":8036,"completion":8037,"start":8038,"enrollment":32,"conditions":8039,"interventions":8041},"NCT02675491","Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors",[95],"2021-12-27","2021-12-28","2016-02-10",[8040],"Advanced Solid Malignant Tumors",[8026],{"trials":8043,"activeCount":105},[],{"trials":8045,"activeCount":105},[],{"trials":8047,"activeCount":105},[],{"trials":8049,"activeCount":105},[],{"intervention":8051,"totalTrials":395,"cells":8052},"CS-0777",{"EARLY_PHASE1":8053,"PHASE1":8055,"PHASE2":8064,"PHASE3":8066,"PHASE4":8068,"NA":8070},{"trials":8054,"activeCount":105},[],{"trials":8056,"activeCount":105},[8057],{"nctId":8058,"briefTitle":8059,"status":136,"phases":8060,"primaryCompletion":4300,"completion":4300,"start":3072,"enrollment":1945,"conditions":8061,"interventions":8063},"NCT00616733","12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients",[95],[8062],"Multiple Sclerosis",[8051,8051,8051],{"trials":8065,"activeCount":105},[],{"trials":8067,"activeCount":105},[],{"trials":8069,"activeCount":105},[],{"trials":8071,"activeCount":105},[],{"intervention":1076,"totalTrials":395,"cells":8073},{"EARLY_PHASE1":8074,"PHASE1":8076,"PHASE2":8082,"PHASE3":8084,"PHASE4":8086,"NA":8088},{"trials":8075,"activeCount":105},[],{"trials":8077,"activeCount":105},[8078],{"nctId":1068,"briefTitle":1069,"status":136,"phases":8079,"primaryCompletion":1071,"completion":1071,"start":1072,"enrollment":550,"conditions":8080,"interventions":8081},[95],[1074],[60,1076],{"trials":8083,"activeCount":105},[],{"trials":8085,"activeCount":105},[],{"trials":8087,"activeCount":105},[],{"trials":8089,"activeCount":105},[],{"intervention":8091,"totalTrials":395,"cells":8092},"vemurafenib",{"EARLY_PHASE1":8093,"PHASE1":8095,"PHASE2":8108,"PHASE3":8110,"PHASE4":8112,"NA":8114},{"trials":8094,"activeCount":105},[],{"trials":8096,"activeCount":105},[8097],{"nctId":8098,"briefTitle":8099,"status":175,"phases":8100,"primaryCompletion":8101,"completion":8101,"start":8102,"enrollment":2373,"conditions":8103,"interventions":8107},"NCT01826448","A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",[95],"2014-09-22","2013-11-05",[8104,8105,8106],"V600-mutated BRAF Unresectable Melanoma","V600-mutated BRAF Metastatic Melanoma","Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor",[382,8091],{"trials":8109,"activeCount":105},[],{"trials":8111,"activeCount":105},[],{"trials":8113,"activeCount":105},[],{"trials":8115,"activeCount":105},[],{"intervention":8117,"totalTrials":395,"cells":8118},"DS-8273a",{"EARLY_PHASE1":8119,"PHASE1":8121,"PHASE2":8129,"PHASE3":8131,"PHASE4":8133,"NA":8135},{"trials":8120,"activeCount":105},[],{"trials":8122,"activeCount":105},[8123],{"nctId":8124,"briefTitle":8125,"status":136,"phases":8126,"primaryCompletion":2870,"completion":2870,"start":6083,"enrollment":897,"conditions":8127,"interventions":8128},"NCT02076451","Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas",[95],[360,3869],[8117],{"trials":8130,"activeCount":105},[],{"trials":8132,"activeCount":105},[],{"trials":8134,"activeCount":105},[],{"trials":8136,"activeCount":105},[],{"intervention":8138,"totalTrials":395,"cells":8139},"DS-1150b",{"EARLY_PHASE1":8140,"PHASE1":8142,"PHASE2":8150,"PHASE3":8152,"PHASE4":8154,"NA":8156},{"trials":8141,"activeCount":105},[],{"trials":8143,"activeCount":105},[8144],{"nctId":8145,"briefTitle":8146,"status":136,"phases":8147,"primaryCompletion":3985,"completion":4298,"start":3985,"enrollment":1102,"conditions":8148,"interventions":8149},"NCT02004678","Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus",[95],[31],[8138],{"trials":8151,"activeCount":105},[],{"trials":8153,"activeCount":105},[],{"trials":8155,"activeCount":105},[],{"trials":8157,"activeCount":105},[],{"intervention":8159,"totalTrials":395,"cells":8160},"Treatment A - 400 mg Fasting",{"EARLY_PHASE1":8161,"PHASE1":8163,"PHASE2":8177,"PHASE3":8179,"PHASE4":8181,"NA":8183},{"trials":8162,"activeCount":105},[],{"trials":8164,"activeCount":105},[8165],{"nctId":8166,"briefTitle":8167,"status":136,"phases":8168,"primaryCompletion":8169,"completion":8170,"start":8171,"enrollment":604,"conditions":8172,"interventions":8174},"NCT03901313","Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers",[95],"2019-05-08","2019-05-22","2019-04-01",[8173],"Healthy Volunteers",[8159,8175,8176],"Treatment B - 400 mg Fed","Treatment C - 200 mg Fed",{"trials":8178,"activeCount":105},[],{"trials":8180,"activeCount":105},[],{"trials":8182,"activeCount":105},[],{"trials":8184,"activeCount":105},[],{"intervention":8175,"totalTrials":395,"cells":8186},{"EARLY_PHASE1":8187,"PHASE1":8189,"PHASE2":8195,"PHASE3":8197,"PHASE4":8199,"NA":8201},{"trials":8188,"activeCount":105},[],{"trials":8190,"activeCount":105},[8191],{"nctId":8166,"briefTitle":8167,"status":136,"phases":8192,"primaryCompletion":8169,"completion":8170,"start":8171,"enrollment":604,"conditions":8193,"interventions":8194},[95],[8173],[8159,8175,8176],{"trials":8196,"activeCount":105},[],{"trials":8198,"activeCount":105},[],{"trials":8200,"activeCount":105},[],{"trials":8202,"activeCount":105},[],{"intervention":8176,"totalTrials":395,"cells":8204},{"EARLY_PHASE1":8205,"PHASE1":8207,"PHASE2":8213,"PHASE3":8215,"PHASE4":8217,"NA":8219},{"trials":8206,"activeCount":105},[],{"trials":8208,"activeCount":105},[8209],{"nctId":8166,"briefTitle":8167,"status":136,"phases":8210,"primaryCompletion":8169,"completion":8170,"start":8171,"enrollment":604,"conditions":8211,"interventions":8212},[95],[8173],[8159,8175,8176],{"trials":8214,"activeCount":105},[],{"trials":8216,"activeCount":105},[],{"trials":8218,"activeCount":105},[],{"trials":8220,"activeCount":105},[],{"intervention":5947,"totalTrials":395,"cells":8222},{"EARLY_PHASE1":8223,"PHASE1":8225,"PHASE2":8231,"PHASE3":8233,"PHASE4":8235,"NA":8237},{"trials":8224,"activeCount":105},[],{"trials":8226,"activeCount":105},[8227],{"nctId":5940,"briefTitle":5941,"status":136,"phases":8228,"primaryCompletion":5943,"completion":5943,"start":5944,"enrollment":29,"conditions":8229,"interventions":8230},[95],[3658],[4246,5947,5948,5949,5950,1065],{"trials":8232,"activeCount":105},[],{"trials":8234,"activeCount":105},[],{"trials":8236,"activeCount":105},[],{"trials":8238,"activeCount":105},[],{"intervention":5949,"totalTrials":395,"cells":8240},{"EARLY_PHASE1":8241,"PHASE1":8243,"PHASE2":8249,"PHASE3":8251,"PHASE4":8253,"NA":8255},{"trials":8242,"activeCount":105},[],{"trials":8244,"activeCount":105},[8245],{"nctId":5940,"briefTitle":5941,"status":136,"phases":8246,"primaryCompletion":5943,"completion":5943,"start":5944,"enrollment":29,"conditions":8247,"interventions":8248},[95],[3658],[4246,5947,5948,5949,5950,1065],{"trials":8250,"activeCount":105},[],{"trials":8252,"activeCount":105},[],{"trials":8254,"activeCount":105},[],{"trials":8256,"activeCount":105},[],{"intervention":5950,"totalTrials":395,"cells":8258},{"EARLY_PHASE1":8259,"PHASE1":8261,"PHASE2":8267,"PHASE3":8269,"PHASE4":8271,"NA":8273},{"trials":8260,"activeCount":105},[],{"trials":8262,"activeCount":105},[8263],{"nctId":5940,"briefTitle":5941,"status":136,"phases":8264,"primaryCompletion":5943,"completion":5943,"start":5944,"enrollment":29,"conditions":8265,"interventions":8266},[95],[3658],[4246,5947,5948,5949,5950,1065],{"trials":8268,"activeCount":105},[],{"trials":8270,"activeCount":105},[],{"trials":8272,"activeCount":105},[],{"trials":8274,"activeCount":105},[],{"intervention":8276,"totalTrials":395,"cells":8277},"DS-8895a",{"EARLY_PHASE1":8278,"PHASE1":8280,"PHASE2":8288,"PHASE3":8290,"PHASE4":8292,"NA":8294},{"trials":8279,"activeCount":105},[],{"trials":8281,"activeCount":105},[8282],{"nctId":8283,"briefTitle":8284,"status":136,"phases":8285,"primaryCompletion":4240,"completion":4240,"start":4298,"enrollment":931,"conditions":8286,"interventions":8287},"NCT02004717","Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors",[95],[541],[8276],{"trials":8289,"activeCount":105},[],{"trials":8291,"activeCount":105},[],{"trials":8293,"activeCount":105},[],{"trials":8295,"activeCount":105},[],{"intervention":8297,"totalTrials":395,"cells":8298},"DS-2248",{"EARLY_PHASE1":8299,"PHASE1":8301,"PHASE2":8311,"PHASE3":8313,"PHASE4":8315,"NA":8317},{"trials":8300,"activeCount":105},[],{"trials":8302,"activeCount":105},[8303],{"nctId":8304,"briefTitle":8305,"status":175,"phases":8306,"primaryCompletion":8307,"completion":8307,"start":8308,"enrollment":2482,"conditions":8309,"interventions":8310},"NCT01288430","A Study of DS-2248 in Participants With Advanced Solid Tumors",[95],"2014-02-13","2011-03-29",[541,130],[8297],{"trials":8312,"activeCount":105},[],{"trials":8314,"activeCount":105},[],{"trials":8316,"activeCount":105},[],{"trials":8318,"activeCount":105},[],{"intervention":8320,"totalTrials":395,"cells":8321},"DS-8273a + nivolumab",{"EARLY_PHASE1":8322,"PHASE1":8324,"PHASE2":8334,"PHASE3":8336,"PHASE4":8338,"NA":8340},{"trials":8323,"activeCount":105},[],{"trials":8325,"activeCount":105},[8326],{"nctId":8327,"briefTitle":8328,"status":175,"phases":8329,"primaryCompletion":8330,"completion":8330,"start":8331,"enrollment":344,"conditions":8332,"interventions":8333},"NCT02991196","Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer",[95],"2017-09-22","2016-12-01",[1583],[8320],{"trials":8335,"activeCount":105},[],{"trials":8337,"activeCount":105},[],{"trials":8339,"activeCount":105},[],{"trials":8341,"activeCount":105},[],{"intervention":8343,"totalTrials":395,"cells":8344},"DS-3078a",{"EARLY_PHASE1":8345,"PHASE1":8347,"PHASE2":8355,"PHASE3":8357,"PHASE4":8359,"NA":8361},{"trials":8346,"activeCount":105},[],{"trials":8348,"activeCount":105},[8349],{"nctId":8350,"briefTitle":8351,"status":136,"phases":8352,"primaryCompletion":4668,"completion":4668,"start":6031,"enrollment":897,"conditions":8353,"interventions":8354},"NCT01588678","A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1\u002F2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",[95],[360,3869],[8343],{"trials":8356,"activeCount":105},[],{"trials":8358,"activeCount":105},[],{"trials":8360,"activeCount":105},[],{"trials":8362,"activeCount":105},[],{"intervention":8364,"totalTrials":395,"cells":8365},"U3-1784",{"EARLY_PHASE1":8366,"PHASE1":8368,"PHASE2":8379,"PHASE3":8381,"PHASE4":8383,"NA":8385},{"trials":8367,"activeCount":105},[],{"trials":8369,"activeCount":105},[8370],{"nctId":8371,"briefTitle":8372,"status":175,"phases":8373,"primaryCompletion":8374,"completion":8374,"start":8375,"enrollment":639,"conditions":8376,"interventions":8378},"NCT02690350","An Open Study Assessing the Safety and Tolerability of U3-1784",[95],"2017-02-28","2016-02-29",[1084,8377],"Hepatocellular Cancer (HCC)",[8364],{"trials":8380,"activeCount":105},[],{"trials":8382,"activeCount":105},[],{"trials":8384,"activeCount":105},[],{"trials":8386,"activeCount":105},[],{"intervention":5991,"totalTrials":395,"cells":8388},{"EARLY_PHASE1":8389,"PHASE1":8391,"PHASE2":8397,"PHASE3":8399,"PHASE4":8401,"NA":8403},{"trials":8390,"activeCount":105},[],{"trials":8392,"activeCount":105},[8393],{"nctId":5984,"briefTitle":5985,"status":136,"phases":8394,"primaryCompletion":5987,"completion":3984,"start":2919,"enrollment":5988,"conditions":8395,"interventions":8396},[95],[1153],[597,5991],{"trials":8398,"activeCount":105},[],{"trials":8400,"activeCount":105},[],{"trials":8402,"activeCount":105},[],{"trials":8404,"activeCount":105},[],{"intervention":1550,"totalTrials":395,"cells":8406},{"EARLY_PHASE1":8407,"PHASE1":8409,"PHASE2":8415,"PHASE3":8417,"PHASE4":8419,"NA":8421},{"trials":8408,"activeCount":105},[],{"trials":8410,"activeCount":105},[8411],{"nctId":1542,"briefTitle":1543,"status":136,"phases":8412,"primaryCompletion":1059,"completion":1545,"start":1546,"enrollment":1102,"conditions":8413,"interventions":8414},[95],[1548],[1515,1550,1551],{"trials":8416,"activeCount":105},[],{"trials":8418,"activeCount":105},[],{"trials":8420,"activeCount":105},[],{"trials":8422,"activeCount":105},[],{"intervention":8424,"totalTrials":395,"cells":8425},"60mg edoxaban",{"EARLY_PHASE1":8426,"PHASE1":8428,"PHASE2":8441,"PHASE3":8443,"PHASE4":8445,"NA":8447},{"trials":8427,"activeCount":105},[],{"trials":8429,"activeCount":105},[8430],{"nctId":8431,"briefTitle":8432,"status":136,"phases":8433,"primaryCompletion":951,"completion":951,"start":4298,"enrollment":2911,"conditions":8434,"interventions":8436},"NCT02047565","A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation",[95],[8435],"Bleeding",[8424,8437,8438,8439,8440],"180mg edoxaban","50 IU\u002Fkg Beriplex P\u002FN","25 IU\u002Fkg Beriplex P\u002FN","10 IU\u002Fkg Beriplex P\u002FN",{"trials":8442,"activeCount":105},[],{"trials":8444,"activeCount":105},[],{"trials":8446,"activeCount":105},[],{"trials":8448,"activeCount":105},[],{"intervention":8437,"totalTrials":395,"cells":8450},{"EARLY_PHASE1":8451,"PHASE1":8453,"PHASE2":8459,"PHASE3":8461,"PHASE4":8463,"NA":8465},{"trials":8452,"activeCount":105},[],{"trials":8454,"activeCount":105},[8455],{"nctId":8431,"briefTitle":8432,"status":136,"phases":8456,"primaryCompletion":951,"completion":951,"start":4298,"enrollment":2911,"conditions":8457,"interventions":8458},[95],[8435],[8424,8437,8438,8439,8440],{"trials":8460,"activeCount":105},[],{"trials":8462,"activeCount":105},[],{"trials":8464,"activeCount":105},[],{"trials":8466,"activeCount":105},[],{"intervention":8438,"totalTrials":395,"cells":8468},{"EARLY_PHASE1":8469,"PHASE1":8471,"PHASE2":8477,"PHASE3":8479,"PHASE4":8481,"NA":8483},{"trials":8470,"activeCount":105},[],{"trials":8472,"activeCount":105},[8473],{"nctId":8431,"briefTitle":8432,"status":136,"phases":8474,"primaryCompletion":951,"completion":951,"start":4298,"enrollment":2911,"conditions":8475,"interventions":8476},[95],[8435],[8424,8437,8438,8439,8440],{"trials":8478,"activeCount":105},[],{"trials":8480,"activeCount":105},[],{"trials":8482,"activeCount":105},[],{"trials":8484,"activeCount":105},[],{"intervention":8439,"totalTrials":395,"cells":8486},{"EARLY_PHASE1":8487,"PHASE1":8489,"PHASE2":8495,"PHASE3":8497,"PHASE4":8499,"NA":8501},{"trials":8488,"activeCount":105},[],{"trials":8490,"activeCount":105},[8491],{"nctId":8431,"briefTitle":8432,"status":136,"phases":8492,"primaryCompletion":951,"completion":951,"start":4298,"enrollment":2911,"conditions":8493,"interventions":8494},[95],[8435],[8424,8437,8438,8439,8440],{"trials":8496,"activeCount":105},[],{"trials":8498,"activeCount":105},[],{"trials":8500,"activeCount":105},[],{"trials":8502,"activeCount":105},[],{"intervention":8440,"totalTrials":395,"cells":8504},{"EARLY_PHASE1":8505,"PHASE1":8507,"PHASE2":8513,"PHASE3":8515,"PHASE4":8517,"NA":8519},{"trials":8506,"activeCount":105},[],{"trials":8508,"activeCount":105},[8509],{"nctId":8431,"briefTitle":8432,"status":136,"phases":8510,"primaryCompletion":951,"completion":951,"start":4298,"enrollment":2911,"conditions":8511,"interventions":8512},[95],[8435],[8424,8437,8438,8439,8440],{"trials":8514,"activeCount":105},[],{"trials":8516,"activeCount":105},[],{"trials":8518,"activeCount":105},[],{"trials":8520,"activeCount":105},[],{"intervention":8522,"totalTrials":395,"cells":8523},"U3-1565",{"EARLY_PHASE1":8524,"PHASE1":8526,"PHASE2":8535,"PHASE3":8537,"PHASE4":8539,"NA":8541},{"trials":8525,"activeCount":105},[],{"trials":8527,"activeCount":105},[8528],{"nctId":8529,"briefTitle":8530,"status":136,"phases":8531,"primaryCompletion":3998,"completion":3998,"start":5114,"enrollment":4427,"conditions":8532,"interventions":8534},"NCT01290471","Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors",[95],[8040,8533],"Advanced Ovarian Cancer",[8522],{"trials":8536,"activeCount":105},[],{"trials":8538,"activeCount":105},[],{"trials":8540,"activeCount":105},[],{"trials":8542,"activeCount":105},[],{"intervention":3872,"totalTrials":395,"cells":8544},{"EARLY_PHASE1":8545,"PHASE1":8547,"PHASE2":8553,"PHASE3":8555,"PHASE4":8557,"NA":8559},{"trials":8546,"activeCount":105},[],{"trials":8548,"activeCount":105},[8549],{"nctId":3862,"briefTitle":3863,"status":136,"phases":8550,"primaryCompletion":3865,"completion":3865,"start":3866,"conditions":8551,"interventions":8552},[95],[3868,3869,3870],[3872,3847],{"trials":8554,"activeCount":105},[],{"trials":8556,"activeCount":105},[],{"trials":8558,"activeCount":105},[],{"trials":8560,"activeCount":105},[],{"intervention":8562,"totalTrials":395,"cells":8563},"Edoxaban low dose",{"EARLY_PHASE1":8564,"PHASE1":8566,"PHASE2":8577,"PHASE3":8579,"PHASE4":8581,"NA":8583},{"trials":8565,"activeCount":105},[],{"trials":8567,"activeCount":105},[8568],{"nctId":8569,"briefTitle":8570,"status":136,"phases":8571,"primaryCompletion":8572,"completion":8572,"start":8573,"enrollment":18,"conditions":8574,"interventions":8575},"NCT02303431","Phase 1 Pediatric Pharmacokinetics\u002FPharmacodynamics (PK\u002FPD) Study",[95],"2021-09-16","2014-11-05",[4099,39],[8562,8576],"Edoxaban high dose",{"trials":8578,"activeCount":105},[],{"trials":8580,"activeCount":105},[],{"trials":8582,"activeCount":105},[],{"trials":8584,"activeCount":105},[],{"intervention":8576,"totalTrials":395,"cells":8586},{"EARLY_PHASE1":8587,"PHASE1":8589,"PHASE2":8595,"PHASE3":8597,"PHASE4":8599,"NA":8601},{"trials":8588,"activeCount":105},[],{"trials":8590,"activeCount":105},[8591],{"nctId":8569,"briefTitle":8570,"status":136,"phases":8592,"primaryCompletion":8572,"completion":8572,"start":8573,"enrollment":18,"conditions":8593,"interventions":8594},[95],[4099,39],[8562,8576],{"trials":8596,"activeCount":105},[],{"trials":8598,"activeCount":105},[],{"trials":8600,"activeCount":105},[],{"trials":8602,"activeCount":105},[],{"intervention":900,"totalTrials":395,"cells":8604},{"EARLY_PHASE1":8605,"PHASE1":8607,"PHASE2":8613,"PHASE3":8615,"PHASE4":8617,"NA":8619},{"trials":8606,"activeCount":105},[],{"trials":8608,"activeCount":105},[8609],{"nctId":892,"briefTitle":893,"status":136,"phases":8610,"primaryCompletion":895,"completion":895,"start":896,"enrollment":897,"conditions":8611,"interventions":8612},[95],[829,830,831,742],[900,742],{"trials":8614,"activeCount":105},[],{"trials":8616,"activeCount":105},[],{"trials":8618,"activeCount":105},[],{"trials":8620,"activeCount":105},[],{"intervention":7318,"totalTrials":395,"cells":8622},{"EARLY_PHASE1":8623,"PHASE1":8625,"PHASE2":8631,"PHASE3":8633,"PHASE4":8635,"NA":8637},{"trials":8624,"activeCount":105},[],{"trials":8626,"activeCount":105},[8627],{"nctId":7310,"briefTitle":7311,"status":175,"phases":8628,"primaryCompletion":7313,"completion":7313,"start":7314,"enrollment":539,"conditions":8629,"interventions":8630},[95],[7316,6039],[882,7318,882],{"trials":8632,"activeCount":105},[],{"trials":8634,"activeCount":105},[],{"trials":8636,"activeCount":105},[],{"trials":8638,"activeCount":105},[],{"intervention":8640,"totalTrials":395,"cells":8641},"DS-5573a",{"EARLY_PHASE1":8642,"PHASE1":8644,"PHASE2":8652,"PHASE3":8654,"PHASE4":8656,"NA":8658},{"trials":8643,"activeCount":105},[],{"trials":8645,"activeCount":105},[8646],{"nctId":8647,"briefTitle":8648,"status":175,"phases":8649,"primaryCompletion":4239,"completion":4239,"start":5929,"enrollment":585,"conditions":8650,"interventions":8651},"NCT02192567","Open Label Study of DS-5573a",[95],[8040],[8640],{"trials":8653,"activeCount":105},[],{"trials":8655,"activeCount":105},[],{"trials":8657,"activeCount":105},[],{"trials":8659,"activeCount":105},[],{"intervention":909,"totalTrials":395,"cells":8661},{"EARLY_PHASE1":8662,"PHASE1":8664,"PHASE2":8670,"PHASE3":8672,"PHASE4":8674,"NA":8676},{"trials":8663,"activeCount":105},[],{"trials":8665,"activeCount":105},[8666],{"nctId":902,"briefTitle":903,"status":136,"phases":8667,"primaryCompletion":905,"completion":905,"start":906,"enrollment":897,"conditions":8668,"interventions":8669},[95],[829],[742,909],{"trials":8671,"activeCount":105},[],{"trials":8673,"activeCount":105},[],{"trials":8675,"activeCount":105},[],{"trials":8677,"activeCount":105},[],{"intervention":8679,"totalTrials":395,"cells":8680},"DS-6157a",{"EARLY_PHASE1":8681,"PHASE1":8683,"PHASE2":8695,"PHASE3":8697,"PHASE4":8699,"NA":8701},{"trials":8682,"activeCount":105},[],{"trials":8684,"activeCount":105},[8685],{"nctId":8686,"briefTitle":8687,"status":175,"phases":8688,"primaryCompletion":8689,"completion":8689,"start":8690,"enrollment":8691,"conditions":8692,"interventions":8694},"NCT04276415","DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)",[95],"2022-03-11","2020-05-08",34,[8693],"Gastrointestinal Stromal Tumors",[8679],{"trials":8696,"activeCount":105},[],{"trials":8698,"activeCount":105},[],{"trials":8700,"activeCount":105},[],{"trials":8702,"activeCount":105},[],{"intervention":145,"totalTrials":395,"cells":8704},{"EARLY_PHASE1":8705,"PHASE1":8707,"PHASE2":8713,"PHASE3":8715,"PHASE4":8717,"NA":8719},{"trials":8706,"activeCount":105},[],{"trials":8708,"activeCount":105},[8709],{"nctId":134,"briefTitle":135,"status":136,"phases":8710,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":8711,"interventions":8712},[95],[44,143],[55,145],{"trials":8714,"activeCount":105},[],{"trials":8716,"activeCount":105},[],{"trials":8718,"activeCount":105},[],{"trials":8720,"activeCount":105},[],{"intervention":8722,"totalTrials":395,"cells":8723},"DS-1093",{"EARLY_PHASE1":8724,"PHASE1":8726,"PHASE2":8735,"PHASE3":8737,"PHASE4":8739,"NA":8741},{"trials":8725,"activeCount":105},[],{"trials":8727,"activeCount":105},[8728],{"nctId":8729,"briefTitle":8730,"status":136,"phases":8731,"primaryCompletion":2058,"completion":2058,"start":951,"enrollment":7508,"conditions":8732,"interventions":8734},"NCT02142400","Multiple Ascending Dose Study of DS-1093 in Healthy Subjects",[95],[8733],"Anaemia",[8722],{"trials":8736,"activeCount":105},[],{"trials":8738,"activeCount":105},[],{"trials":8740,"activeCount":105},[],{"trials":8742,"activeCount":105},[],{"intervention":8744,"totalTrials":395,"cells":8745},"DS-1123",{"EARLY_PHASE1":8746,"PHASE1":8748,"PHASE2":8757,"PHASE3":8759,"PHASE4":8761,"NA":8763},{"trials":8747,"activeCount":105},[],{"trials":8749,"activeCount":105},[8750],{"nctId":8751,"briefTitle":8752,"status":136,"phases":8753,"primaryCompletion":8754,"completion":8754,"start":6607,"enrollment":4032,"conditions":8755,"interventions":8756},"NCT02690337","Study of DS-1123a in Advanced Solid Tumours",[95],"2017-11",[8040],[8744],{"trials":8758,"activeCount":105},[],{"trials":8760,"activeCount":105},[],{"trials":8762,"activeCount":105},[],{"trials":8764,"activeCount":105},[],{"intervention":8766,"totalTrials":395,"cells":8767},"Milademetan Treatment A",{"EARLY_PHASE1":8768,"PHASE1":8781,"PHASE2":8783,"PHASE3":8785,"PHASE4":8787,"NA":8789},{"trials":8769,"activeCount":105},[8770],{"nctId":8771,"briefTitle":8772,"status":136,"phases":8773,"primaryCompletion":8774,"completion":8774,"start":8775,"enrollment":29,"conditions":8776,"interventions":8778},"NCT03647202","Food Effects on Milademetan Pharmacokinetics in Healthy Participants",[94],"2018-09-13","2018-08-16",[8777],"Food Effects on Pharmacokinetics",[8766,8779,8780],"Milademetan Treatment B","Milademetan Treatment C",{"trials":8782,"activeCount":105},[],{"trials":8784,"activeCount":105},[],{"trials":8786,"activeCount":105},[],{"trials":8788,"activeCount":105},[],{"trials":8790,"activeCount":105},[],{"intervention":8779,"totalTrials":395,"cells":8792},{"EARLY_PHASE1":8793,"PHASE1":8799,"PHASE2":8801,"PHASE3":8803,"PHASE4":8805,"NA":8807},{"trials":8794,"activeCount":105},[8795],{"nctId":8771,"briefTitle":8772,"status":136,"phases":8796,"primaryCompletion":8774,"completion":8774,"start":8775,"enrollment":29,"conditions":8797,"interventions":8798},[94],[8777],[8766,8779,8780],{"trials":8800,"activeCount":105},[],{"trials":8802,"activeCount":105},[],{"trials":8804,"activeCount":105},[],{"trials":8806,"activeCount":105},[],{"trials":8808,"activeCount":105},[],{"intervention":8780,"totalTrials":395,"cells":8810},{"EARLY_PHASE1":8811,"PHASE1":8817,"PHASE2":8819,"PHASE3":8821,"PHASE4":8823,"NA":8825},{"trials":8812,"activeCount":105},[8813],{"nctId":8771,"briefTitle":8772,"status":136,"phases":8814,"primaryCompletion":8774,"completion":8774,"start":8775,"enrollment":29,"conditions":8815,"interventions":8816},[94],[8777],[8766,8779,8780],{"trials":8818,"activeCount":105},[],{"trials":8820,"activeCount":105},[],{"trials":8822,"activeCount":105},[],{"trials":8824,"activeCount":105},[],{"trials":8826,"activeCount":105},[],{"intervention":7284,"totalTrials":395,"cells":8828},{"EARLY_PHASE1":8829,"PHASE1":8835,"PHASE2":8837,"PHASE3":8839,"PHASE4":8841,"NA":8843},{"trials":8830,"activeCount":105},[8831],{"nctId":7277,"briefTitle":7278,"status":136,"phases":8832,"primaryCompletion":7280,"completion":7280,"start":7281,"enrollment":4427,"conditions":8833,"interventions":8834},[94],[831],[882,1551,7284],{"trials":8836,"activeCount":105},[],{"trials":8838,"activeCount":105},[],{"trials":8840,"activeCount":105},[],{"trials":8842,"activeCount":105},[],{"trials":8844,"activeCount":105},[],{"intervention":833,"totalTrials":395,"cells":8846},{"EARLY_PHASE1":8847,"PHASE1":8853,"PHASE2":8855,"PHASE3":8857,"PHASE4":8859,"NA":8861},{"trials":8848,"activeCount":105},[8849],{"nctId":823,"briefTitle":824,"status":136,"phases":8850,"primaryCompletion":826,"completion":826,"start":827,"enrollment":22,"conditions":8851,"interventions":8852},[94],[829,830,831,742],[833,742],{"trials":8854,"activeCount":105},[],{"trials":8856,"activeCount":105},[],{"trials":8858,"activeCount":105},[],{"trials":8860,"activeCount":105},[],{"trials":8862,"activeCount":105},[],{"intervention":2900,"totalTrials":8864,"cells":8865},23,{"EARLY_PHASE1":8866,"PHASE1":8868,"PHASE2":8870,"PHASE3":8880,"PHASE4":8918,"NA":8920},{"trials":8867,"activeCount":105},[],{"trials":8869,"activeCount":105},[],{"trials":8871,"activeCount":105},[8872,8876],{"nctId":4162,"briefTitle":4163,"status":136,"phases":8873,"primaryCompletion":4165,"completion":4165,"start":3350,"enrollment":4166,"conditions":8874,"interventions":8875},[96],[28,4168],[2900,2900,2900,2900,4137],{"nctId":2878,"briefTitle":2879,"status":136,"phases":8877,"primaryCompletion":2881,"completion":2881,"start":2882,"enrollment":2883,"conditions":8878,"interventions":8879},[96],[2885],[2887,2860,2888],{"trials":8881,"activeCount":105},[8882,8886,8890,8894,8898,8902,8906,8910,8914],{"nctId":4173,"briefTitle":4174,"status":136,"phases":8883,"primaryCompletion":4176,"completion":4176,"start":4177,"enrollment":4178,"conditions":8884,"interventions":8885},[97],[28],[2900,4092,4181],{"nctId":5050,"briefTitle":5051,"status":136,"phases":8887,"primaryCompletion":5053,"completion":5053,"start":5054,"enrollment":5055,"conditions":8888,"interventions":8889},[97],[4714,4190,4191,4011],[2900,5039,5058],{"nctId":4698,"briefTitle":4699,"status":136,"phases":8891,"primaryCompletion":4701,"completion":4701,"start":4702,"enrollment":4703,"conditions":8892,"interventions":8893},[97],[4705],[2900,4687],{"nctId":4732,"briefTitle":4733,"status":136,"phases":8895,"primaryCompletion":4735,"completion":4735,"start":4736,"enrollment":4737,"conditions":8896,"interventions":8897},[97],[28],[2900,4721,4721,4721,4721],{"nctId":4708,"briefTitle":4709,"status":136,"phases":8899,"primaryCompletion":4711,"completion":4711,"start":1109,"enrollment":4712,"conditions":8900,"interventions":8901},[97],[4714,4566,4190],[2900,4687],{"nctId":4801,"briefTitle":4802,"status":136,"phases":8903,"primaryCompletion":3049,"completion":2921,"start":4804,"enrollment":4805,"conditions":8904,"interventions":8905},[97],[39],[2887,4790],{"nctId":2892,"briefTitle":2893,"status":136,"phases":8907,"primaryCompletion":2895,"completion":2895,"start":2896,"enrollment":2897,"conditions":8908,"interventions":8909},[97],[28],[2900,2860,2901,2902,2903],{"nctId":4809,"briefTitle":4810,"status":136,"phases":8911,"primaryCompletion":2999,"completion":549,"start":4437,"enrollment":4812,"conditions":8912,"interventions":8913},[97],[4814,39],[2887,4790],{"nctId":4195,"briefTitle":4196,"status":136,"phases":8915,"primaryCompletion":4186,"completion":3999,"start":3050,"enrollment":4198,"conditions":8916,"interventions":8917},[97],[4090,28,4200],[4137,2900,2900],{"trials":8919,"activeCount":105},[],{"trials":8921,"activeCount":105},[8922,8930,8940,8948,8956,8965,8973,8982,8991,9000,9009,9017],{"nctId":8923,"briefTitle":8924,"status":136,"phases":8925,"primaryCompletion":8926,"completion":8926,"start":1109,"enrollment":8927,"conditions":8928,"interventions":8929},"NCT02952599","Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Korea and Taiwan (ETNA-VTE-KOR-TWN)",[],"2019-10-29",352,[39],[2900],{"nctId":8931,"briefTitle":8932,"status":136,"phases":8933,"primaryCompletion":8934,"completion":8934,"start":8935,"enrollment":4088,"conditions":8936,"interventions":8937},"NCT05262322","Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation",[],"2021-07-09","2019-02-15",[28],[2900,8938,8939],"Apixaban","Rivaroxaban",{"nctId":8941,"briefTitle":8942,"status":136,"phases":8943,"primaryCompletion":8944,"completion":8944,"start":8945,"enrollment":2693,"conditions":8946,"interventions":8947},"NCT04747496","Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China",[],"2024-11-27","2021-02-26",[4521],[2900],{"nctId":8949,"briefTitle":8950,"status":136,"phases":8951,"primaryCompletion":8952,"completion":8952,"start":4614,"enrollment":8953,"conditions":8954,"interventions":8955},"NCT02944019","Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation",[],"2022-04-13",13980,[28],[2900],{"nctId":8957,"briefTitle":8958,"status":136,"phases":8959,"primaryCompletion":8960,"completion":8960,"start":8961,"enrollment":8962,"conditions":8963,"interventions":8964},"NCT02943993","Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe",[],"2020-12-01","2016-04-06",2809,[39],[2900],{"nctId":8966,"briefTitle":8967,"status":136,"phases":8968,"primaryCompletion":8969,"completion":8969,"start":2099,"enrollment":8970,"conditions":8971,"interventions":8972},"NCT04519944","Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention",[],"2023-07-06",666,[4521],[2900],{"nctId":8974,"briefTitle":8975,"status":136,"phases":8976,"primaryCompletion":8977,"completion":8977,"start":8978,"enrollment":8979,"conditions":8980,"interventions":8981},"NCT04594915","Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey",[],"2023-06-21","2020-08-14",1053,[28],[2900],{"nctId":8983,"briefTitle":8984,"status":136,"phases":8985,"primaryCompletion":8986,"completion":8986,"start":8987,"enrollment":8988,"conditions":8989,"interventions":8990},"NCT05804747","A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation",[],"2025-07-28","2023-02-16",1204,[28],[2900],{"nctId":8992,"briefTitle":8993,"status":136,"phases":8994,"primaryCompletion":8995,"completion":8995,"start":8996,"enrollment":8997,"conditions":8998,"interventions":8999},"NCT02964949","Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical Outcomes",[99],"2018-10-09","2017-01-24",607,[28],[2900],{"nctId":9001,"briefTitle":9002,"status":136,"phases":9003,"primaryCompletion":9004,"completion":9004,"start":9005,"enrollment":9006,"conditions":9007,"interventions":9008},"NCT02951039","Edoxaban Treatment in Routine Clinical Practice for Patients With Atrial Fibrillation in Korea and Taiwan (ETNA-AF-KOR-TWN)",[],"2020-10-15","2017-02-21",3008,[28],[2900],{"nctId":9010,"briefTitle":9011,"status":136,"phases":9012,"primaryCompletion":9013,"completion":9013,"start":9014,"enrollment":4088,"conditions":9015,"interventions":9016},"NCT03247582","Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)",[],"2022-05-03","2017-08-02",[28],[2900],{"nctId":9018,"briefTitle":9019,"status":136,"phases":9020,"primaryCompletion":9021,"completion":9021,"start":9022,"enrollment":2748,"conditions":9023,"interventions":9024},"NCT03247569","Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)",[],"2022-02-28","2017-10-18",[28],[2900],{"intervention":2982,"totalTrials":26,"cells":9026},{"EARLY_PHASE1":9027,"PHASE1":9029,"PHASE2":9038,"PHASE3":9049,"PHASE4":9108,"NA":9142},{"trials":9028,"activeCount":105},[],{"trials":9030,"activeCount":105},[9031],{"nctId":9032,"briefTitle":9033,"status":136,"phases":9034,"primaryCompletion":9035,"completion":9035,"start":2844,"enrollment":604,"conditions":9036,"interventions":9037},"NCT00151814","Olmesartan Pediatric Pharmacokinetic (PK) Study",[95],"2008-02",[25],[2804],{"trials":9039,"activeCount":105},[9040],{"nctId":9041,"briefTitle":9042,"status":136,"phases":9043,"primaryCompletion":3906,"completion":2734,"start":4106,"enrollment":9044,"conditions":9045,"interventions":9048},"NCT00914524","Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy",[96],49,[9046,9047],"Chronic Glomerulonephritis","Diabetic Nephropathy",[2982],{"trials":9050,"activeCount":105},[9051,9059,9063,9070,9074,9078,9082,9086,9093,9097,9101],{"nctId":9052,"briefTitle":9053,"status":136,"phases":9054,"primaryCompletion":7731,"completion":4473,"start":5281,"enrollment":9055,"conditions":9056,"interventions":9058},"NCT00141453","ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial",[97],577,[9047,31,9057],"Proteinuria",[2982],{"nctId":5191,"briefTitle":5192,"status":136,"phases":9060,"primaryCompletion":2811,"completion":2821,"start":3073,"enrollment":5194,"conditions":9061,"interventions":9062},[97],[34],[5197,5180],{"nctId":9064,"briefTitle":9065,"status":136,"phases":9066,"primaryCompletion":2820,"completion":2820,"start":7731,"enrollment":9067,"conditions":9068,"interventions":9069},"NCT00676845","Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection",[97],133,[2823,25],[2982,2982,2982],{"nctId":2796,"briefTitle":2797,"status":136,"phases":9071,"completion":2799,"start":2800,"enrollment":2801,"conditions":9072,"interventions":9073},[97],[25],[2804,2785],{"nctId":2974,"briefTitle":2975,"status":136,"phases":9075,"primaryCompletion":2977,"completion":2978,"start":2979,"enrollment":2264,"conditions":9076,"interventions":9077},[97],[34],[2982,2963],{"nctId":2806,"briefTitle":2807,"status":136,"phases":9079,"primaryCompletion":2809,"completion":2810,"start":2811,"enrollment":2812,"conditions":9080,"interventions":9081},[97],[25],[2804,2785,2815],{"nctId":2984,"briefTitle":2985,"status":136,"phases":9083,"primaryCompletion":2987,"completion":2988,"start":2989,"enrollment":2990,"conditions":9084,"interventions":9085},[97],[34],[2982,2963],{"nctId":9087,"briefTitle":9088,"status":136,"phases":9089,"completion":2765,"start":9090,"enrollment":1017,"conditions":9091,"interventions":9092},"NCT00382213","A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis",[97],"2000-06",[5308],[2804],{"nctId":3069,"briefTitle":3070,"status":136,"phases":9094,"primaryCompletion":3072,"completion":2811,"start":3073,"enrollment":3074,"conditions":9095,"interventions":9096},[97],[34],[3077,3078,3079,3079],{"nctId":5574,"briefTitle":5575,"status":136,"phases":9098,"primaryCompletion":2764,"completion":3351,"start":2756,"enrollment":5577,"conditions":9099,"interventions":9100},[97],[34],[5563,2982],{"nctId":9102,"briefTitle":9103,"status":136,"phases":9104,"primaryCompletion":4078,"completion":4078,"start":2800,"enrollment":9105,"conditions":9106,"interventions":9107},"NCT00151775","Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure",[96,97],362,[25],[2982,2982],{"trials":9109,"activeCount":105},[9110,9114,9118,9122,9126,9130,9134,9138],{"nctId":3083,"briefTitle":3084,"status":136,"phases":9111,"primaryCompletion":2831,"completion":2831,"start":3086,"enrollment":3087,"conditions":9112,"interventions":9113},[98],[25],[2804,3040],{"nctId":2996,"briefTitle":2997,"status":136,"phases":9115,"primaryCompletion":2999,"completion":2999,"start":3000,"enrollment":3001,"conditions":9116,"interventions":9117},[98],[25],[2982,2963],{"nctId":3152,"briefTitle":3153,"status":175,"phases":9119,"primaryCompletion":3155,"completion":3155,"start":2919,"enrollment":3156,"conditions":9120,"interventions":9121},[98],[34,3158],[3013,2982],{"nctId":3033,"briefTitle":3034,"status":136,"phases":9123,"completion":3036,"start":3037,"enrollment":2911,"conditions":9124,"interventions":9125},[98],[25],[2804,3040,2815],{"nctId":2840,"briefTitle":2841,"status":136,"phases":9127,"primaryCompletion":2843,"completion":2843,"start":2844,"enrollment":156,"conditions":9128,"interventions":9129},[98],[25],[2804,2847,2848,2785],{"nctId":3653,"briefTitle":3654,"status":136,"phases":9131,"completion":2987,"start":3656,"enrollment":22,"conditions":9132,"interventions":9133},[98],[3658],[2804,3640,3660],{"nctId":3797,"briefTitle":3798,"status":136,"phases":9135,"primaryCompletion":3800,"completion":3195,"start":3801,"enrollment":358,"conditions":9136,"interventions":9137},[98],[25],[2982,3784],{"nctId":3005,"briefTitle":3006,"status":136,"phases":9139,"completion":3008,"start":1653,"enrollment":2482,"conditions":9140,"interventions":9141},[98],[25,3010,2823],[2804,3012,3013],{"trials":9143,"activeCount":105},[9144],{"nctId":9145,"briefTitle":9146,"status":136,"phases":9147,"primaryCompletion":9148,"completion":9148,"start":9149,"enrollment":1102,"conditions":9150,"interventions":9151},"NCT02848170","Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension",[99],"2017-04","2016-08",[34],[4619,2982],{"intervention":4619,"totalTrials":40,"cells":9153},{"EARLY_PHASE1":9154,"PHASE1":9156,"PHASE2":9162,"PHASE3":9182,"PHASE4":9218,"NA":9220},{"trials":9155,"activeCount":105},[],{"trials":9157,"activeCount":105},[9158],{"nctId":7529,"briefTitle":7530,"status":136,"phases":9159,"primaryCompletion":7532,"completion":7532,"start":7533,"enrollment":7534,"conditions":9160,"interventions":9161},[95],[25,7536],[4619,7522],{"trials":9163,"activeCount":105},[9164,9171,9175],{"nctId":9165,"briefTitle":9166,"status":136,"phases":9167,"primaryCompletion":663,"completion":4008,"start":4615,"enrollment":9168,"conditions":9169,"interventions":9170},"NCT02345057","A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria",[96],365,[9047],[4619],{"nctId":4611,"briefTitle":4612,"status":136,"phases":9172,"primaryCompletion":4614,"completion":2090,"start":4615,"enrollment":4616,"conditions":9173,"interventions":9174},[96],[34],[4619,4620],{"nctId":9176,"briefTitle":9177,"status":136,"phases":9178,"primaryCompletion":2870,"completion":2870,"start":5944,"enrollment":9179,"conditions":9180,"interventions":9181},"NCT02448628","A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment",[96],33,[25],[4619],{"trials":9183,"activeCount":105},[9184,9188,9195,9202,9210],{"nctId":4624,"briefTitle":4625,"status":136,"phases":9185,"primaryCompletion":4627,"completion":4627,"start":4628,"enrollment":4629,"conditions":9186,"interventions":9187},[97],[34],[4619,4602],{"nctId":9189,"briefTitle":9190,"status":136,"phases":9191,"primaryCompletion":9192,"completion":9192,"start":663,"enrollment":1559,"conditions":9193,"interventions":9194},"NCT02807974","Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria",[97],"2017-03",[25],[4619],{"nctId":9196,"briefTitle":9197,"status":136,"phases":9198,"primaryCompletion":4240,"completion":4240,"start":663,"enrollment":22,"conditions":9199,"interventions":9201},"NCT02808026","Study of CS-3150 in Patients With Severe Hypertension",[97],[9200],"Severe Hypertension",[4619],{"nctId":9203,"briefTitle":9204,"status":136,"phases":9205,"primaryCompletion":9206,"completion":9206,"start":662,"enrollment":9207,"conditions":9208,"interventions":9209},"NCT02722265","Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension",[97],"2017-07-08",368,[34],[4619],{"nctId":9211,"briefTitle":9212,"status":136,"phases":9213,"primaryCompletion":9214,"completion":9214,"start":663,"enrollment":1334,"conditions":9215,"interventions":9217},"NCT02807987","Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment",[97],"2017-05-15",[9216],"Hypertension With Moderate Renal Impairment",[4619],{"trials":9219,"activeCount":105},[],{"trials":9221,"activeCount":105},[9222,9231],{"nctId":9223,"briefTitle":9224,"status":136,"phases":9225,"primaryCompletion":9226,"completion":9226,"start":4628,"enrollment":9227,"conditions":9228,"interventions":9230},"NCT02885662","Study of CS-3150 in Patients With Primary Aldosteronism",[99],"2017-07-20",44,[9229],"Primary Aldosteronism",[4619],{"nctId":9145,"briefTitle":9146,"status":136,"phases":9232,"primaryCompletion":9148,"completion":9148,"start":9149,"enrollment":1102,"conditions":9233,"interventions":9234},[99],[34],[4619,2982],{"intervention":4225,"totalTrials":639,"cells":9236},{"EARLY_PHASE1":9237,"PHASE1":9239,"PHASE2":9241,"PHASE3":9251,"PHASE4":9298,"NA":9300},{"trials":9238,"activeCount":105},[],{"trials":9240,"activeCount":105},[],{"trials":9242,"activeCount":105},[9243,9247],{"nctId":4216,"briefTitle":4217,"status":136,"phases":9244,"primaryCompletion":4219,"completion":4219,"start":4220,"enrollment":4221,"conditions":9245,"interventions":9246},[96],[4223],[4225,4226],{"nctId":4228,"briefTitle":4229,"status":136,"phases":9248,"primaryCompletion":1195,"completion":1195,"start":571,"enrollment":4231,"conditions":9249,"interventions":9250},[96],[4233,4223],[4225,4225,4225,4207],{"trials":9252,"activeCount":105},[9253,9262,9269,9278,9286,9290,9294],{"nctId":9254,"briefTitle":9255,"status":136,"phases":9256,"primaryCompletion":9257,"completion":9257,"start":9258,"enrollment":9259,"conditions":9260,"interventions":9261},"NCT02234583","An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia",[97],"2017-04-19","2015-02-04",2485,[4257],[4225],{"nctId":9263,"briefTitle":9264,"status":136,"phases":9265,"primaryCompletion":9192,"completion":9192,"start":2870,"enrollment":2737,"conditions":9266,"interventions":9268},"NCT02607280","DS-5565 Phase III Study for Renal Impairment in Japanese Subjects",[97],[4774,9267],"Post-herpetic Neuralgia",[4225],{"nctId":9270,"briefTitle":9271,"status":136,"phases":9272,"primaryCompletion":9273,"completion":9273,"start":9274,"enrollment":2922,"conditions":9275,"interventions":9277},"NCT02496884","Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease",[97],"2017-07-06","2015-06-26",[9276],"Fibromyalgia",[4225],{"nctId":9279,"briefTitle":9280,"status":136,"phases":9281,"primaryCompletion":9282,"completion":9282,"start":4615,"enrollment":9283,"conditions":9284,"interventions":9285},"NCT02318706","DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain",[97],"2017-06-29",854,[4774],[4225],{"nctId":4250,"briefTitle":4251,"status":136,"phases":9287,"primaryCompletion":4253,"completion":4253,"start":4254,"enrollment":4255,"conditions":9288,"interventions":9289},[97],[4257],[4225,4207],{"nctId":4260,"briefTitle":4251,"status":136,"phases":9291,"primaryCompletion":4262,"completion":4263,"start":4264,"enrollment":4265,"conditions":9292,"interventions":9293},[97],[4257],[4225,4207],{"nctId":4269,"briefTitle":4251,"status":136,"phases":9295,"primaryCompletion":4271,"completion":4271,"start":4272,"enrollment":4273,"conditions":9296,"interventions":9297},[97],[4257],[4225,4207],{"trials":9299,"activeCount":105},[],{"trials":9301,"activeCount":105},[9302],{"nctId":9303,"briefTitle":9304,"status":136,"phases":9305,"primaryCompletion":9306,"completion":9306,"start":4615,"enrollment":9307,"conditions":9308,"interventions":9310},"NCT02318719","DS-5565 Phase III Study for Post-herpetic Neuralgia",[99],"2017-05-25",765,[9309],"Post-Herpetic Neuralgia",[4225],{"intervention":382,"totalTrials":639,"cells":9312},{"EARLY_PHASE1":9313,"PHASE1":9315,"PHASE2":9334,"PHASE3":9378,"PHASE4":9380,"NA":9382},{"trials":9314,"activeCount":105},[],{"trials":9316,"activeCount":105},[9317,9326,9330],{"nctId":9318,"briefTitle":9319,"status":136,"phases":9320,"primaryCompletion":781,"completion":9321,"start":9322,"enrollment":9323,"conditions":9324,"interventions":9325},"NCT01004861","Safety Study of PLX108-01 in Patients With Solid Tumors",[95],"2018-10-25","2009-10-01",132,[2399],[382],{"nctId":533,"briefTitle":534,"status":136,"phases":9327,"primaryCompletion":536,"completion":537,"start":538,"enrollment":539,"conditions":9328,"interventions":9329},[95],[541],[382,249],{"nctId":8098,"briefTitle":8099,"status":175,"phases":9331,"primaryCompletion":8101,"completion":8101,"start":8102,"enrollment":2373,"conditions":9332,"interventions":9333},[95],[8104,8105,8106],[382,8091],{"trials":9335,"activeCount":105},[9336,9345,9349,9357,9366,9370],{"nctId":9337,"briefTitle":9338,"status":136,"phases":9339,"primaryCompletion":9340,"completion":9340,"start":9341,"enrollment":22,"conditions":9342,"interventions":9344},"NCT01217229","Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma",[96],"2012-04-26","2011-03-03",[9343],"Hodgkin Lymphoma",[382],{"nctId":6560,"briefTitle":6561,"status":136,"phases":9346,"primaryCompletion":6563,"completion":6564,"start":6565,"enrollment":918,"conditions":9347,"interventions":9348},[95,96],[6567],[382,6551],{"nctId":9350,"briefTitle":9351,"status":175,"phases":9352,"primaryCompletion":9353,"completion":9353,"start":9354,"enrollment":1406,"conditions":9355,"interventions":9356},"NCT01499043","Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)",[96],"2013-03-11","2012-05-25",[2000],[382],{"nctId":9358,"briefTitle":9359,"status":136,"phases":9360,"primaryCompletion":9361,"completion":9362,"start":9363,"enrollment":4309,"conditions":9364,"interventions":9365},"NCT01349049","Phase 1\u002F2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)",[95,96],"2015-01-20","2018-01-09","2011-11-21",[752],[382,382],{"nctId":370,"briefTitle":371,"status":175,"phases":9367,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":9368,"interventions":9369},[95,96],[378,36,379,380,194],[382,132],{"nctId":9371,"briefTitle":9372,"status":175,"phases":9373,"primaryCompletion":8102,"completion":8102,"start":9374,"enrollment":4001,"conditions":9375,"interventions":9377},"NCT01349036","A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma",[96],"2011-12-03",[9376],"Recurrent Glioblastoma",[382],{"trials":9379,"activeCount":105},[],{"trials":9381,"activeCount":105},[],{"trials":9383,"activeCount":105},[9384],{"nctId":9385,"briefTitle":9386,"status":136,"phases":9387,"primaryCompletion":9388,"completion":9389,"start":6842,"enrollment":1406,"conditions":9390,"interventions":9391},"NCT02975700","A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma",[99],"2018-08-31","2024-10-11",[378],[382],{"intervention":1459,"totalTrials":722,"cells":9393},{"EARLY_PHASE1":9394,"PHASE1":9396,"PHASE2":9412,"PHASE3":9414,"PHASE4":9416,"NA":9418},{"trials":9395,"activeCount":105},[],{"trials":9397,"activeCount":105},[9398,9402,9406],{"nctId":7338,"briefTitle":7339,"status":136,"phases":9399,"primaryCompletion":663,"completion":663,"start":6234,"enrollment":6345,"conditions":9400,"interventions":9401},[95],[831],[1459,1551],{"nctId":1451,"briefTitle":1452,"status":136,"phases":9403,"primaryCompletion":1454,"completion":1454,"start":1455,"enrollment":604,"conditions":9404,"interventions":9405},[95],[1457],[1459,1355],{"nctId":9407,"briefTitle":9408,"status":136,"phases":9409,"primaryCompletion":663,"completion":663,"start":6234,"enrollment":37,"conditions":9410,"interventions":9411},"NCT02790684","A Study Assessing the Mass Balance of a Single Oral Dose of [14C] DS-8500a in Healthy Subjects",[95],[831],[1459],{"trials":9413,"activeCount":105},[],{"trials":9415,"activeCount":105},[],{"trials":9417,"activeCount":105},[],{"trials":9419,"activeCount":105},[9420,9429],{"nctId":9421,"briefTitle":9422,"status":136,"phases":9423,"primaryCompletion":4628,"completion":4628,"start":9424,"enrollment":9207,"conditions":9425,"interventions":9427},"NCT02628392","A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)",[99],"2015-11",[9426],"Type2 Diabetes Mellitus",[1459,9428],"Sitagliptin",{"nctId":9430,"briefTitle":9431,"status":136,"phases":9432,"primaryCompletion":9149,"completion":6606,"start":6607,"enrollment":5988,"conditions":9433,"interventions":9434},"NCT02669732","An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic Clamp",[99],[31],[1459],{"intervention":7897,"totalTrials":146,"cells":9436},{"EARLY_PHASE1":9437,"PHASE1":9439,"PHASE2":9445,"PHASE3":9447,"PHASE4":9449,"NA":9451},{"trials":9438,"activeCount":105},[],{"trials":9440,"activeCount":105},[9441],{"nctId":7891,"briefTitle":7892,"status":136,"phases":9442,"primaryCompletion":1971,"completion":1971,"start":7894,"enrollment":284,"conditions":9443,"interventions":9444},[95],[829],[7897,7884],{"trials":9446,"activeCount":105},[],{"trials":9448,"activeCount":105},[],{"trials":9450,"activeCount":105},[],{"trials":9452,"activeCount":105},[9453],{"nctId":9454,"briefTitle":9455,"status":2012,"phases":9456,"conditions":9457,"interventions":9459},"NCT03746912","Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib",[],[9458],"Acute Myeloid Leukemia With Gene Mutations",[9460],"Quizartinib Dihydrochloride",{"intervention":9462,"totalTrials":146,"cells":9463},"denosumab",{"EARLY_PHASE1":9464,"PHASE1":9466,"PHASE2":9468,"PHASE3":9470,"PHASE4":9476,"NA":9478},{"trials":9465,"activeCount":105},[],{"trials":9467,"activeCount":105},[],{"trials":9469,"activeCount":105},[],{"trials":9471,"activeCount":105},[9472],{"nctId":5785,"briefTitle":5786,"status":136,"phases":9473,"primaryCompletion":5788,"completion":4000,"start":2811,"enrollment":5789,"conditions":9474,"interventions":9475},[97],[5791],[5793,5774],{"trials":9477,"activeCount":105},[],{"trials":9479,"activeCount":105},[9480],{"nctId":9481,"briefTitle":9482,"status":136,"phases":9483,"primaryCompletion":2870,"completion":9484,"start":4298,"enrollment":9485,"conditions":9486,"interventions":9487},"NCT01973569","AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment",[99],"2017-09-19",679,[7559],[9462],{"intervention":8938,"totalTrials":395,"cells":9489},{"EARLY_PHASE1":9490,"PHASE1":9492,"PHASE2":9494,"PHASE3":9496,"PHASE4":9498,"NA":9500},{"trials":9491,"activeCount":105},[],{"trials":9493,"activeCount":105},[],{"trials":9495,"activeCount":105},[],{"trials":9497,"activeCount":105},[],{"trials":9499,"activeCount":105},[],{"trials":9501,"activeCount":105},[9502],{"nctId":8931,"briefTitle":8932,"status":136,"phases":9503,"primaryCompletion":8934,"completion":8934,"start":8935,"enrollment":4088,"conditions":9504,"interventions":9505},[],[28],[2900,8938,8939],{"intervention":8939,"totalTrials":395,"cells":9507},{"EARLY_PHASE1":9508,"PHASE1":9510,"PHASE2":9512,"PHASE3":9514,"PHASE4":9516,"NA":9518},{"trials":9509,"activeCount":105},[],{"trials":9511,"activeCount":105},[],{"trials":9513,"activeCount":105},[],{"trials":9515,"activeCount":105},[],{"trials":9517,"activeCount":105},[],{"trials":9519,"activeCount":105},[9520],{"nctId":8931,"briefTitle":8932,"status":136,"phases":9521,"primaryCompletion":8934,"completion":8934,"start":8935,"enrollment":4088,"conditions":9522,"interventions":9523},[],[28],[2900,8938,8939],{"intervention":9525,"totalTrials":395,"cells":9526},"Pravastatin",{"EARLY_PHASE1":9527,"PHASE1":9529,"PHASE2":9531,"PHASE3":9533,"PHASE4":9535,"NA":9537},{"trials":9528,"activeCount":105},[],{"trials":9530,"activeCount":105},[],{"trials":9532,"activeCount":105},[],{"trials":9534,"activeCount":105},[],{"trials":9536,"activeCount":105},[],{"trials":9538,"activeCount":105},[9539],{"nctId":9540,"briefTitle":9541,"status":136,"phases":9542,"primaryCompletion":9543,"completion":9543,"start":9544,"enrollment":9545,"conditions":9546,"interventions":9548},"NCT05107063","An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes",[],"2018-04-19","2016-01-20",2972,[9547],"Dyslipidemia Associated With Type II Diabetes Mellitus",[9525],{"intervention":9428,"totalTrials":395,"cells":9550},{"EARLY_PHASE1":9551,"PHASE1":9553,"PHASE2":9555,"PHASE3":9557,"PHASE4":9559,"NA":9561},{"trials":9552,"activeCount":105},[],{"trials":9554,"activeCount":105},[],{"trials":9556,"activeCount":105},[],{"trials":9558,"activeCount":105},[],{"trials":9560,"activeCount":105},[],{"trials":9562,"activeCount":105},[9563],{"nctId":9421,"briefTitle":9422,"status":136,"phases":9564,"primaryCompletion":4628,"completion":4628,"start":9424,"enrollment":9207,"conditions":9565,"interventions":9566},[99],[9426],[1459,9428],{"intervention":9568,"totalTrials":395,"cells":9569},"Bempedoic Acid 180Mg\u002FEzetimibe 10Mg Tab",{"EARLY_PHASE1":9570,"PHASE1":9572,"PHASE2":9574,"PHASE3":9576,"PHASE4":9578,"NA":9580},{"trials":9571,"activeCount":105},[],{"trials":9573,"activeCount":105},[],{"trials":9575,"activeCount":105},[],{"trials":9577,"activeCount":105},[],{"trials":9579,"activeCount":105},[],{"trials":9581,"activeCount":105},[9582],{"nctId":9583,"briefTitle":9584,"status":136,"phases":9585,"primaryCompletion":9586,"completion":9586,"start":9587,"enrollment":9588,"conditions":9589,"interventions":9590},"NCT05546398","SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®",[],"2022-11-17","2022-04-22",500,[42,1378],[9568],{"intervention":9592,"totalTrials":395,"cells":9593},"MorphaBond ER",{"EARLY_PHASE1":9594,"PHASE1":9596,"PHASE2":9598,"PHASE3":9600,"PHASE4":9602,"NA":9604},{"trials":9595,"activeCount":105},[],{"trials":9597,"activeCount":105},[],{"trials":9599,"activeCount":105},[],{"trials":9601,"activeCount":105},[],{"trials":9603,"activeCount":105},[],{"trials":9605,"activeCount":105},[9606],{"nctId":9607,"briefTitle":9608,"status":136,"phases":9609,"primaryCompletion":9610,"completion":9610,"start":9611,"enrollment":9612,"conditions":9613,"interventions":9615},"NCT04033094","Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)",[],"2020-12-31","2017-10-16",17566,[9614],"Baseline Epidemiologic Assessment",[9592,9616],"Comparator Drug",{"intervention":9616,"totalTrials":395,"cells":9618},{"EARLY_PHASE1":9619,"PHASE1":9621,"PHASE2":9623,"PHASE3":9625,"PHASE4":9627,"NA":9629},{"trials":9620,"activeCount":105},[],{"trials":9622,"activeCount":105},[],{"trials":9624,"activeCount":105},[],{"trials":9626,"activeCount":105},[],{"trials":9628,"activeCount":105},[],{"trials":9630,"activeCount":105},[9631],{"nctId":9607,"briefTitle":9608,"status":136,"phases":9632,"primaryCompletion":9610,"completion":9610,"start":9611,"enrollment":9612,"conditions":9633,"interventions":9634},[],[9614],[9592,9616],{"intervention":9636,"totalTrials":395,"cells":9637},"Mevalotin",{"EARLY_PHASE1":9638,"PHASE1":9640,"PHASE2":9642,"PHASE3":9644,"PHASE4":9646,"NA":9648},{"trials":9639,"activeCount":105},[],{"trials":9641,"activeCount":105},[],{"trials":9643,"activeCount":105},[],{"trials":9645,"activeCount":105},[],{"trials":9647,"activeCount":105},[],{"trials":9649,"activeCount":105},[9650],{"nctId":9651,"briefTitle":9652,"status":136,"phases":9653,"primaryCompletion":9654,"completion":9655,"start":9656,"enrollment":9657,"conditions":9658,"interventions":9660},"NCT05120895","An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia",[],"2024-09-02","2024-12-27","2021-08-10",3060,[9659],"Dyslipidemia",[9636],{"intervention":9662,"totalTrials":395,"cells":9663},"CPT-11 based regimens",{"EARLY_PHASE1":9664,"PHASE1":9666,"PHASE2":9668,"PHASE3":9670,"PHASE4":9672,"NA":9674},{"trials":9665,"activeCount":105},[],{"trials":9667,"activeCount":105},[],{"trials":9669,"activeCount":105},[],{"trials":9671,"activeCount":105},[],{"trials":9673,"activeCount":105},[],{"trials":9675,"activeCount":105},[9676],{"nctId":9677,"briefTitle":9678,"status":136,"phases":9679,"primaryCompletion":9680,"completion":9681,"start":9682,"enrollment":9683,"conditions":9684,"interventions":9685},"NCT01039506","An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)",[],"2016-04-28","2016-07-01","2009-10-15",1376,[1153],[9662],{"intervention":9687,"totalTrials":395,"cells":9688},"DS1040b",{"EARLY_PHASE1":9689,"PHASE1":9691,"PHASE2":9693,"PHASE3":9695,"PHASE4":9697,"NA":9699},{"trials":9690,"activeCount":105},[],{"trials":9692,"activeCount":105},[],{"trials":9694,"activeCount":105},[],{"trials":9696,"activeCount":105},[],{"trials":9698,"activeCount":105},[],{"trials":9700,"activeCount":105},[9701],{"nctId":9702,"briefTitle":9703,"status":136,"phases":9704,"primaryCompletion":9705,"completion":9705,"start":9706,"enrollment":7709,"conditions":9707,"interventions":9708},"NCT03198715","Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With Thrombectomy",[99],"2020-01-19","2017-07-30",[6085],[9687],{"intervention":9710,"totalTrials":395,"cells":9711},"CPT-11",{"EARLY_PHASE1":9712,"PHASE1":9714,"PHASE2":9716,"PHASE3":9718,"PHASE4":9720,"NA":9722},{"trials":9713,"activeCount":105},[],{"trials":9715,"activeCount":105},[],{"trials":9717,"activeCount":105},[],{"trials":9719,"activeCount":105},[],{"trials":9721,"activeCount":105},[],{"trials":9723,"activeCount":105},[9724],{"nctId":9725,"briefTitle":9726,"status":136,"phases":9727,"primaryCompletion":9728,"completion":9729,"start":9682,"enrollment":9730,"conditions":9731,"interventions":9733},"NCT01040312","An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors",[],"2014-09-29","2015-09-02",321,[496,36,1997,194,9732],"Gastric Cancer (Inoperable and Recurrent)",[9710,9734],"Platinum analogues",{"intervention":9734,"totalTrials":395,"cells":9736},{"EARLY_PHASE1":9737,"PHASE1":9739,"PHASE2":9741,"PHASE3":9743,"PHASE4":9745,"NA":9747},{"trials":9738,"activeCount":105},[],{"trials":9740,"activeCount":105},[],{"trials":9742,"activeCount":105},[],{"trials":9744,"activeCount":105},[],{"trials":9746,"activeCount":105},[],{"trials":9748,"activeCount":105},[9749],{"nctId":9725,"briefTitle":9726,"status":136,"phases":9750,"primaryCompletion":9728,"completion":9729,"start":9682,"enrollment":9730,"conditions":9751,"interventions":9752},[],[496,36,1997,194,9732],[9710,9734],{"intervention":9754,"totalTrials":395,"cells":9755},"Bempedoic acid and\u002For its fixed dose combination with ezetimibe",{"EARLY_PHASE1":9756,"PHASE1":9758,"PHASE2":9760,"PHASE3":9762,"PHASE4":9764,"NA":9766},{"trials":9757,"activeCount":105},[],{"trials":9759,"activeCount":105},[],{"trials":9761,"activeCount":105},[],{"trials":9763,"activeCount":105},[],{"trials":9765,"activeCount":105},[],{"trials":9767,"activeCount":105},[9768],{"nctId":9769,"briefTitle":9770,"status":1192,"phases":9771,"primaryCompletion":9772,"completion":9772,"start":9773,"enrollment":105,"conditions":9774,"interventions":9776},"NCT05798390","Treatment With Bempedoic Acid And\u002FOr Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia",[],"2026-04-01","2023-09-01",[9775,1378],"Primary Hypercholesterolemia",[9754]]